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Abstract 
 
Background 
Unexplained physical symptoms (UPS) that lack an organic explanation, even after 
appropriate investigation, are extremely common amongst UK primary care 
attenders but knowledge about their outcome is limited. 
 
Aim 
In a cohort of adult primary care attenders with UPS, this study aims to:   
1) Investigate the outcome, in terms of the presence of UPS at six months follow-up 
and 2) Identify prognostic factors associated with somatic symptom severity, quality 
of life, anxiety, depression and health care use at six months follow-up. 
 
Methods 
Screening: Consecutive adults attending nine general practices completed a 
screening questionnaire to identify those with UPS. 
Cohort study: Eligible participants completed the baseline questionnaire that 
enquired about somatic symptoms, quality of life, psychological well-being and past 
health and social history, and were followed-up after six months. 
 
Results 
Screening: Questionnaires were completed by 73% (2,826/3,896) of eligible 
attenders. Over two-thirds were female, median age was 42 years (IQR 30, 55) and 
median symptom severity score, based on the PHQ-15 was 7 (IQR 4, 11). Most 
(2,425/2,826 (86%)) had at least one UPS and around half (1,393/2,826 (49%)) had 
symptoms that were all unexplained (no explanation or diagnosis for any of their 
symptoms). Just under half (1,248/2,826, (44%)), had an explanation for their 
symptoms that included functional diagnoses (100/2,826 (4%)), psychological 
explanations (187/2,826 (7%)), or physical explanations or diagnoses (921/2,826 
(33%)).  
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Cohort study:  The cohort included 294 participants, were largely female (231/294 
(79%)), with a median age of 44 years (IQR 32, 57)) and diverse ethnicity (43% white 
British). At baseline, the cohort had a high level of morbidity, with moderately 
severe somatic symptoms (11.5 SD 4.9). Most reported experiencing their 
symptoms for longer than a year. A third had clinically significant comorbid 
depression and anxiety. 
 
Outcome: There was 245/294 (83%) followed-up at six months; mean PHQ-15 score 
was 10.5 (SD 5.3).  Over a half reported unexplained symptoms (135/245 (55%)), 
just under half (103/245 (42%)) reported symptoms were still under investigation 
and only 26/245 (11%) reported that their symptoms had resolved. Options were 
not mutually exclusive and participants could choose more than one.  The 
predictors of more severe somatic symptoms at follow-up were being female 
(B=1.31, 95% CI 0.12 to 2.50), higher somatic symptom severity (B=0.53, 95% CI 0.42 
to 0.64), experience of childhood physical abuse (B=1.86 95% CI 0.27 to 3.45), 
perception of poor financial well-being (B=1.90, 95% CI 0.89 to 2.91) and lower 
physical functioning at baseline (B=-0.10, 95% CI -0.15 to -0.04).  
 
Conclusion: Most people with UPS and high symptom severity are unlikely to 
improve over six months. Historical and current difficulties are associated with 
higher somatic symptom severity at follow-up. Future work should determine 
whether these findings are maintained over longer periods. The value of developing 
prognostic prediction models based on factors identified in this study should be 
explored. 
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Introduction Chapter 1 : 
 
1.0 Chapter overview  
In this chapter, I set the context for my thesis by highlighting the importance of the 
area of inquiry and the complexities surrounding research into the topic. First, I 
define unexplained physical symptoms and describe how terms, definitions and 
diagnostic classification have changed over time. Second, I outline the methods 
used to identify those with unexplained physical symptoms in research. Prevalence 
estimates of unexplained physical symptoms are then presented to highlight the 
extent of its burden globally and in the United Kingdom. This is followed by an 
overview of literature identifying factors associated with unexplained physical 
symptoms, in various settings. Finally, I discuss the burden of unexplained physical 
symptoms in terms of costs to health care, the difficulties in management and the 
impact on individuals.   
 
  Background 1.1
It is estimated that around 40% of primary care attenders experience symptoms 
such as headache, pain, dizziness, bloating and fatigue, which lack an obvious 
pathological explanation, even after appropriate investigation (Kroenke, 2003; 
Haller et al., 2015). These symptoms are often described as medically unexplained 
physical symptoms (Hennsingsen et al., 2011); although this term is considered to 
19 
 
be scientifically neutral by some, others suggest that it carries negative 
connotations for patients (Stone et al, 2002). Debate about the existing terminology 
and diagnostic classifications are on-going and are discussed in section 1.2 and 1.3. 
In this study, I use the broader term ‘unexplained physical symptoms’ (UPS); the 
definition is discussed in section 1.2. 
 
UPS can range from mild and transitory to chronic and debilitating (Brown., 2006; 
Rosendal et al., 2005), often resulting in functional impairment and distress 
(Zonneveld et al., 2013; Olde Hartman et al., 2009). About half of all suffers are 
thought to experience symptoms that persist for longer than one year (Brown, 
2006; Rosendal et al., 2005; Olde Hartman et al., 2009; Steinbrecher and Hiller., 
2011;). Costs incurred are high to both health care and the wider economy due to 
help seeking behaviours and loss of productivity (Bermingham et al., 2010). 
 
Primary care is the first point of contact for most people and doctors report 
difficulties surrounding the appropriate management of patients (Stone, 2014). 
Many are referred to secondary care for specialist input (Olde Hartman et al., 2009); 
prevalence is reported to be as high as between 30 to 70 per cent (Stone et al., 
2009; Nimnuan et al., 2001; Reid et al 2001). Better management at earlier stages in 
primary care may reduce the burden on patients and the numbers who go on to 
require long term care (RCGP, 2009). General Practitioners’ decision making and 
care planning could be assisted by use of a prognostic tool to predict risk of poor 
outcomes like persistence of unexplained somatic symptoms or identify those who 
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will experience a more favourable outcome, such as the remission of symptoms. 
However, few prospective cohort studies have been conducted in primary care to 
explore outcome over time and to identify prognostic factors associated with 
outcome (Olde Hartman et al., 2009; Steinbrecher and Hiller., 2011; Creed et al., 
2012).  
 
My study will investigate the outcome of primary care attenders with UPS and 
identify prognostic factors associated with outcome in terms of somatic symptom 
severity, quality of life, depression, anxiety and health care use at six-month follow-
up. The aims and objectives of the study are discussed in detail in Chapter 3. 
 
 Terminology 1.2
A variety of terms have been used to describe those with physical symptoms that 
lack an obvious explanation in terms of the disease process or structural pathology 
of organs or body systems, even after appropriate examination and investigation 
(Henningsen et al., 2011). These terms have changed with time, accompanied by 
conceptual changes in how disease and illness are defined and understood; they are 
often used interchangeably, widely contested and considered unsatisfactory due to 
the aetiological assumptions many of them convey (Sumathipala, 2005; Dimsdale et 
al.2013). 
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The terms ‘medically unexplained symptoms’ and  ‘medically unexplained physical 
symptoms’ are used interchangeably in the literature and have been widely used in 
clinical and research settings, since the 1980’s (Creed et al., 2011). However, this 
term has been criticised over the years and considered to be unsatisfactory for a 
number of reasons. First, historically ‘medically unexplained symptoms’ were based 
on a biomedical model of illness (Henningsen et al., 2011; Dimsdale et al.,2013; 
Picariello et al., 2015); it was inherently dualistic, reinforcing the view that if disease 
was identified, symptoms were a ‘medical’ problem whilst symptoms that lacked an 
organic explanation were a ‘psychiatric’ problem (Sharpe et al., 2006). The term has 
also been criticised for describing symptoms by what they are not, rather than what 
they are and implying that ‘medicine’ has nothing to offer to those with these 
‘unexplained’ symptoms (Henningsen et al., 2011, Picariello et al., 
2015).  Increasingly, it is used much more loosely to refer to physical symptoms of 
unknown cause, without implying an underlying psychological cause. However this 
term still carries some of the stigma of its historical association with mind body 
dualism (Sumathipala, 2005).   
 
Another term that was widely used since the 1990’s was ‘somatisation’. It referred 
to ‘a tendency to experience and communicate somatic distress in response to 
psychosocial stress and to seek medical help for it’ (Lipowski, 1988). The term 
somatisation implied a psychological cause (Brown, 2006); it is criticised by those 
who were of the view that not all UPS reflect a psychological cause (Sharpe and 
Mayou, 2004). It is still used by some to refer to patients with multiple symptoms 
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without a diagnosis of an organic disease, who seek repeated medical care, 
synonymous with the broader definition of medically unexplained symptoms (van 
der Leeuw et al, 2015). 
 
‘Functional Somatic Symptoms’ or ‘Functional Somatic Syndromes’ are also popular 
terms, historically originating from neurology (Picariello et al., 2015). Some use the 
term functional somatic symptoms to refer to medically unexplained symptoms as 
described earlier (Wessley et al., 1999), whilst others use the term functional 
somatic syndromes to refer to symptoms assumed to be a result of disturbances in 
functioning relating to specific organs and body systems (Picariello et al., 2015; 
Mayou and Farmer, 2002; Wessley., et al 1999).  Certain functional syndromes are 
common to specific areas of medicine; for example, unexplained pain and joint 
stiffness, along with other symptoms such as fatigue are referred to as Fibromyalgia 
in Rheumatology (Mayou et al., 2005). Unexplained abdominal pain accompanied 
with bloating, constipation, diarrhoea and/or nausea is described as Irritable Bowel 
Syndrome in gastroenterology and unexplained chest pain referred to as non-
cardiac chest pain in cardiology (Mayou et al., 2005). It has been suggested that 
these syndromes may not be distinct from one another as there is considerable 
overlap in the symptoms experienced (Wessely et al., 1999). 
 
The term ‘somatoform disorders’ was first used when it was introduced as a 
diagnostic category in The Diagnostic and Statistical Manual for Mental Disorders 
classification, (3rd ed.; DSM-III; American Psychiatric Association [APA],1980) 
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(APA,2014).  The main feature of somatoform disorders is the presence of UPS but 
not all those with UPS meet the criteria for somatoform disorder. Although it has 
undergone many changes over time, somatoform disorders have been considered 
to be on the severe end of the spectrum (Henningsen et al., 2011). This will be 
discussed further in the next section on diagnostic classifications (see section 1.3).  
 
There has been a great amount of dissatisfaction amongst academics and patients 
regarding the terms used to describe patients with symptoms that lack an obvious 
pathological explanation (Creed et al.,2009; Creed et al., 2010). Over time various 
other abbreviations and suggestions have been made along with changes within 
international classifications. One that was and is still often used is abridged 
somatisation, which was originally derived as an abbreviated version of the DSM-III 
construct somatisation (Escobar et al., 1989; 1998a). It was developed to capture a 
wider population presenting with unexplained symptoms. To meet the criteria for 
abridged somatisation requires the presence of at least four symptoms based 
amongst men and six symptoms amongst females on the Somatic Symptom Index 
(Escobar et al 1989).  
 
Other suggested terminology and criteria include ‘Bodily Distress Syndrome’ (Fink 
and Schroder, 2010), ‘Multi-somatoform Disorder’ (Kroenke et al., 2007) and 
Polysymptomatic Distress Disorder (Rief et al., 2011). A recent survey reported that 
amongst 844 lay participants, the most acceptable term was ‘Persistent Physical 
Symptoms’ which was preferred by 20% of respondents. This was closely followed 
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by: ‘Functional Symptoms’ (17%); ‘Medically Unexplained Symptoms’ (15%); and 
‘Body Distress Disorder’ (13%). The least popular term was ‘Complex Physical 
Symptoms’ (5%) (Marks and Hunter, 2014).  In 2013, The Diagnostic and Statistical 
Manual for Mental Disorders (5th ed.; DSM-5; American Psychiatric Association 
[APA],2013) introduced the new ‘Somatic Symptom Disorder’ category. This will be 
discussed in section 1.3.  
 
As the above studies highlight, there appear to be no ideal term and the debate 
continues over which terminology should be used.  I chose to use the term 
unexplained physical symptoms (UPS) at the inception of this study in 2012, as I 
considered it to be better suited for the study materials used in screening, 
recruitment and data collection, than any of the other terms discussed. In my 
opinion it does not carry the negative conations of other existing terms such as 
medically unexplained symptoms. I consider this term to be synonymous to 
medically unexplained symptoms, in its broader definition, referring to physical 
symptoms of unknown cause, but without implying an underlying psychological 
cause. In the next section I discuss the diagnostic classifications often used to 
identify and describe participants clinically and in research. 
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 Diagnostic Classifications 1.3
A majority of studies of UPS use The American Psychiatric Association's Diagnostic 
and Statistical Manual for Mental Disorders (DSM) or the International Classification 
of Disease (ICD) nomenclature devices or coding systems to operationalise 
psychiatric diagnoses (refer Appendix 1.1). Many diagnostic interviews and 
questionnaires are aligned to these classifications and are described in section 
1.4.1. 
 
The DSM-III (APA,1980), introduced ‘somatoform disorders’ for the first time, as a 
diagnosis for syndromes unexplained by general medical conditions but not 
completely psychological, replacing the previous diagnostic category ‘neurosis’ 
(Hyler, 1984; Hiller and Rief, 2005).  
 
Under the umbrella of somatoform disorders were four subcategories: somatisation 
disorder, conversion disorder (or hysterical neurosis, conversion type), psychogenic 
pain disorder and hypochondriasis. However, large numbers of people with 
unexplained symptoms did not meet the diagnostic criteria for any of these 
subcategories therefore they became considered as limited and restrictive (Kroenke 
et al 1997; Dimsdale et al.,2013). 
 
Further revisions in the subsequent Diagnostic and Statistical Manual for Mental 
Disorders third and fourth revisions (3rd ed., rev.; DSM-III-R; American Psychiatric 
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Association [APA], 1987; 4th ed.; DSM-IV; American Psychiatric Association [APA] 
1994) resulted in inclusion of new subcategories such as atypical somatoform 
disorder and undifferentiated somatoform disorders to make the diagnostic 
category more inclusive. This provided a way in which to capture and describe more 
of those in the general population or who were attending primary care with UPS. 
There was a concern that broadening the diagnostic criteria would lead to the over 
medicalisation of physical symptoms resulting in even transitional symptoms being 
labelled and treated in a clinical settings (Barsky and Borus, 1995). On the other 
hand, a more inclusive diagnostic classification would aid in health service 
development and planning by giving a better idea of the incidence (Barsky and 
Borus, 1995).  
 
The DSM-IV (APA., 1994) also included the diagnoses: conversion disorder; pain 
disorder; hypochondriasis; body dysmorphic disorder (refer Appendix 1.1).  
Although these subcategories have features in common with somatisation disorder 
and undifferentiated somatoform disorder, such as the presence of unexplained 
symptoms, diagnoses of these required further specific criteria to be met. For 
example, the diagnoses of pain disorder required an associated psychological 
disorder; and hypochondriasis required the presence of preoccupation with fear, or 
the idea that one has a serious disease, based on misinterpretation of bodily 
symptoms which persists despite appropriate investigation and reassurance.  
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Despite the heterogeneity between the diagnostic categories, some studies 
rationalise that they are similar constructs and often group and study individuals 
meeting the diagnostic criteria for these together (Olde Hartman et al., 2009).  For 
details on specific criteria that must be met for a diagnosis of somatisation disorder 
such as number and duration of symptoms, as well as listing the other categories 
included under somatoform disorders in DSM-IV see Appendix 1.1. 
 
Another diagnostic categorisation system commonly used in the United Kingdom 
(UK) is the International Classification of Diseases (World Health Organisation 
[WHO], 1992). However, the majority of published research appears to refer to DSM 
classifications originating from the USA. Efforts were taken to align the International 
Classification of Diseases 10th revision (ICD-10) to the DSM-IV in terms of the 
diagnostic categories within the wider somatoform disorder category and to some 
extent these are similar (Frances, 2013). Being a general manual of illness, one of 
the main differences between the two diagnostic manuals is that the ICD-10 (WHO, 
1992) emphasises a ‘psychological’ cause whilst the DSM-IV being exclusively a 
psychiatric diagnostic classification assumes a psychological cause and emphasises 
the presence of a significant impairment in day to day, work and social functioning 
as a result of the UPS. Details of ICD-10 (WHO, 1992) are provided in Appendix 1.1. 
 
DSM-IV somatisation disorder was criticised by some, for being too restrictive and 
not capturing the true number of people burdened by UPS (Creed, 2006; Dimsdale 
et al., 2013).  On the other hand, the newly included DSM-IV ‘Undifferentiated 
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Somatoform Disorder’ was considered to be too broad by others; capturing a large 
number of the general population (Dismsdale et al., 2013). An argument in favour of 
revisions was that many of the subcategories within somatoform disorders overlap 
and that there was a lack of clarity between boundaries (APA, 2013). It is suggested 
that the DSM-IV was difficult for non-psychiatrists to use and fundamentally that it 
was difficult to determine whether a symptom was medically unexplained (APA, 
2013). Additionally, labelling individuals with essentially ‘mental disorder’ diagnoses 
through a process of exclusion was considered inappropriate, implying to patients 
that symptoms were not considered ‘real’ (APA, 2013). These arguments resulted in 
a major diagnostic change in The Diagnostic and Statistical Manual for Mental 
Disorders fifth revision DSM-5 (5th ed.; DSM-V; American Psychiatric Association 
[APA], 2013), which was published in 2013 after the inception of my study. 
 
 The Somatic Symptom Disorder (SSD) as defined in DSM-5 focuses on symptom 
behaviours and/or thoughts, which are disproportionate or excessive, but there are 
no requirements that the symptoms should be unexplained (APA, 2013). It is argued 
that the DSM-V criteria is too loose, as it requires only the presence of at least one 
bodily symptoms that has lasted for at least six months and is distressing or 
distributive to the individual (Dimsdale and Levenson, 2013). Critics argue that the 
new classification is over inclusive and will result in increasingly classifying 
symptoms as mental disorders (Frances, 2013). 
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 The purpose of the new SSD classification is to identify those who experience 
burden from their physical symptoms, regardless of whether they are explained or 
not. However, early field work showed high false positive rates, picking up 7% of 
‘healthy’ people in the general population as meeting the criteria for Somatic 
Symptom  Disorder (Frances,2013).  
 
Despite the concerns about how the SSD classification will work in practice and the 
over medicalisation of symptoms, it is important to remember that those who do 
meet the new criteria are likely to be individuals who seek help for their symptoms, 
whether a diagnostic label is attached to them or not. Therefore, such an inclusive 
classification will not only validate the distress and burden experienced by patients 
but also give a better idea of the extent of health care use amongst those undefined 
patients.  
 
On the other hand, a new classification may not mean that attitudes towards those 
with unexplained symptoms will necessarily change overnight. Doctors may 
continue with their own pre-conceived biases and may not necessarily change how 
a patient is viewed or managed; how someone with a SSD and cancer is treated may 
still be very different to someone with SSD whose symptoms are considered 
unexplained. A new diagnostic criterion such as SSD may allow for a more inclusive 
level of identification, classification and estimation of the burden of such 
symptoms, paving the way for innovation in care and management for distressed 
patients. However, how the use of the DSM-5 SSD classification will work in practice 
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and if it will be used widely remains to be seen. In the next section, the 
identification of those with UPS is discussed. 
 
 Identification of UPS in research 1.4
Methods used in research to identify UPS have commonly included: structured 
diagnostic interviews administered by a clinician or suitably trained person; 
structured screening questionnaires either completed with an interviewer or self-
reported; and clinical judgment following patient interview or review of medical 
records (Haller et al., 2015; Hilderink et al., 2013; Van Boven et al., 2011).  
 
 Structured Diagnostic Interviews 1.4.1
Some structured diagnostic interviews which have been commonly used in studies 
of UPS include: Diagnostic Interview Schedule (Robins, 1981); Composite 
International Diagnostic Interview (Robins et al., 1988, Robins, 1981); Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN) (Wing, 1990, Fink et al., 1999, de 
Waal et al., 2004) and Structured Clinical Interview for DSM (SCID)(Spitzer, 1992). 
All were developed for the purpose of diagnosing psychiatric morbidity and were 
aligned to the either or both DSM and ICD manuals. Most were initially designed to 
be used by clinicians; some such as the CIDI and SCID were developed so that they 
could be administered by trained professionals in mental and psychiatric settings 
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(Brugha et al., 2001). They were later extended for use by trained lay interviewers 
(Brugha et al., 2001).  
 
At the initial stages of my study, I considered using a diagnostic interview, 
specifically the Composite International Diagnostic Interview, third revision (CIDI 
3.0, 2004), to identify a population comparable with those identified in previous 
studies but I decided against this for a number of reasons. First, I was interested in 
identifying a population with UPS who did not necessarily have an underlying 
psychological cause, and the interviews available were established for the purpose 
of identifying psychiatric morbidity. Secondly, a few people in primary care meet 
the diagnosis for somatoform disorders, but many more are likely to be burdened 
by UPS. Therefore, its use would likely result in identification of a population with 
limited relevance. Prevalence estimates according to different diagnostic criteria are 
discussed in section 1.5. 
 
 Structured screening questionnaires  1.4.2
Structured screening questionnaires have been used frequently for identification of 
somatic symptoms, explained or otherwise. Self-report questionnaires are valuable 
for gaining insight into patient perception of their symptoms (Paulhus and Vazire, 
2007). Like interviews, they are subjective and can be affected by recall bias; 
however they are quicker to complete and less resource intensive than diagnostic 
interviews, which require trained interviewers and take longer to complete (Bucholz 
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et al., 1993). They are at times used to determine a sample suitable for further in-
depth diagnostic interviewing (Bucholz et al., 1993). 
 
A review of self-report symptom scales to assess somatic symptoms identified 40 
questionnaires; the number of items in each ranged from five to 78, although close 
to half included 15 symptoms (Zijlema et al., 2013).  Some of these questionnaires 
enquired about life time symptom experiences, most were based on the previous 
week or month. Questionnaires identified in the review included: Bradford Somatic 
Inventory (Mumford, 1989; Mumford et al.,1991); BSI-6: Brief Symptom Inventory 
(Derogatis and Melisaratos,  1983); PSC-17: Physical Symptom Checklist (Attanasio 
et al., 1984); Physical Symptom Checklist-51 (de Waal et al 2005); Patient Health 
Questionnaire (Spitzer et al 1999); PHQ-15: Patient Health Questionnaire, somatic 
symptom module (Kroenke et al., 2002); SCL-90: Symptom Checklist-90 
Somatization (Derogatis and Unger, 2010), SSI- Somatic Symptoms Index  (Escobar 
et al., 1989).  Most items included in the questionnaires were found to be aligned to 
DSM and ICD diagnostic categories and many of the questionnaires overlap with 
each other. Most questionnaires provide a somatisation diagnosis or assessed the 
frequency (57%), severity (28%) or both frequency and severity (15%) of symptoms. 
Some of the questionnaires were adapted short forms of longer questionnaires; for 
example the Brief Symptom Inventory (BSI-6) was adapted from the SCL-90 SOM 
(Zijlema et al., 2013).  
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For my study, I chose the Patient Health Questionnaire somatic symptom module 
(PHQ-15) to determine somatic symptom severity (Kroenke et al., 2002).  I provide a 
discussion based on the context under which my decision was made and discuss the 
properties of the PHQ-15 in section 4.9.1.   
 
 Clinician and researcher identification 1.4.3
In some studies, participants with UPS are identified based on general practitioners 
judgment of consultations or review of medical notes (De Gucht et al., 2004; Duddu 
et al., 2008; Morriss et al., 2012). General practitioner (GP) identification can lead to 
considerable variation in the populations identified due to variability in individual 
practitioner’s judgement, especially if a study includes a number of sites and 
general practitioners. Some studies identify participants based on researcher’s 
judgment (Speckens et al., 1996; Kooiman et al., 2004; van Dessel et al., 2014, Van 
der Weijden et al., 2003); similar issues of variability may occur and may be further 
exacerbated when electronic medical notes are reviewed, as these are already 
based on a doctor’s judgement and subject to variation in case recording (Morriss et 
al 2012). Variations can be minimised by using strict inclusion and exclusion criteria 
but this method may be fairly resource intensive requiring the involvement and 
time of doctors and trained researchers. Use of medical records is discussed further 
in the next section (see 1.4.4). 
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 Use of medical records  1.4.4
Some studies use electronic medical records and illness episode statistics for 
identification of those with UPS (van Boven et al., 2011; Morriss et al 2012; 
Dirkzwager and Verhaak, 2007). Electronic medical records have considerable value 
in providing access to large databases and large sample sizes (Khan et al., 2010). 
However, identifying patients with UPS from these are reported to be difficult (Den 
Boeft et al.,2014). Using electronic medical records, Den Boeft et al. (2014), found 
prevalence of patients with functional syndromes was much lower than would be 
expected. There may be variation in the main cause for the consultation entered by 
different clinicians or multiple Read codes1 entered for the same problem (Morriss 
et al., 2012). Morriss et al., (2012) developed an algorithm to identify patients using 
electronic records, but found that the models were too sensitive for use in clinical 
screening. In section 1.5 I discuss the prevalence rates of UPS that have been 
reported. 
 
 Prevalence in primary care 1.5
Differences in how UPS are classified and identified can lead to variations in 
estimates of prevalence. It has been estimated that around 80% to 90% of people 
experience at least one or more symptom such as headache, pain, dizziness, 
bloating and fatigue over a period of two to four weeks (Kroenke, 2003; Olde 
                                                     
1
 Read codes are unique identifiers of clinical terms intended to provide a standard vocabulary for 
recording in primary and secondary care that have been used in the National Health Service (NHS) 
since the late 1980’s (Benson, 2011). 
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Hartman et al.,2013). Although many of these symptoms may be self-limiting, a 
large proportion of people are likely to seek medical care (Kroenke, 2003). 
Therefore, it is important to have an idea of the prevalence, especially in primary 
care, as it is the first port of call for formal help-seeking for the majority of people.  
 
Kroenke, (2003) in a review of five studies found that prevalence of UPS ranged 
from 20% to 74% in primary care, depending on how the symptoms were classified. 
Three of the studies in that review reported that around a third of somatic 
symptoms were unexplained. Kroenke, (2003) therefore suggested that whilst 20% 
is likely to be an underestimation and 74% an overestimation, a third was likely to 
be a reasonable estimate, as three studies involving different samples and methods 
reached similar conclusions. 
 
Heterogeneous populations and methodological differences in existing studies limit 
direct comparisons, nevertheless they provide some insight into the distribution of 
symptom severity in the population based on the classifications they use. For 
example a recent systematic review of 32 studies originating from 24 countries with 
a total of 70,085 people explored the prevalence of somatoform disorders and 
medically unexplained symptoms in primary care (Haller et al., 2015). Studies 
included were based on subcategories of somatoform disorders in DSM-III-R, DSM-
IV or ICD-10 (excluding hypochondriasis and body dysmorphic disorders) as well as 
subthreshold somatoform disorders and ‘medically unexplained symptoms’. In the 
review, those with between six and 13 impairing UPS with a minimum duration of 
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two years were classified as having somatisation disorder, which is considered to be 
on the more severe end of the spectrum of somatoform disorders (Haller et al., 
2015). Abridged somatisation disorder, which has been validated in primary care 
requires the presence of six impairing medically unexplained symptoms in women 
and four in men (Escobar, 1998). The least severe end of the spectrum of 
somatoform disorders, undifferentiated somatoform disorders (refer Appendix 1.1) 
is considered to be over exclusive by some (Kroenke et al., 1997) as it is based on 
the existence of just one unexplained symptom with a minimum duration of six 
months.  
 
The review also includes those classified as having ‘medically unexplained 
symptoms’, which the authors define as those with at least one medically 
unexplained symptom that did not meet any of the diagnostic categories listed 
above (Haller et al., 2015). The studies included in the review reported that the 
point prevalence of somatisation disorder ranged from 0.8%, 95% CI 0.3% to 1.4% 
(using DSM-IV criteria and n= 28,727 participants) to 12.8%, 95% CI 10.2% to 15.3% 
(using questionnaires and n=20, 508 participants). Point prevalence of abridged 
somatisation disorder was 17.8%, 95% CI 14.6% to 21.3% (using clinical interviews 
and n=29,909 participants); undifferentiated somatoform disorder between 9.3%, 
95% CI 6.6% to 12% (ICD-10, n= 2798 participants) and 38.1%, 95% CI 13.1% to 
63.1%(DSM-III-R/DSM-IV, n=1356 participants); and medically unexplained 
symptoms 40.2%, 95% CI 0.9% to 79.4% and n=1237 participants (Haller, 2015). The 
review thus found, that the prevalence of less severe forms of UPS were greater 
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than the severe diagnostic classifications such as somatoform disorder (Haller et al., 
2015). 
 
Based on symptom scores, rather than diagnostic classifications as discussed above, 
Kroenke et al. (2002) explored symptom severity using data from 3000 primary care 
and 3000 obstetrics-gynaecology clinics attenders in USA, using the PHQ-15 
questionnaire (described and discussed in section 4.9.1). The primary care sample 
was recruited from five general internal medicine clinics (n=1422) and three family 
practice clinics (n=1578). Prevalence of somatic symptoms for the primary care 
population by severity group showed that the largest numbers of participants 
scored minimal to low somatic symptom severity and distributions were as follows: 
PHQ-15 0-4 (minimal), 35% (n=1012); 5-9 (low), 35% (n=1012); (moderate) 10-14, 
20% (n=594) and >15 (severe) 10% (n=291). Diagnostic interviews showed that the 
two samples in the study were fairly similar. Symptom severity distributions were 
also similar for the obstetrics-gynaecology sample, despite the sample consisting of 
only females (Spitzer et al., 2000).  
 
Similar distributions have been identified amongst primary care attenders in general 
practices in other countries. For example, in a German primary care study, the 
distribution of symptom severity among 620 consecutive primary care attenders 
was reported to be as follows:  PHQ-15: 0-4 (minimal) 24% (n=145); (low) 5-9 40% 
(n=249); 10-14 (moderate) 28% (n=169) and >15 (severe), 9% (n=57) (Steinbrecher 
and Hiller, 2011). This study is discussed in detail in Chapter 2 in the literature 
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review (section 2.8). Lowe et al. (2008) also found the prevalence of those who 
scored >15 (n=199/ 2091) across 15 primary care sites in the USA to be similar, at 
9.5%. As described in section 4.9.1, this score is considered to be a likely cut-off for 
somatisation disorder; Haller et al (2015) reported a prevalence ranging from 0.8% 
(95% CI 0.3% to 1.4%) to 12.8% (95% CI 10.2% to 15.3%) in their review of studies in 
primary care. Creed et al. (2012), using the somatic symptom index amongst 
primary care attenders in the UK, found that 79% (n=588/741) experienced mildly 
bothersome symptoms (lower severity), regardless of the explained or unexplained 
nature of their symptoms, whilst 21% (153/741) scored more than 26 on the 
somatic symptom inventory which is considered the clinically significant cut-off 
point for moderate severity. The percentages that scored moderately severe 
symptoms were fairly similar to the percentages that met scores for moderate 
severity (scores of 10-14) in the studies described above which used the PHQ-15 
(Creed et al., 2012).  
 
Large variations in estimates of prevalence may lead to an over or underestimation 
of the size of problem, making it difficult to plan services for those with UPS. 
However, the prevalence of UPS may differ depending on how they are classified, 
these studies suggest that the distribution of symptom severity amongst those 
attending primary care are skewed with the majority likely to have mild to 
moderate symptom severity and fewer experiencing severe symptoms. This has 
been supported by the studies based on those at the more severe end of the 
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spectrum such as somatoform disorders, which were discussed earlier in this 
section.  
 
 Prevalence in the UK  1.5.1
Few studies have explored the prevalence of UPS in primary care in the UK and 
estimates ranged from 10% to 35% (Mumford et al., 1991; Peveler et al., 1997; 
Duddu et al., 2008; Morriss et al., 2012).  A frequently cited study of prevalence of 
UPS in primary care, in the UK, is a study by Peveler et al. (1997), based on 
consecutive attenders to 10 General Practices. These patients were assessed by two 
researchers, using the checklist of symptoms derived from the Diagnostic Interview 
Schedule; of the 175 patients assessed, 5% met the criteria for somatization 
disorder using the DSM-III-R criteria and 35% met the criteria for less severe, 
abridged somatisation (Peveler et al., 1997). Generalisation of these findings from 
almost twenty years ago to current estimates of prevalence in primary care may be 
difficult because of changes in population trends, as these have resulted in ageing 
populations and greater ethnic diversity.  
 
However, more recently, Duddu et al. (2008) reported findings similar to Peveler’s 
and colleague’s findings; despite inclusion of a high South Asian population made 
up of 55% Pakistani participants prevalence of medically unexplained symptoms 
was 33% amongst 119 participants identified from a single general practice in 
Manchester (Duddu et al., 2008).  Somatic symptoms were measured using the 13 
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item subscale of the symptom checklist (SCL-90R), which suggested that those with 
medically unexplained symptoms had a higher mean score than those with 
medically explained symptoms (6.9 SD 3.1 vs 4.3 SD 2.9). The presence of medically 
unexplained symptoms was then identified by a researcher with the use of general 
practice medical records, following the patients’ consultation with the doctor.  
 
A recent study used electronic medical records and general practitioner judgement 
to estimate prevalence of medically unexplained symptoms at 15% (127/828) and 
prevalence of severe medically unexplained symptoms at 8.8% (73/828) (Morriss et 
al., 2012). Medically unexplained symptoms were identified by GPs based on a scale 
that ranged from ‘certain’ to ‘definitely not’ and on a scale of severity that ranged 
from ‘severe’ to ‘not relevant’. Severe symptoms were considered to be when the 
medically unexplained symptoms resulted in impaired functioning and distress 
(Morriss et al., 2012). Data from this study was used to develop ‘The Nottingham 
Tool’; it is intended for use for commission purposes and provide an indication of 
numbers of people in a practice who are likely to have UPS (Moriss et al., 2012; 
Commissioning Support for London, 2011). Prevalence of severe medically 
unexplained symptoms was estimated at 0.84%; however due to the specific 
algorithm used, sensitivity was considered to be low. At this rate of prevalence, 
approximately 52,000 people would be expected to be identified with severe 
medically unexplained symptoms, based on Office for National Statistics data for 
2009 (Commissioning Support for London, 2011). Although this translates to a 
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significant number when applied across the UK, rates of prevalence are likely to be 
much higher if a more sensitive algorithm was used.  
 
As reported in international studies, estimates of prevalence also vary greatly in the 
UK. Those with severe UPS are likely to experience a greater burden and require 
more specialised care.  The burden on patients and difficulties in management are 
discussed in sections 1.9 and 1.10; first I provide an overview of potential factors 
associated with UPS. 
 
 
 Potential factors to explore in a study of UPS  1.6
In the section, I discuss a broad range of factors that were explored to inform the 
development of this study; these include sociodemographic, physical, psychological, 
social and historical factors. I evaluated both cross-sectional and longitudinal 
studies of UPS, from various settings including primary and secondary care, to 
identify potential factors that may be associated with UPS. I retrieved studies of UPS 
defined in a variety of ways, such as somatoform disorders, abridged somatisation, 
and somatisation disorder. In order to limit the heterogeneity, I did not explore the 
literature based on functional syndromes (i.e. irritable bowel syndrome, chronic 
fatigue syndrome). I also made an effort to avoid studies based only on 
subcategories of somatoform disorders such as hypochondriasis or pain disorders; 
although some group these subcategories together (Olde Hartman et al., 2009).  My 
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reason for exclusion was based on the fact that they potentially have different 
aetiology and illness course (Creed, 2009); this is discussed further in relation to the 
literature review (see section 2.3.1 and 2.3.2).   
 
I also considered factors that have previously not been extensively explored in 
studies of UPS, based on theoretical decisions of potential association. In this 
situation I expanded my search to previously excluded populations to look at 
potential association of these factors with UPS.   
 
 Socio-demographic factors 1.6.1
Gender is considered to be an important factor associated with symptom reporting. 
Females report experiencing more somatic symptoms, more intensely and more 
frequently compared to males (Kroenke and Spitzer, 1998; Haug et al., 2004; Barsky 
and Borus, 2001). This variation is thought to be due to multiple reasons including 
biological differences in how pain is experienced, appraised, reported and social 
construction of gender, which is more accepting of female expressions of distress 
(Barsky and Borus, 2001).  Studies in various settings report a higher prevalence of 
UPS in females, especially on the more severe end of the spectrum (Speckens et al., 
1996; Kronke and Spitzer, 1998; Escobar et al., 1998; Verhaak et al., 2006). This 
association with gender is not so pronounced at the lower end of the severity 
spectrum, such as with abridged somatisation (Creed and Barsky et al, 2004; 
Escobar et al., 1998). Some studies report that the presentation and burden of UPS 
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are associated with a younger age in both primary and secondary care (Morriss et 
al., 2012; Nimnaun et al., 2001) whilst others find it to be the case among older 
populations attending both primary and secondary care (Escobar et al., 1998; 
Verhaak et al.,2006; Speckens et al., 1996; Gureje et al., 1997). Other factors 
identified as associated with a greater burden of unexplained symptoms include 
being unemployed (Fink et al., 1999; Verhaak et al., 2006), having a lower education 
level (Fink et al.,1999; Hotopf, 1999); being from a lower socioeconomic class (Fink 
et al., 1999; Nimnuan et al., 2001); and being widowed, divorced, or separated 
(Hotopf et al., 1999; Creed et al., 2012).   
 
 Number of symptoms, duration and severity 1.6.2
Having more symptoms, or a higher severity or longer duration of symptoms at 
presentation has been suggested to be associated with severity or persistence of 
UPS (Duddu et al., 2008; Jackson and Passamonti, 2005; Speckens et al., 1996; 
Kooiman et al., 2004). 
 
A prospective study of 100 participants conducted in general medical out-patient 
clinics in the Netherlands, found that a greater number of UPS at baseline were 
associated with no improvement at 12 months follow- up (Speckens et al., 1996). 
However, this study included those with either somatisation disorder (thirteen 
symptoms prior to the age of 30 years) or hypochondriasis. A cross-sectional 
primary care study conducted in the UK reported that those with UPS (n=39) had a 
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greater number of symptoms compared to those with medically explained 
symptoms (n=73) (considered to be organic) (Duddu et al., 2008).  This study was 
based on participants identified using three criteria, which included the absence of 
a diagnosis based on researcher judgement with the use of general practitioner 
notes, however the sample size of was fairly small. More recently, there is a 
growing body of literature which suggests that a greater number of symptoms, 
regardless of whether they are explained or unexplained, contribute to poor 
outcome (Creed et al.,2012; Jackson and Passamonti et al.,2005).  This has been 
reported in a number of studies, including in UK primary care (Creed et al.,2012). 
Such findings of the burden associated with a greater number of symptoms 
regardless of the unexplained or explained nature have resulted in changes to DSM 
criteria and the introduction of the term somatic symptom disorder (see section 
1.3).  A recent review by Tomenson et al (2013) where secondary analysis was 
conducted on studies from four different sites, it was reported that total somatic 
symptom score was a better predictor of follow-up health status than UPS. 
 
With regard to duration, shorter duration of symptoms at presentation is suggested 
to be associated with a better outcome. For example, in a study of consecutive 
primary care attenders in the USA (n=500), shorter duration of symptoms at 
presentation was associated with improved recovery at both three month and five 
year follow-up (Jackson and Passamonti, 2005).  
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Increasing the value of exploring somatic symptom scores and their association is 
being recognised. For example, in a review by Tomenson et al (2013) based on nine 
population-based studies (total population of 28,377), total somatic symptom 
scores was found to be associated with health status, after adjusting for depression, 
anxiety and general medical illness. In cross-sectional analyses based on five of the 
studies, total somatic score was correlated with past health care use after adjusting 
for confounders. In one prospective study baseline total somatic symptom score 
was correlated with retrospective but not prospective health case use. 
 
This review included seven cross-sectional studies conducted in Germany, Norway 
and Sri Lanka and only two prospective studies conducted (one in Germany and one 
in the UK). The prospective study conducted in Germany was based on a cohort 
who were a part of the Prevention of Renal and Vascular End Stage Disease 
(PREVEND) study, which included an enhanced sample with elevated urinary 
albumin concentration; therefore it did not meet the criteria for my literature 
review but the UK based prospective study identified has been discussed in detail in 
Chapter 2.  
 
Interestingly, in four sites where it was possible to explore the association of 
correlates with both the number of UPS and with total somatic symptom score, it 
was found that somatic symptom score had a greater association with health status 
than number of medically unexplained symptoms even after adjusting for 
46 
 
confounders.  Hence, this review supports the use of total somatic symptom score 
as a better predictor of follow-up health status compared to UPS.  
 
  Comorbid anxiety and depression 1.6.3
Multiple somatic symptoms or UPS can occur with anxiety and depression (Kroenke, 
2003; Smith et al., 2005; Van der Sluijs et al., 2015). Many primary care attenders 
with depression, present with somatic symptoms (Smith et al 2005; Tylee and 
Ghandi, 2005). Such presentation of somatic symptoms have been considered more 
common amongst certain cultures and groups where there is stigma attached to 
presenting with psychological distress (Bhugra and Mastrogianni., 2004), although 
there is a growing amount of literature that suggests that this is not necessarily 
always the case (Sidhaye et al 2013). Dowrick, (2004) suggests that some of the 
difficulties in distinguishing between UPS and different depressive disorders might 
be a result of the overlap and lack of distinction between symptom pattern, illness 
experiences and diagnostic categories.  
 
Those with UPS are more likely to have higher rates of anxiety and depression 
compared to those with physical symptoms or UPS alongside physical symptoms 
(Van der Sluijs et al. 2015). It is estimated that around 50-75% of patients with UPS 
have a depressive disorder and approximately 40-50% have an anxiety disorder 
(Kroenke, 2003). The comorbidity between depression and/or anxiety and 
somatoform disorders range from 11% to 50%  (De Waal et al., 2004, Lowe et al., 
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2008; Mergl et al., 2007; Rosmalen et al.,2010;  Steinbrecher et al., 2011; Van der 
Sluijs et al. 2015).  
 
The relationship between UPS, and anxiety and depression is likely bidirectional and 
the temporal relationship remains unresolved (Lieb et al., 2007). Kroenke et al. 
(1994), found that the as the number of physical symptoms increased, the 
likelihood of both mood disorders and anxiety also increased for primary care 
patients (Kroenke et al., 1994). In this sample, the prevalence of anxiety disorder 
was 1%, 7%, 13%, 30%, and 48% for patients with 0-1, 2-3, 4-5, 6-8, 9+ symptoms; 
the prevalence of mood disorders was to 2%, 12%, 23%, 44% and 60%, respectively. 
Escobar et al. (2010) reported similar findings in a community based cross-sectional 
study in the USA of 4,864 individuals with both general physical symptoms and UPS. 
On the other hand, a large prospective study of mental illness in 15 primary care 
centres across 12 countries, found that baseline depression predicted the onset of 
abridged somatoform disorder (Gureje and Simon et al, 1999).  
 
Therefore, some people may have somatic symptoms associated with depression or 
anxiety; some may experience depression and anxiety as a result of distress caused 
by their UPS; in others, symptoms may be considered physical or psychological 
expressions of common distress and treated as UPS with coexisting depression and 
anxiety (Henningsen et al., 2003). It is worth noting, however, that many people 
with UPS have no formal anxiety and depressive disorder or only have sub-
threshold symptoms (Weselley et al, 1996; Jackson and Passamnoti, 2005). 
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 Health related quality of life 1.6.4
Health related quality of life is an important and multi-dimensional concept that 
lacks a common definition (Tian-Hui et al., 2005).  The WHO definition broadly 
includes social, physical and mental aspects (Guyatt et al., 1993).  In the past, it was 
observed that despite improvements to medicine and technology resulting in 
changing patterns of morbidity, those with similar clinical characteristics and 
physiological measures did not always have the same outcomes (Guyatt et al., 
1993).  Therefore, self-reported measures of health related quality of life came to 
be regularly used to determine outcome amongst those with various diseases and 
long term conditions, including UPS.  
 
The terms self-perceived health, self-reported health status, health related quality 
of life, quality of life, functioning and impairment are often used interchangeably 
but all essentially refer to the same concept. Studies of UPS frequently explored 
physical, mental or social functioning which are important components of quality of 
life (Koch et al., 2007; Koch et al., 2009; Löwe et al., 2008; Verhaak et al., 2006). In 
my study I use the term quality of life and refer to physical and mental health 
functioning.   
 
Kroenke et al. (2002) observed that as bodily symptoms increased, painful and 
physical dimensions of health status all showed greater impairment; those who had 
the most severe symptom scores on the PHQ-15 had the greatest impairment in 
health status. Similar findings of, increasing symptom severity and association with 
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poor quality of life have been reported by others (Jackson and Passamonti, 2005).  A 
population based cohort study that distinguished between unexplained and 
explained symptoms found a stronger association between medically unexplained 
symptoms and health related quality of life (HRQoL), compared with explained 
symptoms and HRQoL (Hinderlink et al., 2015). On the other hand, Gureje and 
Simon (1999) in their large prospective cohort based on 15 primary care centres in 
12 countries found that that baseline perception of poor physical health was 
associated with the persistence of abridged somatisation at follow-up.  
  
 Childhood experiences 1.6.5
Childhood experiences such as exposure to illness in family members, poor 
childhood health, and traumatic experiences such as abuse and poor family 
dynamics are reported to be associated with UPS in adults. Stuart and Noyes (1999) 
suggest that childhood experiences may impact on stress responses and the 
development of personality, which in turn impact the experience and response to 
somatic symptoms as adults. In the following sections, I discuss a number of 
different types of childhood experience, which have been reported to be associated 
with UPS. 
 
1.6.5.1 Experience of physical and mental health in family members  
The experience of both physical and mental illness in parents during childhood and 
adolescence has been found to be significantly associated with multiple physical 
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symptoms and unexplained symptoms (Hotopf, 2002; Stuart and Noyes, 1999; 
Essau., 2007).  
 
 A nested case-control study carried out on a prospective birth cohort with over 
3000 participants explored the association of childhood exposures at the age of 15 
years with multiple physical symptoms in adults who were 36 years old (Hotopf, 
2002). Poor health of parents but not the death of a parent was found to be 
associated with UPS, suggesting that experience of non-life threatening illness or 
medically unexplained symptoms in family members may impact illness behaviours 
such as increased symptom monitoring (Hotopf et al 2002).  
 
In another study, Essau (2007) found that amongst adolescents (12 to 17 years) 
followed-up on average over 15 months; parental psychiatric disorders were 
associated with chronicity of somatoform disorders. Although this study was large 
(n=1,035), these findings are based on 64 individuals who met the criteria for DSM-
IV somatoform disorder at baseline. At follow-up 23/ 64 still met the criteria for any 
somatoform disorder (including undifferentiated somatoform disorder, chronic pain 
disorder and conversion disorder) but it is not clear how many were lost to follow-
up (Essau, 2007).    
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1.6.5.2 Experience of poor health during childhood 
Craig et al. (1993) in the longitudinal South London Somatisation Study, found that 
among adult somatisers (n=44) identified in primary care, those with UPS had 
experienced a greater number of serious childhood illness compared with adults 
with physical, mixed or psychologising symptoms. In a later study which included 
women identified using general practice records and specialist units, Craig et al. 
(2002) found that the daughters of mothers considered to have suffered from 
somatisation were almost three times more likely to report that they had been 
exposed to illness in a parent. These same individuals were also more likely to 
report experience of neglect in childhood compared to other women who did not 
have somatising mothers (OR 2.9; 95% CI 1.4 to 6.1). Hotopf (2002) also explored 
the impact of childhood diseases on adult physical symptoms and found that only 
abdominal pain in childhood was associated with multiple physical symptoms in 
adults. 
 
1.6.5.3 Experience of trauma during childhood 
Studies suggest that childhood abuse is associated with long-term health 
consequences such as greater number of physical symptoms, poor mental health, 
somatisation disorder and high health care utilisation in adults (Arnow, 2004; 
Kamiya et al; 2015; Norman et al 2012; Springer et al., 2007; Stone,2013; Spitzer et 
al., 2008;).   
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A cross-sectional study based on participants identified in a family practice clinic in 
the USA found that women with a history of child sexual abuse reported 
significantly higher somatisation scores based on the somatic symptom scale (SCL-
90) compared to those who had not experienced abuse (Springs and Friedrich, 
1992). McCauley et al. (1997) also found that on average women who had 
experienced abuse as children had more physical symptoms, somatisation, 
depression, anxiety and low self-esteem than those who had not.  In a smaller study 
that included only 28 participants with DSM-IV somatisation disorder, Spitzer et al. 
(2008) identified sexual abuse as the only significant predictor of somatisation 
disorder. These findings must be interpreted with caution due to the small sample 
size. Whilst abuse may be on the extreme end of childhood trauma, other factors 
such as frequent arguments, conflict, emotional distance, poor support and low 
levels of cohesion within families are associated with UPS (Spitzer et al 2008; Brown 
et al 2005).    
 
1.6.5.4 Stressful, negative or traumatic experiences 
Several studies have found an increase in UPS following stressful or traumatic 
events such as psychosocial stress, conflict within families, experience of violence or 
abuse, accidents or large scale events such as natural disasters or war amongst 
adults (Cluaw et al 2003; Dorner et al., 2010; Wahlstrom et al 2013).  
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Dorner et al. (2010) explored factors associated with ten common physical 
symptoms, which included headache, pain, gastric complaints and insomnia in a 
cross-sectional study that used data from a survey of health-check-ups of 312 men 
and 374 women who attended clinics in Austria. They found that psychosocial stress 
was associated with greater numbers of physical symptoms. Discomfort in 
family/partnerships and pressure at work were associated with the number of 
symptoms experienced among males. Amongst females, discomfort in 
family/partnerships was strongly associated with physical symptoms, as well as 
several other factors: sexual dissatisfaction, pressure at work and social stress 
Dorner et al. (2010).   
 
Many studies of abuse and violence focus on female experiences. In a cross-
sectional study of 1931 women recruited from four sites that included community, 
primary care and internal medicine, McCauley et al. (1998) found that the number 
of physical symptoms increased, as severity of violence increased. Physical 
symptoms in the previous six months were measured using the Symptom Checklist 
22 (SCL-22). They found that those who had experienced high levels of violence had 
higher SCL-22 scores than those who experienced low level of violence, who in turn 
had higher scores than those who had experienced no violence.  Low-severity of 
violence was considered having been grabbed or being threatened with physical 
harm, whilst high severity violence referred to physical abuse (such as being hit or 
kicked) or being sexually abused (McCauley et al., 1998).  
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It has also been reported that UPS are common after disasters (Van der Berg et al., 
2005). Several studies were conducted in the Netherlands after a large airplane 
crash in Amsterdam (Yzermans and Gersons, 2002) and an explosion at a firework 
factory, which impacted a whole town (Van Kamp et al., 2006). In a review of UPS 
after disasters, Van der Berg et al. (2005) identified factors such as female gender, 
physical damage (including themselves, loved ones or property) and post-traumatic 
stress symptoms were found to be significant predictors of UPS. However, due to 
the vast heterogeneity of the studies in terms of design, the authors found it was 
difficult to draw definite conclusions (Van den Berg et al., 2005).  
 
Traumatic experiences such as war have been widely explored, mostly under the 
term ‘Gulf-war syndrome’ amongst veterans; high rates of distress and multiple UPS 
have been widely reported (Clawu et al., 2003; Iverson et al., 2007). However, as my 
study is a UK primary care population study, it is likely that the prevalence of those 
with such severe types of trauma and stress will be low. 
 
 Social support 1.6.6
A few studies have explored the role of practical or emotional support from family 
and friends in those with UPS. In a review of guidelines for doctors on managing 
UPS, Edwards et al. (2010) suggests that lack of social support is a predisposing and 
precipitating factor, initiating and maintaining UPS. Blankenstein, (2001) used data 
from two intervention studies in the Netherlands and identified social support as a 
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key factor associated with an increase in subjective health amongst participants 
identified with somatising patients.  Some studies have reported on the role of 
current family relationships and unexplained symptoms qualitatively (see section 
1.10). 
 
I also identified some studies that explored the role of social support in unexplained 
symptoms but focused on functional syndromes specifically e.g. chronic fatigue 
syndrome (Prins et al., 2004; Brown et al., 2010). A Dutch primary care study used 
electronic medical records from 192 patients and found that those with persistent 
UPS reported more social isolation than those with a medical diagnosis or without 
persistent UPS (Dirkzwager and Verhaak, 2007).  
 
 Self-efficacy  1.6.7
A person’s belief in their ability to exercise control over their lives and environment 
is an essential aspect of their ability to cope with difficult or unexpected situations 
(Falvo, 2013). Self-efficacy is regarded as an important factor influencing how 
people respond to trauma and stress as well as, increasingly, how individuals adapt 
to chronic illness (Scholz et al., 2002).  Bandura described self-efficacy to be a fluid 
concept, regulated by external factors as well as personal factors regarding how 
people think (cognition), feel about themselves (affect), motivate themselves 
(motivation) and behave (decision-making) (Bandura, 1997).  
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Despite the potential role of self-efficacy in mediating how people perceive their 
symptoms and respond to them, few studies have explored its role amongst those 
with UPS. Existing studies have focused on samples that have experienced trauma 
(Murphy, 1998; Bödvarsdóttir and Elklit, 2004; Elikit and Christiansen, 2009). 
Murphy (1998) found that lower self-efficacy predicted somatisation amongst 
survivors after a volcanic eruption. Bödvarsdóttir and Elklit (2004) identified low 
self-worth, considered to be a proxy for self-efficacy, as associated with somatic 
symptoms, amongst those who had experienced the traumatic event of an 
earthquake but who had also developed post-traumatic stress disorder. In another 
study of 169 adults who had been affected by an explosion at a firework factory, 
Elikit and Christiansen (2009) found that feeling incompetent, was associated with 
somatization. Self-efficacy may therefore be a potentially valuable variable to 
explore in terms of outcome among primary care attenders with UPS.  
 
 Health service use 1.7
Patients with UPS make up a high proportion of primary care attenders and several 
studies have shown that UPS are associated with increased health care use as well 
as increased health care costs (Bermingham et al., 2010; de Waal et al., 2008; 
Veerhak et al., 2006; McDaid et al.,2011; Zonneveld et al., 2013).  Studies 
consistently show that those with UPS have higher rates of GP contact, compared to 
those with diagnoses (de Waal et al., 2008). For example, in the USA, Barsky et al. 
(2005) found that somatising patients, when compared with non-somatising 
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patients had on average more primary care visits (five vs three) and more specialty 
visits (eight vs five). Similar rates of average attendance (five over a period of one 
year) were identified amongst patients identified with UPS by GPs, at ten practices 
in the UK (Taylor et al., 2012).  
 
Much higher rates of an average of 20 contacts per year, per patient were found 
amongst 227 participants from three general practices in London (Commissioning 
Support for London, 2011). This rate was based on those with very severe somatic 
symptoms; approximately 1% of those registered in the practice.  Patients were 
identified using specific criteria, which included frequent attendance, opiates use 
and high scores on the Nottingham Tool; this study was described in section 1.4.4 
(Commissioning Support for London, 2011).  
 
 The cost of UPS 1.8
Patients with UPS consume healthcare disproportionately in all health care settings 
and incur high costs to health services and the wider economy (Bermingham et al., 
2010). In the UK the ICD-10 category, which includes UPS is considered to be the 
fourth most expensive category in primary care and the most costly diagnostic 
category amongst outpatients (Creed et al., 2011).  Estimates of costs may vary 
depending on how UPS are defined, the study populations included, the costs 
assigned to specific services, as well as the year and country in which the study was 
conducted. 
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Bermingham et al. (2010) estimated cost of UPS to the NHS, for those aged between 
18 and 65 years, at £3 billion between the years 2008-2009; 10% of the annual 
healthcare budget that year. Costs based on GP consultations alone were estimated 
at £837 million. The annual cost to the wider economy as a result of output losses 
from sickness absence and reduced quality of life was estimated to be £14 billion.   
The Commissioning Support for London (2011) report estimated a cost of £307,000 
to primary care for 227 patients with severe medically unexplained symptoms; this 
was a total cost of £2,200 per patient per year, including secondary health care 
costs (Commissioning Support for London, 2011).  
 
Barsky et al. (2005) in a study conducted in the USA estimated that in 2002, at a 
national level, UPS accounted for 16.8% of the annual health care budget (almost 50 
billion that year, in 2002 dollars).  In a more recent study (Zonneveld et al., 2013), 
health care use of patients with UPS in the Netherlands was estimated at €3,123 
(SD = €2,952), which increased to €6,815 per patient per year, when work related 
costs such as work absence and productivity were considered.  
 
Referral rates to secondary care are high contributing to further costs incurred to 
primary care (Nimnuan et al.,2001; Stone et al., 2009; Burton et al.,2012). A case 
study of a patient with UPS and a diagnosis of somatisation disorder, spanning over 
20 years estimated a cost of £209,391 (2003 cost), based on secondary care use 
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alone (i.e outpatient visits, inpatient stays, procedures and investigations) (Kinder et 
al 2004).  
 
  Difficulties for doctors in identifying and managing UPS  1.9
UPS are identified in clinical practice through a process that often involves the 
exclusion of serious physical diseases or potential psychiatric disorders (Rosendal et 
al., 2005). Although tests and investigations may be used to rule out any organic 
disease, a qualitative study with newly qualified doctors reported some ordering 
tests and investigations even when they were certain that no underlying organic 
cause would be found. Reasons for this included: to provide reassurance to the 
patient and for themselves; to avoid difficult consultations; and protect themselves 
against future litigation (Yon et al., 2015).  
 
Some general practitioners have reported feeling pressured by patients to provide 
investigation and intervention (Wileman et al., 2002; Ring et al., 2004). However, 
unnecessary testing, inappropriate treatment or overtreatment may lead to 
iatrogenic consequences (Ring et al., 2004). These can result in a cycle of distress, 
anxiety and fear in patients, and encourage long term illness-behaviours such as 
repeated consulting (Hatcher and Arroll, 2008).  Efforts to normalise symptoms, 
through for example use of negative investigations to reassure patients that 
likelihood of disease was unlikely, resulted in patients intensifying symptom 
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presentations, introducing new symptoms or providing evidence in support of their 
symptoms (Dowrick et al., 2004).  
 
A large survey of 284 general practitioners in the UK found that the majority felt 
that UPS should be managed in primary care and saw their role as gatekeepers to 
prevent inappropriate investigations and provide reassurance to patients (Reid et 
al., 2001). However, half of the respondents felt that clearly effective management 
strategies were lacking. In another large study of 280 physicians in the USA, only 
25% of physicians acknowledged their ability to help patients with UPS as very good 
or excellent; only 14% were very satisfied with their management of these patients 
and many doctors felt frustrated and unsatisfied with these consultations (Hartz et 
al., 2000). Others have also reported finding it difficult to engage in a helpful 
therapeutic relationship with such patients (Stone, 2013).  A review of expert 
opinions in the management of UPS identified such as long-term and trusting 
relationships between the doctor and patient, good communication and 
reassurance as important in effective management of patients in the long term 
(Heijmans et al., 2010). 
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  The impact of UPS on patients from a qualitative 1.10
perspective 
Qualitative studies are invaluable in providing in-depth insight into the lived 
experiences of those with UPS. These studies provide insight into patient 
experiences of accessing health care, their relationship with the doctors, the effort 
to make sense of their symptoms, the search for a diagnosis as well as the impact 
on their day to day lives and interpersonal relationships (Salmon et al., 2004; Ring et 
al., 2005; Nettleton, 2006; Sumathipala et al., 2008; Dwamena et al., 2009;).   
 
The acute period following onset of UPS is reported as one of distress and 
uncertainty (Kornelsen et al., 2016; Nettleton et al., 2005) described by some 
patients as an ‘emotional rollercoaster’ (Kornelsen et al., 2016). Following early 
investigations and negative results, patients are in a state of conflict; in 
juxtaposition between the relief at lack of a serious illness and a continued sense of 
anxiety that no definitive cause has been found (Kornelsen et al., 2016; van 
Bokhoven et al., 2009).  The search for a medical diagnosis is reported as an effort 
to find legitimacy for their symptoms (Charmaz, 1995; Nettleton et al.,2005). 
Patients report feeling that a lack of a diagnosis limits the treatment options 
available (Kornelsen et al., 2016) and the unpredictable illness course and trajectory 
makes it more difficult for them to come to terms with their symptoms (Stone, 
2013).  
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Difficulties have been reported in terms of work and social life. The lack of a clear 
diagnosis and the uncertainty surrounding the trajectory of their symptoms creates 
pressure on work, finances and families (Korlsen et al., 2015; Nettleton et al., 2005). 
Strains on family relationships have been reported where patients who are more 
disabled by their symptoms feel entitled to be relieved from social obligations and 
receive greater support from their family (Dwamena et al., 2009). Such perceived 
unmet needs place a strain on relationships. 
 
Patients feel further strain as they often feel misunderstood, disbelieved or rejected 
by doctors (Dirkzwager and Verhaak, 2007; Epstein et al., 2007). Repeated studies 
report that patients want to be taken seriously (van Bokhoven., 2009) and it is 
important that doctors believe their symptoms are genuine and that they are ‘not 
made to feel like a drug seeker’ (Kornelsen et al., 2016).    
 
 The clinical context of UPS 1.11
UPS are extremely common in primary care (see section 1.7) with considerable cost 
implication (see section 1.8) and management difficulties (see section 1.9). 
Unpublished research (Warner et al., 2013) revealed that many doctors learn to 
manage UPS through daily clinical experience with those consulting with the 
problem and/or by witnessing the clinical care delivered to these people by others, 
rather than through formal teaching or the use of guidance on management of 
people with UPS.  
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National Institute for Clinical Excellence (NICE) has not published any formal 
guidance on the management of UPS. There is, however, a document titled  
‘Guidance for health professionals on medically unexplained symptoms’ developed 
by Chitnis and colleagues (2014) and endorsed by the Royal College of General 
Practitioners (RCGP), Psychiatrists (RC PSYCH), Royal College of Surgeons (RC 
Surgeons), UK Faculty of Public Health (FPH) and Rethink (mental illness charity).  
Developed by practitioners who have considerable expertise in the care of people 
with UPS, it outlines the cost and burden of UPS, potential risk factors, outcomes, 
potential interventions and it provides useful suggestions on consultation 
techniques in dealing with this problem in practice.  Whilst some of the suggestions 
made in this document are likely to have arisen from the authors extensive clinical 
experience, a more careful assessment of the references used in this guideline, 
particularly those relating to the risk factors and outcomes highlights the scarcity of 
evidence on UPS in primary care, especially in the UK.  Many of the studies 
mentioned in this document were conducted on those likely to differ from people 
attending primary care clinics who often present with multiple UPS.  Rather, the 
studies included people with other psychiatric disorders, hypochondriasis, hysteria 
or somatoform disorder and most of the work was conducted on those seen in 
secondary care or living in the community rather than on people seen in primary 
care. These populations could have a very different course of illness, outcomes and 
risk factors. 
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 Summary  1.12
This chapter has highlighted that UPS exist on a continuum, with a wide range of 
symptom severity in patients attending primary care (van Dessel et al., 2014). 
Terminology and diagnostic classification have changed over time, are considered to 
be unreliable by some and are still widely contested, making UPS difficult to 
identify, measure and manage. Methodological differences in studies have led to 
high heterogeneity making comparison difficult.  Nevertheless, exploration of 
existing studies suggests that factors which may be associated with UPS over time 
can include: socio-demographic factors such as gender, age, level of education, 
financial well-being and employment status; the number, severity and length of 
symptoms; comorbid anxiety and depression; physical and mental health 
functioning; childhood experiences such as trauma and abuse; and current life 
experiences such as stress. Other aspects such as availability of social support, self-
efficacy and health service use may also provide insights into the outcomes over 
time amongst those with UPS. In Chapter 2, I present my systematic review; which 
was carried out to identify studies that have explored outcome of those with UPS 
over time and identify prognostic factors associated with these outcome.  
 
Understanding the outcome of patients over time and the factors associated with 
improvement of symptoms, quality of life and other aspects of well-being can 
provide insights into potential ways in patients can be managed and the best course 
of action for individual patients. 
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Systematic review of factors Chapter 2 : 
associated with unexplained physical 
symptoms in primary care 
 
 Chapter overview 2.0
In this chapter, first I discuss the rationale, aims and objectives, and the methods 
used to identify the relevant literature for this systematic review. Second, the 
longitudinal studies that have been identified are described and synthesised with 
reference to the objectives of the review. Following a discussion of the identified 
studies and comparison to other existing literature, the strengths and limitations of 
the review are discussed. In the course of this chapter, when discussing individual 
studies I refer to the terminology originally provided in the studies. A discussion of 
wide range of terminology in this area was provided in section 1.2.  
 
 Introduction 2.1
A literature review was conducted to explore what is already known and to provide 
a rationale for my PhD study by systematically highlighting the knowledge gaps in 
the field and to inform the objectives of the study discussed in Chapter 3. 
Contextual information relevant to both the literature review and the study as a 
whole, with reference to terminology, diagnostic classifications and methods of 
identification were discussed in Chapter 1. Findings from this chapter along with 
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supplementary literature on factors associated with unexplained physical symptoms 
discussed in section 1.6 helped to inform the development of this study in terms of 
outcomes and prognostic variables explored.  
 
 Aim 2.2
The main aim of this literature review is to systematically identify and describe the 
outcomes over time in studies of participants with unexplained physical symptoms 
(UPS) in primary care and to determine which prognostic factors are associated with 
the identified outcomes.  
 
 Objectives 2.2.1
The specific objectives of this review are: 
 
1) To conduct a systematic review of the literature on longitudinal studies of UPS, of 
adults (aged 18 years and above) who present to primary care, to determine 
outcomes in terms of somatic symptoms, quality of life (physical and mental health 
functioning), depression, anxiety and primary health care use. 
 
2) To determine which risk factors are associated with poor outcome within these 
studies identified in objective 1. 
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 Study Criteria   2.3
 Terminology and diagnostic classifications 2.3.1
Conducting a literature review in the area of UPS was challenging due to the 
heterogeneity in terminology, diagnostic criteria and methods used for 
identification of study participants (refer sections 1.2 to 1.4).  
 
I wanted to identify studies that included participants with physical symptoms 
lacking an organic explanation but not necessarily with underlying psychiatric 
morbidity. Many of the studies in the area of UPS have focused on those meeting 
psychiatric diagnostic classifications such as somatoform disorder (see section 1.3). 
But characteristics of those with more severe symptomology and are likely to differ 
and they make up a smaller proportion of those attending primary care (Haller et 
al.,2015). 
 
Therefore, the usefulness of existing studies as applied to primary care populations 
may be limited. Hence, I chose to include studies based on UPS in the broad sense 
as discussed in section 1.2.  Due to the wide heterogeneity and at times imprecise 
use of terms, regardless of the aetiology, I used a variety of terms related to UPS 
(Sumathipala,2005). Key words used are discussed in section 2.4 and shown in 
Appendix 2.0.  I also included populations with somatic symptoms in keeping with 
the changing trends in terminology that were discussed in section 1.2.  
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Although I included somatoform disorders (DSM-IV and onwards), in order to 
reduce the variation in individual studies, I excluded papers published before 1994, 
which was the year in which DSM-IV (APA, 1994) was published (for details on 
diagnostic criteria see section 1.3). I also excluded studies based solely on diagnostic 
classifications conversion disorder, pain, hypochondriasis and body dysmorphic 
disorder, which are found under the umbrella of somatoform disorders. These 
disorders require further specific characteristics to be present in addition to UPS; 
inclusion would result in further heterogeneity of this already very heterogeneous 
body of literature. The key words used in the search are shown in Appendix 2.0. 
 
 Population  2.3.2
I chose to include studies based on adults aged 18 years and above, with UPS, 
identified in primary care. I decided to exclude studies which restricted participants 
to a single symptom localised to one specific area, such as studies based specifically 
on back pain. This is because the course is likely to be different when compared 
those UPS that are not localised to one specific area. I excluded studies based on 
frequent attenders with UPS.  
 
Studies based exclusively on restricted populations such as those with psychiatric, 
psychological or emotional morbidity e.g. unexplained symptoms in people with 
depression only or which focused on severe personality dimensions such as 
alexithymia/neuroticism, were also excluded. Such studies would identify different 
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(potentially more adverse) outcomes compared to those with UPS, who were not 
specifically identified based on their level of psychological morbidity.   
 
Finally, studies based solely on functional syndromes such as irritable bowel 
syndrome were excluded due to the possibility that they may have a different 
aetiology compared to those with multiple UPS across several domains and because 
of the presence of a medical ‘label’ such as irritable bowel syndrome or chronic 
fatigue syndrome may impact the course of the disorder and its symptoms. 
 
 Study design   2.3.3
I included only longitudinal cohort studies as my study focused on outcomes over a 
specified period of time; prospective studies were chosen in keeping with this 
design (Gordis, 2014). Cohort studies tend to be the most appropriate study design 
for exploring outcome over time. Other study designs such as case-control studies 
are retrospective, as the outcome has already been determined when identifying 
participants as cases and controls. Case-control studies are also likely to be prone to 
various sources of bias, including selection, recall and observational bias and may 
be impacted by reverse causality (Gordis, 2014; Sedgwick, 2014). The reasons for 
excluding intervention studies are discussed in the following section.  
 Intervention 2.3.4
I excluded studies based on interventions, as participants who agree to take part in 
a trial are likely to be different to those taking part in other types of studies (such as 
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observational) and therefore are not an externally valid and representative sample 
(Kennedy-Martin et al., 2015). Even if data from the control group or a waiting list 
sample were to be used, it is possible that those who entered/recruited into the 
trial as a control group (without an intervention) may subsequently show an 
improvement in outcomes due to potential placebo effect (Gupta and 
Verman,2013). Therefore, studies based on cohorts with UPS that were originally 
set up for other purposes, such as the delivery of an intervention were excluded.  
 
 Comparison group 2.3.5
In epidemiological studies, comparison groups may be: internal comparison groups, 
which are unexposed members of the same cohort; external comparison groups, 
which are unexposed cohorts with similar characteristics to the cohort of interest; 
or be drawn from the general population, a comparison that is used when only a 
small percentage of the cohort population are expected to be exposed (Gordis, 
2014). As initial literature searches suggested that there were a limited number of 
studies in the area, I decided not to place any restrictions on comparison groups 
included. 
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 Outcome  2.3.6
I decided not to restrict outcomes, as one of the objectives of the review was to 
identify all the outcomes that have been explored in prospective studies of UPS in 
primary care. 
 
 Search strategy 2.4
First, I conducted a quick exploration of the evidence base to identify potentially 
relevant studies in the area. I identified a systematic review by Olde Hartman and 
colleagues, conducted on the course and outcome of somatoform disorders, 
hypochondriasis and medically unexplained symptoms in primary, secondary and 
community settings (Olde Hartman et al., 2009).  This helped inform the search 
strategy for my review but was further refined following discussion with my 
supervisors and with advice from a library specialist, on developing the keywords 
that would be utilised for the search strategy.  Despite the decision not to exclude 
those identified based on the presence of psychological morbidity, as discussed in 
section 2.3, I decided to keep search criteria broad. Therefore keywords used 
included somatoform disorder, psychosomatic medicine, somatisation, non- 
organic, unexplained medical (symptoms, problems, conditions or complaints) (see 
Appendix 2.1). 
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Keywords for primary care identified using the database thesauri included primary 
care, general practice and family physician (see Appendix 2.2). Search terms were 
mapped onto MeSH subject headings where possible, combined using Boolean 
operators ‘OR’ and ‘AND’ and searched for within title and abstracts. Initial 
exploratory searches were carried out in order to refine the search strategy. 
Inclusion of keywords for prognostic and longitudinal studies such as prospective, 
prognostic, outcome, epidemiology, survival, risk, and follow-up were considered 
however these resulted in a considerable reduction in the number of papers 
(Altman, 2001; Wilczynski and Haynes, 2005). For example on MEDLINE this 
resulted in a reduction from 1783 to 380 papers. To minimise the risk of missing any 
potentially eligible studies, which may not have been captured using a more specific 
search strategy, I chose to include only keywords for UPS and primary care to 
increase the sensitivity of the search. 
 
I conducted the final search in December 2012 using electronic databases MEDLINE 
(via Ovid 1946 to December to December 2012); Psychinfo (via Ovid 1806 to 
December2012), EMBASE (via Ovid 1947 to December 2012) and CINAHL (via 
EBSCO, 1982 to December 2012). I limited the search to the English language and 
human studies only. The Cochrane library was searched for any relevant reviews 
and the British Library database was searched for any relevant dissertations or 
theses. In addition, reference lists of key papers and texts as well as included papers 
were screened for further relevant records.  
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 Study Selection 2.5
Studies identified from the search were screened through a two-stage process, 
which are discussed below. 
 Titles, abstracts and full text screening 2.5.1
2.5.1.1 Stage 1:  
First, I went through the database and removed papers judged to be definitely 
irrelevant; either not meeting the inclusion criteria for this review in terms of 
subject matter (for example studies that were based on functional syndromes) or 
study design (for example biomedical research) by referring to the title and when 
necessary, viewing the abstract to confirm irrelevance. 
 
2.5.1.2 Stage 2: 
At the second stage, I excluded studies that were not 1) longitudinal in design, 2) 
based in primary care or 3) on adult populations with UPS by once gain referring to 
the title and abstract and when necessary the full text.  An independent assessor 
repeated this screening process. A cautious and inclusive approach was taken to 
resolve any discrepancy and where there was any disagreement, the paper was 
included in the next stage (see section 2.5), along with potentially eligible articles.  
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 Data extraction and quality assessment 2.6
Data was extracted from papers considered to be potentially relevant to the review, 
using a data extraction sheet that was developed taking into account section A of 
the Critical Appraisal Skills Programme checklist for cohort studies (CASP,2013) and 
reference sources for the evaluation of quality of prognostic studies (Hayden and 
Bombardier, 2006).  Type of data extracted included details on: the population of 
the study; outcomes measured; how the cohort was recruited; measurement of and 
controlling for confounding variables; and terminology and diagnostic criteria used. 
Irwin Nazareth (IN), the primary supervisor, and I went through the study 
summaries that I had prepared with consideration to the specific inclusion and 
exclusion criteria discussed in section 2.3. When necessary IN and I went back to the 
full text and consulted the rest of the study team (two supervisors with experience 
in general practice and epidemiology and one in statistics). The quality of eligible 
papers was critically appraised by adapting the STROBE statement for cohort 
studies (Von Elm et al., 2008). The full checklists with results are shown in Table 2.2 
and included aspects of the research question, sample size and study design. To 
ensure a high-level of reliability, two independent reviewers carried out quality 
assessment.  The authors of the included studies were contacted for further 
information to clarify on the methods and findings of the studies. 
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 Data synthesis 2.7
Meta-analysis is considered to be the highest standard for combining data from a 
number of sufficiently similar studies (Gordis, 2014). However, when I first 
conducted a scoping search to familiarise myself with the published literature, it 
was evident that there were limited numbers of studies relating to the focus of my 
review and that amongst these, there was substantial heterogeneity particularly in 
terms of the how the populations had been identified.  Therefore it was anticipated 
that the literature would be synthesised narratively. This decision was confirmed 
when only two studies were identified as meeting the eligibility criteria. The Centre 
for Review and Dissemination (CRD, 2009) suggest that when conducting narrative 
synthesis the descriptive process should be rigorous. In the following sections I 
describe the studies in detail with reference to the objectives of this review. 
 
 Results   2.8
 Identification of studies 2.8.1
In total 5,663 papers were identified from the database searches that included: 
1,783 papers identified using MEDLINE, 2,236 using EMBASE, 443 using CINAH and 
1,201 using PsychInfo. After the first stage of screening, described in section 2.5.1.1, 
3,524 papers remained.  Following the second stage described in section 2.5.1.2, 
data was extracted from the full text of 29 potentially eligible studies, as described 
in section 2.6, and summarised.  For some studies, there were multiple reasons for 
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exclusion (see figure 2.1 and Appendix 2.3). Finally, two studies were identified that 
met the inclusion criteria for the review. Most papers (n=27) were excluded 
because they were based on UPS amongst primary care attenders with 
psychological or emotional morbidity or included cohorts that had been established 
for the another purpose (i.e. testing an intervention) and were therefore based on a 
different populations to that which I was interested in for the purpose of this 
review. The PRISMA diagram in Figure 2.1 shows the study selection process and 
papers that were excluded and the reasons for their exclusion. 
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Figure 2.1 PRISMA diagram showing study identification and selection process 
 
* For some papers, there were multiple reasons for exclusion 
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 Characteristics of the included studies  2.8.2
Two studies were identified for inclusion in the final review. One study was 
conducted in the UK, by Creed and colleagues (Creed et al., 2012) and the other 
conducted in Germany by Steinbrecher and Hiller, (2011). The two studies were 
very different in terms of the way in which participants were defined, method of 
recruitment and how the analyses were conducted.  
 
 The study by Creed et al. (2012) was based on participants identified from general 
practice lists and based on somatic symptom count, including those with explained 
and unexplained symptoms. The study by Steinbrecher and Hiller, (2011) was based 
on primary care attenders who met DSM-IV diagnostic criteria for somatoform 
disorders as well as a group with medically unexplained symptoms. It is not very 
clear who is included in the latter group. Efforts to contact the authors were 
unanswered.  But by referring to another paper based on the same study 
(Steinbrecher et al., 2011), it appeared that this group included those with >1 
medically unexplained symptom who did not meet the criteria for somatoform 
disorder at follow-up, although this is not explicitly stated in the paper 
(Steinbrecher et al., 2011).  Both studies included one year follow-up and details of 
the studies are provided in Tables 2.1; the variables collected and questionnaires 
used in the study are detailed in Table 2.6. 
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2.8.2.1 Creed et al. (2012) 
Creed et al. (2012) identified the study cohort from a sample of 2,985 general 
practice patients, aged between 25-65 years. The authors reported that they were 
unable to contact some people who were identified at the start of the study, due to 
incorrect addresses or death (n=495). Of the 1,999 who returned questionnaires, 
they excluded close to a quarter of returned questionnaires due to missing 
information (n=553). Baseline data were therefore only available for 1,443/2,490 
(58%); non-responders were reported to be more likely to be male and younger in 
age.   
 
Postal questionnaires included the Somatic Symptom Inventory (SSI), a similar 
measure to the PHQ-15 (see section 4.9.1 for details on PHQ-15), to determine 
symptom severity at baseline and follow-up. The SSI is based on 13 somatic 
symptoms: muscle soreness, fatigue and weariness, pain in the lower back, fullness 
in head, hot or cold spells, pain in the abdomen, muscles twitching, trouble with 
vision, ringing or buzzing in ears, faintness or dizziness, constipation, breathing 
difficulty, nausea or vomiting. Unlike the PHQ-15, it excludes gender exclusive 
symptoms such menstrual problems. Symptoms are rated on a scale ranging from 1 
(not at all) to 5 (a great deal) over the previous six months and scores can range 
from 13-65. At one year follow-up the authors reported that questionnaires were 
returned by 741 out of the 1443 (51%) people who responded at baseline. 
Responders and non-responders were described as similar in terms of their baseline 
somatic symptom severity (Creed et al., 2012). Further details of the study are 
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provided in Table 2.1. The findings of this study in relation to the objectives of this 
review are discussed in section 2.9. 
 
2.8.2.2 Steinbrecher and Hiller (2011)  
Steinbrecher and Hiller (2011) used the Patient Health Questionnaire, somatic 
symptom module (PHQ-15) (see 4.9.1 for details on PHQ-15) to screen consecutive 
general practice attenders for somatic symptom severity.  Those with more than 
two questions missing, under the age of 18 years, with language problems (non-
German speakers or other difficulties) or psychotic disorders were excluded. 
Although a stated aim of the study was to identify a high risk group, the paper 
reported that 312/620 (50%) of those who were screened at the first stage were 
consecutively selected and invited for the next stage of the study. I contacted the 
authors to clarify how this high-risk group was identified using a consecutive 
sampling method but I received no response.   
 
I was able to obtain some clarity on the sampling method by referring to another 
paper based on the same study, in which Steinbrecher and Hiller (2011) highlighted 
that the authors had aimed to recruit at least 80% of the ‘high scorers’. Therefore, it 
appeared that patients within each of the severity groups (i.e. PHQ-15 0-4; 5-9; 10-
14; 15>) were consecutively selected and those within the high severity group were 
oversampled, rather than a consecutive selection process amongst all those who 
were screened (n=620). The sample included 79% of those who scored PHQ-15 >15 
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and 27% of those who scored PHQ-15 0-4; this would explain to some extent the 
larger proportions of high scorers were recruited using the quoted consecutive 
recruitment method. This is however an assumption and no details of a stratified 
sampling method are given in the paper (Steinbrecher and Hiller, 2011).  
 
Of those who were screened, 308/312 (99%) completed a baseline diagnostic 
interview; it included questions based on the modified version of the somatoform 
disorder module from the Composite International Diagnostic Interview. In 
addition, symptoms that were identified during the interview were assessed by the 
GP as medically unexplained, mixed or explained. The authors reported there were 
no significant differences between those who were recruited for diagnostic 
interviews and those who were not; in terms of age, education and household 
composition, although a greater number of females took part and the sample 
included greater numbers with higher PHQ-15 scorers. I discuss the findings of this 
study in further detail, with reference to the objectives of this review in section 2.9. 
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Table 2.1 Study characteristics of the papers included in the review 
First author, 
year, country  
Creed et al., 2012 Steinbrecher and Hiller, 2011 
Type of study Prospective population-based 
cohort study of primary care 
patients 
 
Prospective cohort study 
Country England 
 
Germany 
Aims   To determine the risk factors 
for high total somatic symptoms  
 
 To determine whether high 
baseline total somatic symptom 
count predicts poor health status 
one year  
 
 
 
 
 
 To compare different courses 
of SFD (remission, persistence, 
incidence) to each other in 
reference to psychosocial 
impairment, cognitive illness 
representation and attribution 
style. 
 
 To identify significant 
predictors for the course of 
somatoform disorder and 
medically unexplained 
symptoms 
Terminology 
used 
Somatic symptoms Somatoform disorders, 
Medically Unexplained 
Symptoms 
 
Method of 
identification  
Somatic symptom inventory   PHQ-15 
 Diagnostic interview 
 GP confirmation of explained or 
unexplained nature of symptoms  
 
Sampling Simple random sampling Consecutive attending patients 
 
Setting Two general practices in North 
West England (one rural and one 
inner-city area) 
Two primary care practices in 
Muniz Germany 
 
 
Initial 
sample/screened 
 2985 questionnaires posted 
 495/2985 wrong address or 
dead 
 1999/2985 returned 
questionnaires 
 553/1999 returned 
questionnaire were not useable 
 1443/1999 returned 
questionnaires were included at 
baseline  
 Consecutive sampling 
identified n=648 
 4.3% excluded or dropped out 
 312/620 invited for interview 
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Baseline sample 
characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sample size: 1443  
 Mean age of responders 
(N=1443): 47 years  
 
Other data provided only for 
those who completed both 
baseline and follow-up N=741 
 
 Female: 432/741 (58%)  
 Mean age: 49 years 
  < 12 years education: 207/741 
(28%)  
 Two or more current illnesses: 
59/741 (8%)  
 Sample size n=308 
 Females: 220/308 (71%)  
 Mean age: 46 years (SD 16)   
 <12 years education:  
 125/308 (49%)  
 Mean PHQ-15 score 9.8 (SD 
5.1) 
 Mean number of MUS:  
Females=3.8 (SD 4.1)/ Males=2.8 
(SD 4.4)  
 Mean number of MES: 
Females 1.6 (1.7) /Males 1.8 
(2.1) 
 Mean number of mixed 
symptoms: Females 4.2 (3.6)/ 
Males 2.3 (3) 
  
Follow-up sample 
characteristics  
 
Sample size N=741  
 
Sample size N=277 
Mean age: 47.7 years (SD 16.4) 
Response rate  1443/2490 (58%) returned 
usable baseline questionnaires  
 
 741/1443 (51%) returned 
follow-up questionnaires 
 648 patients screened 
consecutively (does not report 
total sample approached) 
 308/312 (99%) completed 
diagnostic interview and a set of 
questionnaires 
 277/308 (90%) had follow-up 
data 
Length of follow-
up 
One year One year 
 
 
 Quality of the studies  2.8.3
Both studies were judged to be of moderate or poor quality. The study by Creed et 
al. (2012) met acceptable standards of reporting in 17/21 areas considered in the 
quality assessment tool and was judged as moderate in quality. The second study, 
by Steinbrecher and Hiller (2011), met acceptable levels of reporting on only 14/21 
of the areas in the quality assessment tool and was judged to be of poor quality. 
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There were issues on key aspects such as a lack of a sample size calculation, a small 
sample size and too many variables included in the prognostic models. Details of 
the assessment of the studies are shown in table 2.2. However, due to the limited 
numbers of relevant studies, neither was excluded from the review based on the 
quality. 
 
 
Table 2.2 Quality checklist of the studies included in the review, developed using 
the CASP tool (CASP, 2013) and references sources for evaluation of prognostic 
studies (Hayden et al., 2006). 
 Creed et al., 2012 
 
Steinbrecher and Hiller, 
2011 
1. Research question defined? Yes Yes 
2. a) Sample size calculated? 
   b) Sample size adequate? 
Yes 
Yes 
Not calculated 
No 
3. Study design adequate? Yes Yes 
4. Source population clearly 
described 
Yes Yes 
5. Symptom duration at 
inception taken to account? 
No No (reported but unclear if 
used in modelling) 
6. Is the study population 
representative? (Did a 
reasonable number from those 
eligible take part in the study or 
were those who took part in the 
study similar in characteristics 
to those who did not take part 
in the study?) 
No: Those sent 
questionnaires were 
assumed to be 
representative of GP list 
populations. Baseline: 
non-responder were more 
likely to be young and 
male. Follow-up: 
responders, older and 
more likely to be married. 
No: More educated than 
the general population 
and more females. 
Oversampled for those 
with higher symptom 
severity on PHQ-15 
 
7. Completeness of follow-up 
described (Are those lost 
follow-up significantly different 
from those who took part in the 
Yes (as above) No 
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whole study?) 
8. Completeness of follow-up 
adequate-Response rates is 
>70%? 
No Yes 
9. Prognostic factors/ risk 
factors well defined? 
Yes Yes 
10. Prognostic factors 
measured appropriately 
Yes Yes 
11. a) Outcome defined  
      b) Is the outcome 
appropriateness  
Yes 
Yes 
Yes 
Yes 
12. Confounders defined and 
measured 
Yes Yes 
13. Confounding accounted for 
by appropriate methods? 
Yes Yes 
14. Analysis described Yes Yes 
15. Analysis appropriate Yes No (too many variables 
included in the models) 
16. Analysis provides sufficient 
presentation of data 
Partly Yes 
17. External validation of 
results -are the study findings 
generalisable? 
No No 
18. a) Follow-up length 
described? 
      b) Is the follow-up length 
appropriate? 
Yes 
Yes 
Yes 
Yes 
21. General internal validity- Is 
there risk of bias within the 
study? 
Unsure Unsure 
22. Evidence supporting 
conclusions 
Yes No 
Number of areas meeting 
acceptable standards and 
overall quality 
17/21- Moderate 14/ 21-Poor 
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 Outcomes of UPS  2.8.4
2.8.4.1 Symptom related outcomes 
As described in section 2.2, the aim of this study was firstly, to describe the 
outcomes identified in eligible studies. Both studies identified primarily explored 
outcomes relating to symptoms, although these were defined and measured in 
different ways. Creed et al (2012) referred to somatic symptoms, using the Somatic 
Symptom Inventory (SSI) which was described in section 2.8.2.1. The SSI scores 
were divided into categories: <25, 26-30 and >31. High scorers were considered to 
be those who scored >26. The percentages of participants who scored <25 and >26 
on the SSI were similar at baseline and one year follow-up and are shown in Table 
2.3. Data related to change in somatic symptom severity over time, from baseline to 
follow-up were not provided in the paper, although 104/741 (14%) were reported 
to have high scores >26 at both baseline and follow-up. The authors were contacted 
and provided mean SSI scores for baseline and follow-up. These showed only minor 
changes in the overall mean SSI scores over time (21.35, SD 6.56 and 20.99, SD 6.56 
respectively).  I was unable to obtain data on the change in symptom severity score 
of participants from baseline to follow-up; for example, number of participants who 
scored >26 at baseline and experienced a reduction in symptoms from baseline to 
follow-up. Creed et al. (2012) also did not report on the percentage of those with 
unexplained or mixed symptoms, which may have been useful for cross comparison 
with existing studies on UPS. Further details on outcome are reported in Table 2.3. 
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Table 2.3 Creed et al. (2012): proportion of participants with severity scores <26 
vs. ≥ 26 (using the SSI scores), at baseline and at follow-up 
Severity scores (somatic 
symptom Inventory) 
Baseline N= 1443  
n/ N (%) 
Follow-up N=741  
n/N (%) 
<25 (low severity) 1139/1443 (79%) 588/741 (79%)   
>26 (high severity) 304/1443 (21%) 153/741 (20%) 
 
 
Steinbrecher and Hiller (2011) focused on changes in somatoform disorder in terms 
of persistence (no change in symptoms), new (increase in number of symptoms), 
and remission (reduction of symptoms) at follow-up. The Diagnostic Interview (a 
modified version of the Composite International Diagnostic Interview), International 
Diagnostic Checklist (to enquire about current and previous psychological disorders 
and to evaluate and operationalise the DSM-IV individual mental disorders) and GP 
diagnoses were used to determine whether symptoms were medically unexplained, 
explained or mixed and to obtain somatoform disorder diagnoses. 
 
Steinbrecher and Hiller (2011) reported findings only for those who took part in 
both the baseline and follow-up (n=277). At baseline, 84/277 (30%) screened met 
the criteria for DSM-IV somatoform disorder. This included 39 with undifferentiated 
somatoform disorder (any one or more symptoms that result in very strong 
impairment) and 43 who met the criteria for somatoform pain disorder (>1 impact 
of the symptom pain, is greater than that of any other symptoms, present for 
twelve months or more). At follow-up, 43/84 (51%) who met the criteria for 
somatoform disorder at baseline were identified with persistent somatoform 
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disorder, 41/84 (49%) had remitted somatoform disorder. In addition, 13/277 (5%) 
met the criteria for a new somatoform disorder (see Table 2.4) 
 
Table 2.4 Symptom related outcomes explored in the included studies 
 Creed et al., 2012 Steinbrecher and Hiller, 2011 
Outcomes 
 
 
 
 
 
 
 
High somatic symptoms 
 153/741 (21%)scored >26 on 
SSI at follow-up 
 Persistent high symptoms- 
104/741 (14%) scored >26 at 
baseline and follow-up 
 
Course of somatoform 
disorder  (SFD) 
 Persistent - 43/84 (51%) 
 Remission – 41/84 (49%) 
 New somatoform disorder 
at follow-up (n=13) 
Recovery rate Recovery rate was not 
reported clearly; in discussion 
section it suggests that two-
thirds of those with high 
scores had ‘numerous’ 
symptoms 1 year later 
Remitted in n=41/84 (49%) 
with somatoform disorders 
 
2.8.4.2 Quality of life/ self-reported health status 
As discussed in section 1.6.4, a number of different terms are used to refer to 
quality of life.  Most studies use variations of the Medical Outcome Survey Short 
Form Questionnaire (Ware and Sherbourne, 1992). Creed et al., (2012) explored 
quality of life as a secondary outcome, referred to in the paper as impaired health 
status, using the 12- item Medical Outcome Survey Short Form Questionnaire (SF-
12) (Ware et al 1996). The SF-12 has 8 health domains which include: physical 
functioning, bodily pain, general health, vitality, social functioning and emotional 
and mental health. The scoring algorithm generates aggregated physical and mental 
health component summary scores, weighted against general population norms; 
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scores range from 0 (the lowest level of health) to 100 (the highest level of health). 
In addition, Creed et al. (2012) used the EuroQol thermometer (Williams, 1990) to 
determine self-reported health on the day, and includes questions on mobility, self-
care, usual activities, pain/discomfort and anxiety/depression. The EuroQol 
generates an overall score ranging from 0 (worst imaginable) to 100 (best 
imaginable).  
 
Findings of SF-12 and EuroQol thermometer scores at baseline and follow-up are 
shown in Table 2.5.  Creed et al., (2012) found that mean physical functioning 
scores decreased amongst all severity groups; the greatest decrease at one year  
follow-up amongst those who had the highest baseline SSI scores (>31) (mean at 
baseline = 40.0, SD 12 vs. mean at follow-up = 38.7, SD 12.8) . Mean mental health 
functioning scores decreased slightly from baseline to follow-up, amongst those 
who scored 26-30 (mean at baseline= 45.5, SD 10.6 vs mean at follow-up= 44.5, SD 
10.8) and >31 (mean at baseline=36.3, SD 11.8 vs mean at follow-up= 35.4, SD 12.1). 
Those who scored <25 at baseline showed a slight increase in mental health 
functioning at follow-up (mean at baseline= 49.9, SD 9.4 vs mean at follow-up= 50.9 
SD 9.2). This suggests that the most severely affected had worse mental health at 
follow-up, whereas those less severely affected tended show some small 
improvement. The EuroQol thermometer also showed a decrease in functioning 
amongst the two high severity groups; this was largest amongst those who had 
scores >31 (mean baseline score 60.2, SD 21.9 vs mean follow-up score 55.7, SD 
22.4).  
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Table 2.5 Change in mean physical and mental health functioning scores and 
EuroQol from baseline to 12 month follow-up. 
Instrument used Baseline 
Mean (SD) 
Follow-up 
Mean (SD) 
 SSI <25 SSI 26-30 SSI >31 SSI <25 SSI 26-30 SSI >31 
Physical health 
functioning (SF-12) 
52.1(7.8) 44.6 
(9.7) 
40 (12) 51. 9 
(7.5) 
44.1 
(10.8) 
38.7 
(12.8) 
Mental health 
functioning (SF-12) 
49.9 
(9.4) 
45.5 
(10.6) 
36.3 
(11.8) 
50.9 
(9.2) 
44.5 
(10.8) 
35.4 
(12.1) 
EuroQol 
thermometer 
82.9 
(13.1) 
73.7 
(16.1) 
60.2 
(21.9) 
83.2 
(13.4) 
71.1 
(17.2) 
55.7 
(22.4) 
 
 
 Prognostic factors associated with outcomes identified from 2.8.5
the included studies 
2.8.5.1 High somatic symptoms scores, medically unexplained symptoms and 
somatoform disorders diagnostic 
 
Overall, both studies collected data on similar baseline variables and explored their 
associations with the outcomes including: sociodemographic factors; symptoms at 
baseline; psychological factors (such as depression and anxiety); quality of life/ 
health functioning; personality dimensions; and current experiences (see Table 2.6 
for questionnaires that were used). However, they also explored a number of 
variables which were unique to their own study including social support and health 
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service contact (Creed et al.,2012) and childhood experiences (Steinbrecher and 
Hiller,2011). 
 
Table 2.6 Baseline variables collected and standardised measures used in the two 
included studies 
Baseline variables collected and standardised measures used 
 Creed et al., (2012) Steinbrecher and Hiller, 2011 
Socio-demographic 
characteristics   
 Age, gender, marital status, 
years of education, 
employment 
 Age, gender, marital status, 
education (<12 or >12 years) 
Somatic symptoms  Somatic symptom count- 
Somatic symptom inventory 
 Number of chronic 
diseases/somatic symptoms- -
Composite International 
Diagnostic Interview 
 No of MUS -GP assessment 
 Somatization -Brief Symptom 
Inventory 
Psychological 
functioning 
 Anxiety and depression – 
Hospital anxiety and 
depression score 
 
 Depression, Anxiety, Hostility,      
Phobic anxiety, Paranoid 
ideation, Psychoticism, Global 
severity, Obsessive-compulsive, 
Interpersonal sensitivity - 
Brief Symptom Inventory 
Functioning  Physical and mental health 
functioning -SF-12 and 
EuroQoL 
 Functional disability due to 
health condition - WHO-
Disability-Assessment-Schedule 
II 
Social support Presence of a close confidant X 
Personality   Personality traits of 
neuroticism and other 
correlates -The Revised NEO 
Personality Inventory 
 
 Cognitive and emotional 
representations of illness and 
illness comprehension-The Brief 
Illness Perception 
Questionnaire- (Causal 
attributional styles: 
vulnerability, psychological 
factors, somatic disease, 
distress) 
 
 Dysfunctional cognitive 
characteristics associated with 
somatisation and 
hypochondriasis –Cognitive 
Characteristics Associated 
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Cognitions About Body in 
Health Questionnaire: 
Catastrophizing cognitions; 
Autonomic sensations; Bodily 
weakness; Intolerance of bodily 
complaints; Health habits 
 
 Hypochondriasis -Whitley Index 
Childhood 
experiences 
 Physical or sexual abuse <16 
years age -The Child Physical 
and Sexual Abuse 
questionnaire  
 
 Perceived maternal care and 
support-The Parental Bonding 
Instrument 
X 
Current 
experiences 
 Stressful/Negative 
experiences List of 
Threatening Life Experiences 
 Stressful/Negative experiences 
List of Threatening Life 
Experiences 
Health service 
contacts 
x 
 
 Number of GP consultations in 
previous twelve months 
 No of psychotherapeutic 
sessions 
 
Creed et al. (2012) conducted multiple regression analyses to explore the 
association between baseline variables and somatic symptom score (high somatic 
symptoms >26 vs <25). Due to the small sample size in the higher SSI groups, those 
scoring SSI >26-30 and >31 were grouped together into a single category (n=104). 
All models were adjusted for gender, anxiety, depression and recent injury or illness 
and each additional variable from those listed in Table 2.6 was, in turn, added to the 
model one at a time. Baseline factors which were significantly associated with high 
SSI scores (>26) included being separated, widowed or divorced (OR= 2.84, 95% CI 
1.37 to 5.88), having less than 12 years of education (OR= 3.34, 95% CI 1.82 to 6.12), 
no close confidante (OR= 2.56, 95% CI 1.11 to 5.94), being off work due to illness or 
injury (OR=4.43 95% CI 2.20 to 8.89) and recent serious illness or injury (OR= 2.40, 
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95% CI 1.04 to 5.56) adjusted for gender, anxiety and depression, and recent serious 
illness.  
 
High SSI scores were also significantly associated with: older age (mean 49.8, SD 
11.1); neuroticism (mean 26.9. SD 8.4); anxiety (mean 9.9, SD 3.9); depression 
(mean 7.6, SD 4.4); and impaired health status on the SF-12 physical component 
score (mean 40.0, SD 12.0) and the EuroQol (mean 60.2, SD 21.9). Odds ratios for 
these associations were not provided by the authors (Creed et al., 2012).  
 
Steinbrecher and Hiller (2011) used ANCOVA to compare baseline psychological 
characteristics between the different somatoform disorders groups (persistent 
n=43, new n=13, remitted=41) at follow-up and two additional groups ‘other mental 
disorder at baseline’ (n=27) and ‘no mental disorder at baseline’ (n=153) and 
conducted post-hoc pairwise comparisons across group to identify where the 
significant effects occurred. This process alongside theoretical considerations 
informed the variables included in the multiple regression analysis to identify 
predictors of somatoform disorders and medically unexplained symptoms at follow-
up.  However, due to the multiple pairwise comparisons, it is likely that some 
significant findings were due to chance. Furthermore, the sample size is too small to 
robustly test so many variables in the models; hence the findings of this study need 
to be interpreted with caution. The more variables one wants to include in the 
model, the larger the sample size is required. Additionally, although it is described 
as a prognostic model, they did not check the fit of the model or check for validity. 
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Steinbrecher and Hiller, (2011) conducted prediction model for two groups; those 
identified as having medically unexplained symptoms (n=220) and those who are 
reported as those with somatoform disorders (n=65). It is not clear why there is a 
reduction in numbers included in the prognostic models from the total of 277 in the 
study. 
 
 They included 25 independent variables, which included all the variables shown in 
Table 2.6 and individual components of some of the questionnaires used. These 
were: gender, education, age, number of chronic somatic diseases,   
number of mental disorders, number of routine psychotherapeutic sessions, current 
depression disorder, current anxiety disorder, negative life events, total number of 
symptoms, number of medically unexplained symptoms, illness perception, causal 
attribution: vulnerability, causal attribution: psychological factors, causal 
attribution: somatic disease, causal attribution: distress, catastrophising cognitions, 
autonomic sensation, bodily weakness, intolerance of bodily complaints, health 
habits, illness anxiety, functional disability, psychosocial impairment and number of 
GP consultations.  
 
Baseline depression was significantly associated with a decrease in the likelihood of 
persistence of medically unexplained symptoms at follow-up (OR=0.12, 95% CI 0.01 
to 0.85). Other factors associated with a reduced likelihood of medically 
unexplained symptoms at follow-up included number of medically unexplained 
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symptoms at baseline (OR=0.77, 95% CI 0.70 to 0.80), illness perceptions (OR= 0.97,  
95% CI 0.94 to 0.99), casual attribution style: distress (OR=0.90, 95% CI 0.82 to 0.98) 
and catastrophising cognitions (OR=0.91, 95% CI 0.84 to 0.99). Negative life events 
(OR=1.30, 95% CI 1.00 to 1.60), causal attribution style: vulnerability (OR=1.10, 95% 
CI 1.0 to 1.20) and somatic disease (OR= 1.10, 95% CI 1.00 to 1.20) were predictive 
of persistence of medically unexplained symptoms at follow-up, although for many 
of the variables significance was borderline, as indicated by the confidence 
intervals.  
 
With regard to the prediction of somatoform disorder at follow-up, again all 25 
variables that were included in the medically unexplained symptom model were 
included. Current depressive disorder (OR=0.001, 95% CI 0.00 to 0.72), causal 
attribution style: vulnerability (OR=0.64, 95% CI 0.42 to 0.97) and functional 
disability (OR=0.72, 95% CI 0.54 to 0.97) all appeared to be significantly protective, 
reducing the likelihood of somatoform disorder persistence. On the other hand, 
odds of persistence of somatoform disorder increased by three times for each 
negative life event (OR=3.20, 95% CI 1.10 to 9.60) experienced at baseline. The 
model for MUS was reported to correctly predict 75% of cases for medically 
unexplained symptoms and that for somatoform disorder 81% of cases.  
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2.8.5.2 Quality of life/ self-reported health status 
Creed et al. (2012) also explored the association between baseline high somatic 
scores and health status at the end of the 12 month follow-up using ANOVA with 
SF-12 and EQ-5D as dependent variables.  The authors described that the baseline 
high somatic symptoms score was highly significantly associated with a worse 
physical health functioning but not with mental health functioning (based on the SF-
12) and worse overall health (based on the EQ-5D). However, no effect sizes were 
provided in the paper. 
 
 Discussion  2.9
This systematic review highlights the paucity of prospective cohort studies exploring 
course and outcome of UPS in primary care. Only two papers that met the inclusion 
criteria were identified. Following quality assessment by two independent 
reviewers, it was determined that that the study by Creed et al. (2012) was of 
moderate quality and that by Steinbrecher and Hiller (2011) was of poor quality. 
This was largely due to flaws in the study design and analyses. The substantial 
heterogeneity of the two studies meant they were difficult to compare as it would 
not be appropriate to combine their findings.  
 
In the following section, I discuss the two studies included with respect to 
objectives of my systematic review. I compare the findings with some studies that 
did not meet the specific inclusion and exclusion criteria for my review (see section 
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2.3); reasons for exclusion are also highlighted in Figure 2.1 and summarised in 
Appendix 2.3. These included, the cohort being recruited as a part of an 
intervention, inclusion of those who specifically have psychological or emotional 
distress (for example somatised mental disorders), participants not identified from 
primary care or other reasons such as inclusion of a very specific study cohort. 
These studies provide some insight into rates of symptom remission and 
persistence amongst those identified with UPS in primary care, as well as potential 
prognostic factors that may be significantly associated, despite the differences 
study designs and specific populations that are included.  
 
 Outcomes of UPS in the included studies and comparison to 2.9.1
studies excluded from the review 
 
In the study by Creed et al. (2012) there is limited information on the outcome of 
participants over time. The percentages that met the criteria for low and high 
severity were similar, at both baseline and follow-up however, information on 
change in severity from baseline to follow-up was limited. For instance, they 
reported that 14% had high severity (SSI >26) at both baseline and follow-up. It may 
be possible that some with high scores at baseline moved to the lower score group 
(i.e. an improvement). Equally it is not possible to determine the percentage of low 
scores at baseline went on to experience an increase in symptoms at follow-up. 
Only slight changes in physical and mental health functioning, as well as on overall 
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quality of life based was observed; those with higher scores on the SSI showed a 
decrease in functioning at follow-up. Steinbrecher and Hiller, (2011) provide more 
information in terms of symptom related outcome. At follow-up 51% met the 
criteria for persistent somatoform disorder and 49% had remitted somatoform 
disorder. 
 
Rates identified by Steinbrecher and Hiller (2011) are similar to two studies of 
medically unexplained symptoms in primary care, identified by Olde Hartman et al. 
(2009) in a review of the course and prognosis of somatoform disorders, 
hypochondriasis and unexplained symptoms. These two studies did not meet the 
inclusion criteria for my review as they included different populations to that of 
interest to my study (De Gutch et al., 2004; Gureje and Simon, 1999). De Gutch et 
al. (2004) reported that 169/318 (53%) experienced a decrease in their number of 
symptoms, whilst 107/318 (34%) had an increase and 31/318 (10%) remained the 
same at six month follow-up (De Gutch et al., 2004).2 Gureje and Simon, (1999) 
found 522/1071 of study completers continued to meet the criteria for current 
abridged somatistion at one year; a weighted estimate of 45.9%.3  Another study 
primary care study that did not meet the inclusion criteria (but was also not 
included in the review by Olde Hartman et al.,2009), found lower rates of resolution 
                                                     
2
 This study of primary care attenders in Netherlands identified those with medically unexplained 
symptoms and personality dimensions such as neuroticism and alexithymia using a self-reported 
questionnaire with DSM-IIIR/DSM-IV somatisation headings, physical examination by their physician, 
patient’s medical record and/or the results of additional diagnostic testing.  
3
 This study used data from 15 sites in 14 countries; only 20% of those included in the study met the 
criteria for abridged somatisation disorders at baseline but the sample also included those with 
depression and anxiety disorders. At the screening stage this study oversampled for those with 
higher psychological distress using the General Health Questionnaire. 
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of symptoms.4 At three month follow-up 37% of the cohort reported complete 
symptom resolution; 43% felt better, 12% were unchanged, and 8% were worse. 
When this cohort was studied using the criterion of multi-somatoform disorder, 
that is three unexplained symptoms which had been present for a period of two 
years, 56% (23/41) reported symptom improvement at three month follow-up 
(Jackson and Kroenke, 2008). 
 
 Prognostic factors associated with outcomes identified from 2.9.2
the included studies and compared to studies excluded from 
the review 
 
With regard to the second objective of this review, Creed et al. (2012) identified 
factors such as marital status, absence of a close confidant, being off work due to an 
illness or injury, recent serious illness or injury, older age, lower physical health 
functioning, lower self-perceived quality of life, anxiety, depression and childhood 
psychological abuse were associated with higher somatic symptoms at one year 
follow-up. These factors are consistent with what has been reported in other 
studies of UPS (see section 1.6) and that were excluded from my review for reasons 
highlighted in Figure 2.1. These studies also identified many of the similar factors as 
associated with poor outcomes relating to symptoms (see Appendix 2.4. for 
                                                     
4
 This study was carried out based on a cohort initially set up several years before for an educational 
trial of doctors; all consecutive attenders were eligible for participation. Symptom severity was 
measured using the PHQ-15 (Jackson & Passamonti, 2005).  
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individual prognostic factors and effect sizes). These symptoms related outcomes 
included: persistence of symptoms, increase in their severity, persistence of 
diagnostic status (i.e. somatisation or abridged somatisation) and emergence of a 
new syndrome (Craig et al., 1993; De Gutch et al., 2004; Gureje and Simon, 1999; 
Hilbert et al., 2010 and Koch et al., 2009; Jackson and Passamonti, 2005).   
 
Creed et al. (2012) also explored a secondary outcome quality of life and found that 
high somatic symptoms at baseline were significantly associated with poor physical 
functioning and quality of life at follow-up. Similar findings have been reported by 
others (Hansen et al., 2011; Kroenke et al.,2002).  Hansen et al., (2011) 5 found that 
higher symptoms, specifically more than four symptoms at baseline were associated 
with poor quality of life, based on the physical and mental functioning domains, at 
one year follow-up.   A fairly recent review by Tomenson et al (2013) warrants 
mention.  Based on nine population-based studies (total population of 28,377) they 
found that total somatic symptom score was associated with poor health status, 
after having making adjustments for depression, anxiety and general medical 
illness. However, this review included seven cross-sectional studies and two 
prospective studies.   The prospective study conducted in Germany was based on a 
cohort who were a part of the Prevention of Renal and Vascular End Stage Disease 
(PREVEND) study (Rosmalen et al 2011), which included an enhanced sample with 
elevated urinary albumin concentration hence, not meeting the criteria for inclusion 
in my literature review.  But the other UK based prospective study by Creed and 
                                                     
5
 This study also did not meet the inclusion for the review as it had been originally set up for 
intervention to improve recognition and treatment of functional disorders by GPs. 
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colleagues that has already been discussed in this chapter was included (Creed et al 
2012). Interestingly, in the same review by Tomenson and colleagues (2013), data 
was used from four sites to explore the association of correlates with both the 
number of UPS and with total somatic symptom score. Somatic symptom scores 
had a greater association with health status than the number of medically 
unexplained symptoms even after adjusting for confounders.   
 
Steinbrecher and Hiller, (2011) observed that negative life events, autonomic 
cognitions and chronic physical illness at baseline were significant predictors of 
poor outcome at follow-up, in terms of persistence of medically unexplained 
symptoms and somatoform disorder. On the other hand, a greater number of 
medically unexplained symptoms at baseline, illness perceptions, distress 
cognitions, catastrophising cognitions and functional disability were significantly 
associated with better outcome (reduced likelihood of the persistence of medically 
unexplained symptoms and somatoform disorders). Incidentally, they identified the 
causal attribution style, vulnerability as associated with persistence of medically 
unexplained symptoms but with lower likelihood somatoform disorder persistence. 
This difference in findings, may be due to chance; limitations relating to study 
methodology are discussed in section 2.10  
 
Some of these findings identified by Steinbrecher and Hiller (2011) are counter 
intuitive to what may be expected and contradict previous findings.  They found 
higher levels of symptoms at baseline were associated with recovery over time but 
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others have reported that higher baseline symptoms are associated with a poor 
outcome (Jackson and Passamonti, 2005; Speckens et al., 1996; Kooiman et al., 
2004). However, Jackson and Passamonti (2005) did not distinguish between those 
with explained and unexplained symptoms in their study. Speckens et al (1996) and 
Kooiman et al., (2004) also found similar findings to Jackson and Passamonti (2005) 
but were carried out with outpatient setting.   
 
Steinbrecher and Hiller, (2011) identified depression as a protective factor against 
persistence of medically unexplained symptoms and somatoform disorders, whilst 
Gureje and Simon (1999) for example found depression and anxiety to be 
associated with a worse outcome. Steinbrecher and Hiller (2011) suggest that 
comorbid depression may lead to earlier help-seeking and professional treatment 
and that remission of these disorders may result in remission of the somatic 
symptoms. Whilst this may be a possibility, it is more likely that other unexpected 
findings identified by Steinbrecher and Hiller (2011) are a result of the study design 
and methods used in the analysis. Most notable error is that the sample size of the 
somatoform disorder group was small (n=63) and too many variables were included 
in the multivariable analyses. Most confidence intervals for factors identified as 
significant are wide and large confidence intervals place greater uncertainty on the 
findings. These issues are discussed in detail in the section 2.10.  
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  Strengths and limitations of the studies included in the 2.10
systematic review 
 
Both studies move away from the traditional view of UPS as expressions of 
psychological distress by using symptom counts such as the SSI and the PHQ-15. 
Although, Steinbrecher and Hiller (2011) still uses the DSM-IV somatoform disorders 
to identify groups within the study.  
 
The two included studies had several methodological weaknesses, which call for 
caution in interpreting their results.  Internal and external validity are important 
aspects of epidemiological studies. Internal validity refers to the strength of the 
study based on the way in which it has been carried out. It takes into consideration 
any bias that may have occurred as a result of how participants were selected, drop 
outs and the methods of analysis. External validity refers to how generalisable 
findings from the study sample are, to the populations from which they were 
drawn, as well as to other (Gordis,2014). Boffetta, (2011) argue that the focus on 
external validity of studies is often misguided as populations are continuously 
changing and representativeness even within the source population will not be 
maintained. They therefore suggest that greater emphasis should be placed on the 
internal validity of a study (Boffetta, 2011). Nevertheless both external and internal 
validity are important concepts in epidemiology and in the following section I will 
discuss both but focus more on the latter. 
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 External validity  2.10.1
Both studies included patients from two GP practices.  Creed et al. (2012) included 
two general practices from two areas with different socioeconomic features; one 
rural and the other non-rural. However they report that baseline non-responders 
were likely to be young and male whilst the follow-up responders were older and 
more likely to be female. Steinbrecher and Hiller, (2011) on the other hand did not 
provide much information on the characteristics of the population from which their 
sample were drawn. They do however report that the study sample was more 
educated and more likely to be females which can limit the external validity and the 
generalisability of these findings.  
 
 Internal validity 2.10.2
In the following section I discuss important aspects of internal validity: selection 
bias, response rates and statistical power, in relation to the papers included in my 
systematic review. 
2.10.2.1 Selection bias 
As mentioned in the previous section, Creed et al. (2012) report differences in those 
who took part in the study compared to those who did not respond. This is often 
the case with primary care studies, and may reflect the characteristics of general 
practice attenders (Patel et al., 2003). Steinbrecher and Hiller (2011) oversampled 
for high scorers; this does not appear to be accounted for in the analysis, leading to 
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concerns about the internal validity of the study. Limited information is provided on 
the source population. Over half of the baseline respondents were reported to be 
twice as educated as the general German population; those with higher education 
may have been more inclined to participate. Furthermore, Steinbrecher and Hiller 
(2011) do not provide information on the size of the source population other than 
to say that 620 consecutive primary care attenders completed the questionnaires 
during the screening stage and therefore it is unclear how many were actually 
approached. 
 
2.10.2.2 Drop out / response rate 
Creed et al. (2012) initially report a response rate of 75% in their paper, based on 
those who agreed to be contacted for follow-up when returning baseline 
questionnaires (741/988) rather than calculating this based on all those who 
returned baseline questionnaires (n=1,443). Therefore, their actual response rate is 
much lower than they initially report and closer to 50% (741/1,443). Lower 
response rates are likely to lead to potential bias, especially if those who response 
differ in a meaningful way, to those who do not. The authors do note this as a 
limitation and point out that the sample was older and included more females than 
the sample from which it was drawn. However SSI scores amongst those who 
responded at follow-up and those who didn’t are noted to be similar and the 
authors mention adjusting for non-response in their analyses.  
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In the study by Steinbrecher and Hiller, (2011), response rate at follow-up was 90% 
which is highly satisfactory, considering the well-known difficulties in achieving high 
response rates in primary care studies (Patel et al., 2003).   
 
2.10.2.3 Statistical power  
Creed et al. (2012) were unable to reach the sample size which they had initially 
calculated, and provided a post-hoc power calculation. This suggests that the study 
has 80% power to include up to 26 covariates and provides some confidence in the 
results. Post-hoc sample size calculations are considered to be unacceptable under 
conventional methods of sample size calculation (Hoening and Heisey et al 2001). 
However, it does suggest that the findings of the regression analyses can be 
interpreted with some confidence, especially as only few variables are included in 
each of the models.   
 
Steinbrecher and Hiller, (2011) did not report a sample size calculation for their 
study. The sample size of the somatoform group was very small (n=63) and 25 
covariates were included in the prognostic model. A rule of thumb is often used to 
determine sample size for regressions and prognostic models which use continuous 
outcome (Harrell et al., 1996; Mallet et al., 2010). It suggests that for each 
independent variable included in the model at least ten participants should be 
included and for categorical variables, this is based on ten events per independent 
variable in the smaller group (Harrell et al., 1996; Mallet et al., 2010). This would 
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suggest that the sample size calculation for this study was inadequate for the 
number of variables included in the predictive models.  For the medically 
unexplained symptom model, although the sample size is much larger (n=220), it is 
likely that the number of covariates included is still too high.  Therefore, the 
findings must be interpreted with caution; regardless of the reporting of significant 
findings, the large confidence intervals place uncertainty on these findings.  In the 
next section, I discuss the strengths and limitations of my systematic review. 
 
  Strengths and limitations of my systematic review 2.11
One of the main strengths of this review is that the protocol and design of this 
review was conducted with discussion and feedback from clinicians practising in 
general practice with expertise in UPS. I tried to ensure that all relevant papers 
were identified by careful development of a comprehensive search strategy and the 
use of four key e-databases for identification of the literature (see section 2.4). The 
British Library database was searched for any relevant PhD theses and reference 
lists of selected key papers were hand searched. Two reviewers were involved in 
deciding which papers met the inclusion criteria and in judging the quality of the 
included papers. Due to the time and resource intensive process of translating 
studies, I decided to limit the review to papers to those which were in English only. 
However, it is possible that limiting the language to English may have resulted in 
missing some relevant studies. It is also possible that some relevant papers within 
the grey literature may have been missed.  
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It can be argued that the strict inclusion and exclusion criteria may have resulted in 
exclusion of relevant literature from the systematic review.  However, I believe that 
this has resulted in identification of two studies which are relevant to the primary 
care attenders and changing concepts of UPS.   
 
Studies that were excluded from the review warrant mention as they highlighted 
the extent of the heterogeneity amongst studies that are widely acknowledged in 
the UPS literature.  These studies highlighted the variability in terminology, 
definitions, diagnostic criteria and study designs. In addition to the outcomes 
already discussed relating to symptoms and quality of life in relation to the studies 
included in the this systematic review (see section 2.9), a number of studies have 
also explored predictors of high health care use or high levels of health care visits in 
primary care (Blankenstein, 2001, De Waal et al., 2008, Hilbert et al., 2010, Hansen 
et al., 2011, Kisely and Simon 2006). These studies identified factors such as being 
female, higher health care use at baseline, presence of medically unexplained 
symptoms (as opposed to explained symptoms), and less availability of social 
support as being significantly associated with higher health care use at follow-up. 
Some of the excluded studies also report that UPS at baseline were associated with 
depression and anxiety at follow-up (Cape et al., 2001; Downes-Grainer et al., 1998; 
Kisely and Simon, 2006).  
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  Conclusion 2.12
Despite UPS being reported to be extremely common in primary care, this 
systematic review highlights the limited number of good quality studies that explore 
UPS amongst primary care populations. It has shown that around half of people 
identified with somatoform disorder continue to meet the criteria a year later. 
Some limited information based on somatic symptom scores suggested that around 
14% of those with high scores at baseline continue to have high scores at follow-up. 
 
The two studies included in my review have identified prognostic factors that may 
be important to explore when examining the longer-term outcome for people with 
UPS. These include: sociodemographic characteristics (being female, marital status, 
years of education, age), past experiences (negative life events) and current physical 
health (being off work due to illness or injury, recent serious illness or injury, 
chronic physical illness, physical health functioning), social factors (no close 
confidante) and psychological factors (anxiety, depression, mental health 
functioning) factors. Prognostic factors relating to high somatic symptom scores 
were similar to those identified in studies of UPS based in other settings and on 
populations identified using different diagnostic criteria.   
 
However, there is a need for consistency and agreement on how populations with 
UPS in primary care are defined. Studies should move beyond the narrow diagnostic 
criterions such as somatoform disorders used in the past, to those which have 
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broader inclusion criteria resembling patients encountered in primary care (Scot 
and Sensky,2003).  
 
This systematic review therefore supports the development of studies which 
recruitment participants with varying degrees of UPS as a symptom based approach 
may be more appropriate for primary care.  
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Rationale, aims and objectives Chapter 3 : 
 
 Chapter overview 3.0
In the introductory and systematic review chapters, I discussed the challenges of 
conducting research into unexplained physical symptoms, due to different and 
changing terminology, diagnostic classifications and methods of identification used 
in studies over time. In this chapter, I will discuss the rationale for my study as well 
as the aims and objectives.  
 
 Study rationale  3.1
Very few studies have explored the course of unexplained physical symptoms in 
primary care populations or the prognosis of patients with unexplained physical 
symptoms (Olde Hartman et al, 2009; Steinbrecher and Hiller 2011; Creed et al 
2012). The use of a prognostic tool can inform general practitioners’ decision 
making and care planning for individuals with unexplained physical symptoms.  It 
could also predict the risk of poor outcomes like persistence of unexplained somatic 
symptoms and/or could identify those who will experience a more favourable 
outcome, such as the remission of symptoms.  
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Hemingway and colleagues, (2013) describe prognostic research under the four 
components outlined below.  They suggest that such research should inform clinical 
decision-making, management approaches and health policy.  
 
i) Overall prognostic research, which describes future outcomes in people with a 
specific disease or health condition, in relation to diagnostic and treatment 
practices. 
ii)  Prognostic factor research, which aims to identify specific factors, associated 
with outcomes of interest. 
iii) Prognostic model research where multiple prognostic factors are combined to 
predict the risk of a future clinical outcome amongst individual patients. This 
includes model development, external validation and evaluation of impact. 
iv) Finally, use of prognostic information to effectively manage and treat based on 
individual characteristics. 
 
My study focuses on identifying prognostic factors associated with a number of 
outcomes, a key component in the development of prognostic models and clinical 
prognostic tools. The aims and objectives of my study are described in detail in 
section 3.2 and 3.3.  
 
For the purposes of this thesis, I use the term unexplained physical symptoms (UPS), 
to describe those who report somatic symptoms on the patient health 
questionnaire somatic symptoms module (PHQ-15) as bothersome, but for which no 
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known explanations or diagnosis is reported. Those that met the study inclusion 
criteria had a minimum of three UPS and a score of five on the PHQ-15. These 
eligibility criteria are discussed further in section 4.3. Within this context, the next 
section will describe in detail the study aims and objectives.  
 
UPS includes symptoms of various forms. I have already highlighted the 
heterogeneity in the definition of UPS in other studies (see chapter 1.2, 1.4, 2.8 and 
appendix 2.3).  Many studies have included people with single symptoms, functional 
syndromes or those meeting specific diagnostic criteria. In my study, I have chosen 
to focus on those with multiple UPS.  The rationale for this is that those with 
multiple UPS have a different underlying aetiology to those with single symptoms; 
they also have a greater illness burden and present more complex management 
dilemmas to doctors than those with single UPS.  As discussed in chapter 2.3.2 
those with functional syndromes such as irritable bowel syndrome are likely to have 
a different aetiology compared to those with multiple UPS across several domains. 
The presence of a medical ‘label’ such as irritable bowel syndrome or chronic 
fatigue syndrome may impact on the course of the disorder and its symptoms. 
Those meeting the diagnostic criteria for somatoform disorders are likely to be 
burdened by higher levels of psychiatric morbidity and be on the more severe end 
of the spectrum, compared to those attending primary care.  Likewise, I have not 
focused on frequent attenders alone.  Although, this group presents its challenges 
with respect to their management in primary care and even though some of them 
may include people with UPS, many will have existing chronic physical conditions, 
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severe mental disorders and other types of psychological distress and thus 
constitute too heterogeneous a study group.  This would make the epidemiological 
investigation of such people less meaningful.   With these considerations in mind, 
the next section will describe in detail the study aims and objectives 
 
 Study aims 3.2
In a cohort of adult primary care attenders with UPS, this study aims to:   
i) Investigate the outcome in terms of the presence of UPS at six months follow-up. 
ii) Identify prognostic factors associated with somatic symptom severity, quality of 
life, anxiety, depression and health care use at six months follow-up. 
 
3.3 Objectives  
The objectives of each stage of the study are as follows: 
 
Stage 1: Screening 
 
To describe the characteristics of primary care attenders in terms of current somatic 
symptoms, self-reported explanation or previous diagnosis for the symptoms, 
whether they were consulting about the symptoms on that day, gender and age for 
the complete cohort and stratified by symptom severity.   
 
115 
 
Stage 2: Longitudinal study 
 
i) To describe the characteristics of the cohort with UPS, stratified by gender. 
 
ii) To describe the outcome of primary care attenders with UPS in terms of 
proportion of participants whose symptoms are resolved, received an explanation 
for symptoms, still under investigation or were unexplained at six months.  
 
iii) To investigate prognostic factors associated with persistence of somatic 
symptoms at six month follow-up. 
 
iv) To investigate prognostic factors associated with secondary outcomes namely, 
reduction in quality of life or increase in depression, anxiety and primary health 
service use at six month follow-up. 
 
In the next chapter I will discuss the methods of the study in detail. 
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Methods Chapter 4 : 
 
4.0 Chapter overview 
In this chapter I present details on the design of my study, including study setting, 
study population, ethical considerations and recruitment. Second, I discuss the 
development of questionnaires for data collection (including the selection of the 
tools and scales used). Finally, I discuss the methods used in the analysis of data 
collected. 
 
 Study design  4.1
 The study consisted of two main components: 
 
i) Identification eligible participants in general practice waiting rooms using a 
screening questionnaire.  
ii) A prospective cohort study with six month follow-up. 
 
Each component of the study is discussed in turn.  
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 Study setting 4.2
I recruited general practices with the support of the North and Central London 
Research Consortium (NoCLoR) Research Network. Emails were sent out to twenty 
research active practices in sub-urban and urban boroughs located in areas of North 
and Central London with study information (see Appendix 3.1 and Appendix 3.2). 
Recruitment took place in practices with varying levels of deprivation to ensure a 
variety of participant demographics and characteristics. Nine general practices 
located across four North and Central London boroughs agreed to participate. I 
decided that this was a feasible number of practices to travel to and recruit at, in 
the time I had available for data collection and would not place undue burden on 
individual practices.  Based on data for year 2012/2013, Index of Multiple 
Deprivation (IMD) deciles of the practices included in my study range from 1 to 8 
(Public Health England, 2015). IMD deciles range from one, being the most 
deprived, to 10, the least deprived (Public Health England, 2015). Two practices 
included in the study had a score of 1 (practice 6 and 8), two practices had a score 
of two (practice 5 and 4), two practices had a score of three (practice 7 and 3), two 
practices had a score of five (practice 2, 9) and one practice had a score of 8 
(practice 1). Practice list sizes varied from 5,122 to 17,494 and the number of 
General Practitioner surgeries per day during recruitment periods ranged 1 to 8 and 
the number of surgeries held by nurses and health care assistants varied from 0 to 
6. In addition to these, in three of the practices there was a psychologist who 
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carried out sessions in the practice, in two of the surgeries there was a podiatrist 
and in another a phlebotomist. 
 Study population 4.3
All adults above the age of 18 years, who were registered at one of the nine general 
practices and attending during the time the I was attending the practice between 
the study period of January to December 2013, were considered potentially eligible 
(see Figure 4.1). Below I describe the specific inclusion and exclusion criteria for the 
screening stage of the study and for the cohort study. 
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Figure 4.1 The diagram below shows a summary of the steps involved in identification of participants and collection of data. 
 
Eligibility 
screening          
  
•Information leaflet given to consecutive primary care attendess in GP receptions/waiting rooms 
•All registered attenders invited to complete a brief screening questionnaire on somatic symptoms (PHQ-15), any known explanations or diagnoses for 
these symptoms  and provide contact details if interested in next stage of study 
 
Participant 
identification 
for cohort 
• Those scoring >5 on the PHQ-15 (at least three unexplained symptoms after any known diagnosis are considered) were eligible 
• Invitation letter, information leaflet, questionnaire, consent form and return envelope sent by post  
•Telephone call made to those who preferred this option 
 
Baseline 
questionnaire 
• Booklet contained items on somatic symptoms (PHQ-15), preferences for management, quality of life, work and social adjustment, self-efficacy  , life 
events (in past six months and when growing up),anxiety, depression ,panic, past family physical and mental health, and some demographic questions 
 
6 month 
follow-up 
•Follow-up questionnaire booklets included the outcome measures, all which were also included in the baseline questionnaire.  
 
 
 
Extraction of 
data from 
medical 
records 
•Data on number of primary care face-to-face to telephone conslutation with GP, nurse, health care assisstants, out of hours visits/calls, A&E 
attendace, referrals to secondary care or mental health services,  psychotrophic drug prescriptions were collected for the year prior to study 
participation and during the study participation period.  
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 Inclusion and exclusion criteria for the screening stage 4.3.1
Consecutive attenders over the age of 18 years who were registered at one of the 
nine general practices were eligible to complete screening questionnaires. Those 
who were unable to complete the questionnaires in English due to language 
difficulties or cognitive impairment, registered at the GP practice temporarily  or 
planned to move away in the next six months were excluded.   
 
 Inclusion and exclusion criteria for the cohort study 4.3.2
Inclusion criteria for the cohort study were a PHQ-15 score of five or more (at least 
three or more symptoms), without any stated medical condition likely to fully 
explain their somatic symptom were considered and ability to complete the 
questionnaire in English. Exclusion criteria were having a medical explanation or 
diagnoses, which explained fully all symptoms or having a terminal illness.  
 
 Ethical considerations 4.4
Prior to the commencement of the study, I obtained ethical approval from Brent 
Local Research Ethics Committee. Local R&D clearence was granted from the North 
and Central London Research Consortium. Written informed consent was obtained 
from all participants, to be returned with the written questionnaire or prior to the 
telephone interview. In face-to-face meetings, the patient information leaflet was 
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sent to the participant prior to the meeting and the written consent was obtained 
at the meeting, prior to completing the questionnaire. The consent form also 
requested access to medical records. Participants were given the option to refuse to 
access to medical records but could continue to take part in the rest of the study.  
Each participant was given an identity number and all questionnaires and electronic 
records were anonymised. I carried out the screening at all the general practices, 
completed questionnaires by telephone or the face-to-face for with those who 
requested this and extracted all health care data from medical records. A research 
assistant with full clearance to access data supported with questionnaire posting 
and completed one telephone interview.  All identifiable paper records such as 
consent forms were kept separately in a locked cabinet. Identifiable electronic data 
were stored in a secure password protected server in anonymised format. All study 
data were stored in accordance with the Data Protection Act 1998.  
 
 
 Recruitment of patients  4.5
I asked receptionists at the GP practices to give a short information leaflet to all 
those checking in for appointments and to inform them about the presence of a 
researcher in the waiting room (see Appendix 3.3).  Posters were also put up in the 
waiting rooms (see Appendix 3.4) and leaflets left out for practice attenders to pick 
up to inform them of the study. I approached consecutive attenders in the waiting 
areas to ask whether they had read the leaflet and whether they had any queries 
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about the study. All waiting room attenders registered at the practice who were 
interested in the study were encouraged to complete the self-administered 
screening questionnaire to ascertain eligibility and asked to indicate their interest in 
being contacted regarding the next stage of the study (Appendix 3.5). I checked 
each screening questionnaires to ascertain eligibility and any uncertainty was 
discussed with the rest of the study team. I contacted those who were eligible and 
who had provided their contact details within two weeks, regarding the next stage 
of the study. When preference was indicated for contact by telephone, potential 
participants were contacted to arrange completion of questionnaire over the 
telephone or face-to-face, either at their GP surgery, their home or at a neutral 
venue such as the UCL campus. Participants were considered fully recruited to the 
study when they returned a signed consent form (see Appendix 3.8).   
 
 Stage 1: Screening  4.6
I used an initial screening questionnaire to identify potential participants (see 
Appendix 3.5). It consisted of the validated PHQ-15 questionnaire (Spitzer et al., 
1999), which was chosen following an review of the literature (discussed in detail in 
section 4.9.1).  The PHQ-15 is made up of fifteen questions for females and fourteen 
questions applicable to males, about specific body symptoms including stomach 
pain, back pain, headaches and trouble sleeping. Respondents are asked to rate 
how much they have been bothered by these somatic symptoms and are given the 
options not at all, a little or a lot. Additional supplementary screening questions 
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were included to collect information on self-reports of any known diagnoses or 
medical explanation for the symptoms, whether the doctor was being consulted 
about any of the symptoms bothering them that day, and basic socio-demographic 
information about age and gender.  Respondents were asked to indicate their 
interest in the study and preferred method of being contacted (either telephone or 
by post) as well as to provide their contact details.  
 
 Stage 2: Cohort Study  4.7
As described in section 4.3.2, eligible and consenting participants were sent an 
information leaflet describing the study in detail, a questionnaire booklet (refer 
section 4.8.1) a consent form and return envelope, approximately within two weeks 
of completing the screening questionnaire. If the baseline questionnaire booklet 
was not returned within two weeks of being sent to the potential participant, the 
complete package was re-sent along with a reminder letter. The reminder letter 
invited the participant to complete the baseline questionnaire or to return a reply 
slip indicating whether they wanted to discuss the study further or were no longer 
interested and if possible, to give a reason for their decision. Those who did not 
return the questionnaire or the reply slip within the next two weeks were contacted 
by telephone, if they had provided their telephone contact details. If I was unable to 
get through to them, no messages were left to maintain confidentiality and to avoid 
burdening the potential participant. Up to four telephone calls were made; if these 
were not successful, these participants were considered to be non-respondents.  
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Six months after the baseline questionnaire booklet was returned, a follow-up 
invitation letter and questionnaire booklet was sent to the participant. The same 
steps as with the baseline questionnaire were taken if the follow-up questionnaire 
was not returned after two weeks. The original study design included six months 
and one year follow-up, however, due to resource and time limitations, this was 
revised to six months only. The questionnaire booklets used in the study will be 
discussed in the next section. 
 
 Questionnaire booklets 4.8
 The baseline questionnaire booklet 4.8.1
The baseline questionnaire booklet that I developed was informed by the literature 
on UPS (see Appendix 3.9). These included studies from any settings (primary, 
secondary, community) and of any study design (cross-sectional or cohort studies) 
discussed in section 1.6 and a limited number of studies that have explored 
prognostic factors in primary care, presented in section 2.8; some of which met the 
criteria for the systematic review and some of which did not.  Inclusion of possible 
prognostic factors was discussed with my supervisors based on their expertise as 
practicing GPs, in order to determine clinical relevance. Having agreed a list of 
potential prognostic factors, the literature was searched to identify validated, short 
and easy to complete questionnaires. These are listed in Table 4.1. The 
questionnaire booklet was designed to take no longer than thirty minutes to 
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complete, in order to reduce the burden on the participant. Where it was not 
possible to find short validated questionnaires such as for childhood trauma, some 
modified scales with short questions were developed and included. These will be 
discussed further in section 4.9.  
 
The potential prognostic factors considered at baseline were: 
1) Somatic symptom severity  
2) Quality of life 
3) Preferred sources of support 
4) Management of symptoms  
5) Work and social adjustment 
6) Self-efficacy 
7) Stressful life events 
8) Depression 
9) Anxiety 
10) Panic 
11) Family health during childhood (physical and mental) 
12) Traumatic experiences in childhood 
13) Experience of abuse a child (emotional, physical or sexual) 
14) General sociodemographic questions on age, sex, education, employment, 
socioeconomic status/well-being, and perceived social support 
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 The follow-up questionnaire booklet 4.8.2
I chose the predefined primary and secondary outcomes based on reference to the 
literature and clinical relevance. Data were collected (at six-months after baseline) 
on the progress of symptoms in terms of whether symptoms were still unexplained, 
under investigation, referred for further investigation or they had received a 
diagnosis (for six month questionnaire booklet please see Appendix 3.11). Validated 
measures were used to gather data on the following:  
 
1) Somatic symptom score (primary outcome) 
2) Quality of life (secondary outcome) 
3) Depression 
4) Anxiety 
 
 Instruments and questions used 4.9
The instruments and questions that have been included in the each of the 
questionnaire booklets are shown in Table 4.1. I first discuss the primary and 
secondary outcomes followed by the other baseline variables collected. These were 
also discussed in reference to existing studies in Chapter 1 and Chapter 2. 
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Table 4.1 Potential prognostic variables and measures used in my study and the 
questionnaires booklets they were included in. 
Potential  prognostic variables/ 
instruments or questionnaires used 
Baseline 
questionnaire 
booklet 
Six month follow-
up questionnaire 
booklet 
Somatic symptom severity/ PHQ-15 
(Primary outcome) 
X X 
Quality of life/ (SF-12) X X 
Depression (PHQ-9) X X 
Anxiety (GAD-7) X X 
Panic (PHQ-PD) X X 
Management of symptoms/ 
questions developed for study 
X  
Social functioning/WSAS X  
Self-efficacy/GSE X  
Stressful life events/LTE-Q X  
Childhood experiences/ questions 
developed for study 
X  
Socio-demographic information 
including: 
gender, age, ethnicity, marital 
status, employment status,  
socioeconomic stuatus/well-being, 
education level and perceptions of 
social support/ questions 
developed for the study, ethnic 
categories informed from the ONS 
study 
X  
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 The primary outcome: somatic symptom severity 4.9.1
Somatic symptom severity, the primary outcome of my study, is measured using the 
PHQ-15.  The shorter PHQ-15 is a self-administered questionnaire derived from the 
longer Primary Care Evaluation of Mental Disorders (PRIME-MD) questionnaire 
(Spitzer et al., 1994).  PRIME-MD is a criteria-based diagnostic instrument of mental 
disorders common to primary care, developed and validated in the early 1990s by 
Spitzer and colleagues(Spitzer et al., 1994).  It included a 27 item screening tool and 
a follow-up structured interview with a clinician; it took up to 12 minutes to 
complete for patients with a mental disorder diagnosis, and was therefore 
considered difficult to use in busy clinical settings. This led to the development and 
validation of a self-administered version, the PHQ-15 (Spitzer et al., 1999; Kroenke 
et al., 2002). The PHQ-15 includes an initial question ‘during the past 4 weeks, how 
much have you been bothered by any of the following problems,’; followed by 
fifteen questions for females and fourteen questions for males, about specific body 
symptoms (Appendix 4.x). These include stomach pain, back pain, headaches and 
trouble sleeping with options to answer ‘not bothered at all’ (equal to a score of 0), 
‘bothering a little’ (equal to a score 1) or ‘bothering a lot’ (equal to a score 2) 
(Kroenke et al., 2002). It is suggested that the PHQ-15 includes 90% of the most 
common somatic symptoms with which people consult (Kroenke et al., 2002). 
 
The PHQ-15 was intended to function as a continuous measure of somatic symptom 
severity with a potential to score from zero indicating no somatisation to 30 
indicating severe somatisation.  Clinical cut-off points are frequently used with 0-4 
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considered as minimal severity; 5-9 considered to be low severity; 10-14 considered 
to be moderate severity; and >15 high severity (Kroenke et al., 2002). In order to 
meet the threshold for low severity, at least three symptoms must be rated as 
bothersome; to meet the threshold for moderate severity a minimum of five 
symptoms must be rated as bothersome and at least eight symptoms to reach the 
threshold for high severity. The cut-off points were chosen pragmatically; however, 
Kroenke et al. (2002) found that the associations between increasing PHQ-15 
severity and measures of construct validity did not change with these cut-off points. 
A moderate effect size in functional status measured using six domains of the short-
form 20 (SF-20) was found when PHQ-15 somatic symptom severity increased from 
one severity level to the next (Kroenke et al., 2002).  These cut-off points are 
increasingly being used in research (Mewes et al., 2008, Steinbrecher and Hiller, 
2011, Korber et al., 2011). I chose to use the cut-off point of a score of >5, in order 
to exclude those with minimal severity.  
 
Other potential screening instruments that can be used to identify participants with 
UPS were discussed in section 1.4.2.  As I explored recent studies of UPS, I found 
that the use of the PHQ-15 was increasing. This is likely a result of its ease of use; 
being easy to understand and quick to complete. Additionally, it is reliable and 
validated for use in primary care and has been used effectively in longitudinal 
studies (Kroenke et al., 2010). In the original validation study that included 6,000 
patients from general internal medicine and family practice clinics, internal 
consistency for the PHQ-15 was Cronbach’s α of 0.80 (Kroenke et al., 2002). In 
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another validation study of 906 high-risk primary care patients, internal consistency 
was the same as in the larger study with a test-retest correlation of 0.83 when using 
the PHQ-15 on a continuous scale (van Ravesteijn et al., 2009). 
 
I conducted a scoping review using the key words ‘PHQ-15’ and ‘patient health 
questionnaire’ along with key words for unexplained physical symptoms such as  
‘medically unexplained’ OR ‘somatic symptoms’ in May 2012, to determine how 
frequently the PHQ-15 was being used in research, in what types of studies and in 
which settings.  Since the publication of the first validation study of the PHQ-15, I 
identified 32 papers that used the PHQ-15, to identify somatic symptom severity.  
 
These papers included several validation studies that translated the questionnaire 
to other languages including Korean, German and Spanish (Han et al.,2009; Körber 
et al.,2011; Ros Montalbán et al.,2010)  were conducted in different health care 
settings including primary care (Burton et al., 2012; Clarke et al., 2008; Hanel et al., 
2009) the general population (Rief et al., 2010), outpatient settings (Ros Montalbán 
et al.,2010) and more specific populations such as sick list employees (Hoedeman et 
al.,2009). Several intervention studies used the PHQ-15 to determine change in 
severity of symptoms including drug studies (Kroenke et al., 2006), it had been used 
in complex interventions (Burton et al., 2012; Escobar et al., 2007) and longitudinal 
studies to explore severity of symptoms and symptom change over time 
(Steinbrecher and Hiller, 2011, Jackson and Passamonti, 2005).  
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An updated search highlighted the growing popularity of the PHQ-15, as I identified 
an additional 16 papers published between June 2012 and February 2014  that used 
the PHQ-15 to measure severity of somatic symptoms  for research. I also found 
that the PHQ-15 is used in clinical practice. For example the NHS programme 
‘Improving Access To Psychological Therapies’ (IAPT) recommends that the PHQ-15 
is used to assist clinical judgements in identifying patients with unexplained physical 
symptoms (UPS), alongside other tools that are being developed for commissioning 
purposes (Commissioning Support for London,2011).  
 
High symptom severity according to the PHQ-15, with a minimum of eight 
symptoms and a score above fifteen is reported to likely predict clinically significant 
somatisation disorder (Löwe et al., 2008).  Although I did not intend to identify 
those meeting the criteria for somatoform disorder, this reported alignment does 
allow for comparison of new findings with existing studies. Many items overlap with 
validated somatisation screening questionnaires further increasing the utility of 
PHQ-15 (Kroenke and Rosmalen, 2006). It is reported to be highly correlated with 
clinician-rated symptom counts but is more advantageous for use as it is less 
resource intensive, not needing clinician evaluation  (Kocalevent et al., 2013; Rost et 
al., 2006; Interian et al., 2006). However, as the PHQ-15 does not identify the 
nature or cause of the symptoms, in my screening questionnaire, I included an 
additional question to enquire whether the participant knew of an explanation or 
diagnosis for their symptoms, in order to determine whether or not their somatic 
symptoms were unexplained. The PHQ-15 was also included in the baseline 
132 
 
questionnaire to determine whether the symptom score had changed following the 
initial screening questionnaire and chosen as the primary outcome measure for the 
follow-up questionnaire.  
 
 Secondary outcomes 4.9.2
4.9.2.1 Quality of life 
Health related quality of life relating to functioning and well-being was measured 
using the validated, self-report short-form questionnaire (SF-12) (Ware et al., 1996).  
Based on the widely used 36 question SF-36 survey (Ware and Sherbourne, 1992), 
the shorter SF-12 contains only twelve questions enquiring about the impact of 
symptoms on the participants’ lives in physical, mental and social dimensions. The 
scores can be coded and analysed to form two separate sub scales of physical and 
mental functioning. Correlation for the general population physical component 
summary (PSC) score for the SF-12 compared to the SF-36 was 0.905 and for the 
mental component summary (MCS) score was 0.938 (Ware et al.,1996). The SF-12 
has been used in variety of research settings including in studies of UPS (McGorm et 
al., 2010; Burton et al.,2012) and is considered suitable for generic and disease 
specific health surveys (Ware et al.,1996).  Test-retest (2-week) correlations of 0.86 
and 0.77 were observed for the 12-item Physical Component Summary and the 12-
item Mental Component, in the UK (Ware et al., 1996). It is included in both the 
baseline and follow-up questionnaires and is a secondary outcome measure.   
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4.9.2.2 Psychological well-being: Depression and Anxiety 
Depression and generalised anxiety disorder were measured using the Patient 
Health Questionnaire depression module (PHQ-9) (Kroenke et al., 2001),and the 
generalised anxiety disorder assessment (GAD-7) (Spitzer et al., 2006)  which are 
brief, reliable and validated questionnaires.  
 
4.9.2.2.1 Depression 
The PHQ-9 is the self-report version of the PRIME-MD diagnostic instruments 
(Kroenke et al., 2001). It has been translated into several languages and is widely 
used in research and routinely in clinical practice (Gilbody et al., 2007). It scores 
each of the nine DSM-IV criteria for depression on the extent to which these have 
bothered the respondent in the previous two weeks. The response categories are 
not at all (scored 0) several days (scored 1), more than half the days (scored 2) and 
nearly every day (scored 3).  Scores of 5, 10, 15, and 20 are suggested to represent 
the cut-off points for mild, moderate, moderately severe and severe depression, 
respectively with a maximum possible score 27; although it can be used on a 
continuous scale as I have used in my study (Kroenke et al., 2010).  
 
With increasing severity on the PHQ-9, worse functioning, greater symptom related 
difficulty, greater numbers of sick days and higher health care utilization have all 
been reported (Kroenke et al., 2010). In the original study of 6000 patients, at a cut-
off point of >10 was suggested to be clinically significant; the sensitivity was found 
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to be 0.88 and the specificity 0.88. The internal validity was between Cronbach α 
0.86 to 0.89 and re-test reliability was 0.84 (Kroenke et al., 2001). The PHQ-9 is 
considered to be a good diagnostic measure; a number of meta-analyses have 
compared the validity of the PHQ-9 to DSM-IV major depressive disorder diagnosis 
and find good rates of agreement between them (Gilbody et al., 2007; Wittkampf et 
al .,2007). Gilbody et al. (2007) combined findings from 14 studies with a total of 
5,026 participants to validate the PHQ-9 against major depressive disorder; they 
report sensitivity of 0.80 (95% CI 0.71–0.87) and specificity of 0.92 (95% CI 0.88–
0.95) (Gilbody et al., 2007).  However, it has been suggested that a higher cut-off of 
>12 may improve the accuracy without compromising on specificity (Gilbody et al., 
2007b; Kendrick et al., 2009).  
 
4.9.2.2.2 Anxiety 
The GAD-7 is a seven item scale was used to screen and measure anxiety and is 
similar to the PHQ-9 in terms of its response categories. It is considered to be a 
measure of severity; the use of a diagnostic interview is recommended to confirm a 
clinical disorder (Kroenke et al., 2010). Increasing scores on the GAD-7 are also 
associated with multiple domains of functional impairment (Spitzer et al., 2006).  
GAD-7 anxiety severity is calculated by assigning scores of 0, 1, 2, and 3, to the 
response categories of not at all, several days, more than half the days and nearly 
every day respectively and the total score for the seven items ranges from 0 to 21. 
Scores of 5, 10, and 15 represent cut-off points for mild, moderate, and severe 
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anxiety, respectively and once again as with the PHQ-9, it is used as a continuous 
measure in this study. The GAD-7 has been shown to be a valid tool for identifying 
patients with generalised anxiety disorder with a sensitivity of 89% and specificity of 
82% at a cut-off point of >10 ( Spitzer et al., 2006). Although developed much later 
than the PHQ-15 and PHQ-9, it is increasingly used in clinical practice and in 
research. It has shown to have good convergent validity to more established anxiety 
scales such as the Beck Anxiety Inventory and anxiety subscale of the symptom 
checklist (SCL-90) (Spitzer et al, 2006) 
 
4.9.2.3 Health service use data collection from electronic patient medical records 
Information about health care use was extracted from the participant’s general 
practice records. Eight of the practices in the study used the electronic patient 
record software EMIS whilst one used InPS vision. I identified primary health care 
contacts as either face-to-face to telephone meetings with doctors, nurses, health 
care assistants or out of hours GP services. I also recorded secondary health care 
contacts which were secondary care referrals, mental health referrals and A&E 
access. I also recorded psychotropic drug prescriptions specifically antidepressants, 
anti-hypnotics and antipsychotics. Data were collected from twelve months prior to 
baseline data collection and during the period of study participation.   
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 Potential prognostic factors to consider  4.9.3
4.9.3.1 Management of symptoms  
This section included questions on management of UPS, in terms of who/what 
sources of support they chose to turn to and what strategies they may have used 
based on work by Walters and colleagues, (2008), on help seeking in populations 
with sub-clinical emotional disorders and emotional distress. 
 
4.9.3.2 Social functioning  
The Work and Social Adjustment Scale (WSAS) was used to measure functional 
impairment relating to work and social aspects (Marks, 1986). It is a short, reliable, 
valid measure consisting of five questions with nine categories for each response, 
from zero indicating no impairment at all to a score of eight indicating very severe 
impairment. There is a total possible score range of 40 (Mundt et al., 2002).  A 
WSAS score above 20 suggests moderately severe or worse functional impairment, 
scores between 10 and 20 are associated with significant functional impairment but 
less severe clinical symptomatology and scores below 10 are associated with 
subclinical populations. It has been found to have strong psychometric properties in 
populations with depression, anxiety and alcohol misuse disorders with good 
internal consistency and positive correlation with depressive symptom severity 
(Mundt et al., 2002).  It has been used in studies of patients with functional and UPS 
(Deale et al., 1997; Cella et al., 2011). A validation study of two groups of patients 
with chronic fatigue syndrome (CFS), one enrolled in a large randomized controlled 
137 
 
trial (cohort 1) and the other accessing a clinical service (cohort 2) resulted in 
comparable findings, supporting its acceptability as a measure of disability in both 
research and in everyday clinical contexts. Lower scores on the WSAS were 
modestly associated with better physical functioning (Cella et al.,2011).  
 
4.9.3.3 Self-efficacy  
Increasingly, self-efficacy is considered as a favourable characteristic in adapting to 
chronic illness. It is positively associated with quality of life, activities of daily living, 
social and family functioning, well-being and self-care (Scholz et al., 2002).  The 
General Self-Efficacy (GSE) questionnaire enquires about the sense of perceived 
self-efficacy, optimism and self-belief with regard to personal competence to deal 
effectively with a variety of difficult tasks, adversity or stressful situations 
(Schwarzer and Jerusalem, 1995). The ten item validated questionnaire has been 
translated into several languages (Scholz et al., 2002).  Reponses are based on a 
four point scale on the extent of agreement to each statement with one being no 
agreement at all and four being considerable agreement. The final composite score 
ranges from 10 to 40.  It has been shown to correlate with positively with self-
esteem and optimism and negatively with anxiety, depression, stress, health 
complaints and physical symptoms. In samples from 23 nations, Cronbach’s alpha 
ranged from 0.76 to 0.90 with a majority greater than 0.80 (Scholz et al., 2002).  
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4.9.3.4 Life events 
The 12 item ‘list of threatening experiences’ questionnaire (LTE-Q) (Brugha et al., 
1985) was used to obtain information about difficult and stressful life events 
experienced relating to illness, death, relationships, job or financial crisis in the 
previous six months. It is a short and reliable questionnaire that has been 
recommended for use in studies relating to psychiatry, psychology and social 
studies, in which intervening variables such as social support, coping, and cognitive 
variables are of interest. The responses are binary for whether an event has 
happened or not and the number of events that the respondent considers are still 
affecting them are counted. The questionnaire does not have a cut-off point and is 
scored on the basis that the more life events the adult has been through, the higher 
the score and therefore the greater the likelihood of some form of longer term 
impact. In a recent study eight questions from the LTE-Q were used to determine 
association of stressful life events with unexplained chronic syndromes (Aggarwal et 
al., 2006). This study found that having one stressful life event in the previous six 
months was associated with having increased odds of having unexplained chronic 
symptoms (OR 1.5 (95% CI 1.2 to 1.9)) compared to those who had not experienced 
any, whilst those who had experienced between two and eight adverse events in 
the previous six months participants were 2.5 times (95% CI 2.0 to 3.0) more likely 
to be included in the group.  
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4.9.3.5 Panic 
The PHQ- PD (Spitzer.,1999) was used to screen for panic disorder. The panic 
questionnaire includes an initial question that screens out those who have not 
experienced panic or an anxiety attack. This is followed by 14 questions with two 
possible responses either ‘no’ (0 points) and ‘yes’ (1 point) to be answered only by 
those who had experienced a recent anxiety or panic attack in the previous two 
weeks (Spitzer et al., 1999).  The original algorithm requires the first four questions 
to be answered as yes, along with four or more of the following eleven questions. 
Due to the fairly low prevalence of panic disorder Wittkampf et al. (2011) suggests 
the use only the initial question in primary care; it is reported to have high 
sensitivity (0.71, 95% CI 0.54–0.83). For the purpose of this study, I follow this 
suggestion and use only the initial question in the analyses.  
 
4.9.3.6 Childhood experiences  
As discussed in section 1.6.5, studies have found that experience of illness in the 
family during childhood may impact on unexplained symptoms (Hotopf, 2002; 
Stuart and Noyes, 1999; Essau, 2007; Craig et al 1993).  It has been suggested that 
growing up in an environment with an ill parent and exposure to help-seeking may 
develop a pattern of illness behaviour which focuses more on somatic symptoms 
and learn to use symptoms as a way in which to receive more sympathy, care and 
support (Mumford et al 1991; Craig et al 1993). For my study, I developed two 
questions that asked about family history of long-term physical and mental health 
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with two open ended question for participants to explain the nature of the 
condition and which family member was affected.  
 
Negative life events and trauma during childhood relating specifically to abuse and 
particularly to sexual or physical abuse have been suggested to impact on later 
somatization (Stuart and Noyes, 1999; Essau, 2007). Due to the long and sensitive 
nature of many questionnaires on trauma and abuse that are commonly used, I 
included only two short screening questions in the baseline questionnaire booklet. 
In order to build up to the sensitive question on abuse I first include a more general 
question that asked whether the participant had experienced any type of trauma 
whilst growing up and to clarify what this was. This was followed by a question 
about whether they had experienced any type of abuse as a child. Options for 
response were based on the Childhood Trauma Interview (Bernstien & Fink,1998) 
and included five options from never true to very often true. An option to clarify 
whether abuse was physical, sexual or emotional was also included.  It was also 
emphasised that respondents could skip this question if they did not wish to answer 
it.  
4.9.3.7 Sociodemographic information 
I included sociodemographic questions on gender, age (date of birth), ethnicity, 
marital status, employment, perception of financial well-being, educational level 
and availability of social support.  For ethnicity, participants were given a list of 
seventeen options, under five broader categories adapted from the census options 
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(Ethnic group, ONS). For employment options included being in paid employment, 
retired, unable to work due to poor health, studying, looking after family, 
volunteering or doing ‘something else’ with an option to clarify what this was. 
 
To determine financial situation, I used a question that enquired about how well 
they were managing financially with options ranging from living very comfortably to 
finding it very difficult, on a Likert scale (Weich and Lewis, 1998). An additional 
question was included on perceived social support, which asked whether the 
participant had someone they could turn to for emotional or practical support and 
who this person/ people were. I used postcodes of study participants to generate 
Index of Multiple Deprivation (IMD) scores using GeoConvert (Geoconvert); this 
online tool maps postcode to IMD, 2007 scores (Noble et al., 2008). IMD provides 
an indication of relative socioeconomic deprivation localised to the Lower layer 
Super Output Area and is based on the English Indices of Deprivation and higher 
scores indicate higher deprivation (Noble et al., 2008).  
 
 Analysis 4.10
 Data entry, cleaning and verification 4.10.1
In order to ensure consistent coding and entering of data at each stage of the study, I 
developed a coding booklet.  I carried out the majority of data entry of anonymised data 
with the assistance of research assistants.  Data from screening questionnaires, baseline 
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and follow-up questionnaire were entered into separate SPSS databases.  For each stage 
of data entry, between 10-25% of data was randomly selected and double entered. The 
two versions were compared and data entry error rate was calculated for inconsistencies 
identified. An error rate of up to 1% was considered acceptable. For each variable I 
checked for outliers, tabulations and histograms. Any values that lay outside the 
permitted ranges were cross checked against original data and corrected as appropriate. 
 
 Sample size calculation 4.10.2
Sample size calculations were made at the start of the study to ensure that it was 
adequately powered to be able to detect a difference, if one exists. Traditionally for 
most studies, power calculations are carried out with consideration to confidence 
intervals (error rate), confidence level (significance) and standard deviation 
(variance in response). However, where studies use regression analyses or are 
conducted for the development of prognostic models, a rule of thumb is commonly 
used, that provided the primary outcome is continuous, for every independent 
predictor variable at least ten outcome events or cases should be included (Harrell 
et al., 1996; Mallet et al., 2010). This rule thumb is based on estimates of the 
stability of coefficient estimates for individual variables in the prognostic models 
(Mallet et al., 2010). Variables that contain multiple discreet options for responses 
(more than two responses) are considered as multiple variables and continuous 
responses are considered as single variables (Harrell et al., 1996).  
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Sample size was calculated based on the assumption that a maximum of 23 
variables would be included in the model based on existing literature (Chapter 1 
and Chapter 2) which also informed the development of the baseline questionnaires 
as discussed in 4.6 and 4.7.  I decided a priori, that the primary outcome would be 
treated as a continuous measure, as it allows for valid analyses to be conducted 
with smaller sample sizes and has greater sensitivity than categorical outcomes 
(Mallett et al.,2010). Hence, using the rule of thumb described, I calculated that at 
follow-up it would be necessary for 230 participants with UPS to be present, if the 
model were to contain 23 variables. It was assumed that 20% would be lost to 
follow-up, which indicated that 287 participants would need to be recruited to the 
longitudinal study.  Table 4.2 shows the potential predictors that will be included in 
the models a priori. 
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Table 4.2 Potential predictors that may be included in the regression models 
Explanatory 
variables at 
baseline  
Somatic 
symptom 
severity 
Quality of 
life 
 
Depression 
 
Anxiety 
 
Health 
service 
use 
Somatic symptom 
severity  
X X X X X 
Duration of 
symptoms 
X X X X X 
Quality of life X X X X X 
Management of 
symptoms  
X X X X X 
Social functioning X X X X X 
Self-efficacy  X X X X X 
Stressful life events X X X X X 
Depression X X X X X 
Panic  X X X X X 
Anxiety X X X X X 
Family health 
during childhood 
X X X X X 
Traumatic 
experiences in 
childhood 
X X X X X 
Age X X X X X 
Sex X X X X X 
Education X X X X X 
Employment  X X X X X 
Financial situation X X X X X 
Perceived social 
support 
X X X X X 
GP practice where 
participant 
 was recruited 
X X x x x 
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 Statistical analysis 4.10.3
I used Stata version 12 (StataCorp, 2011) to conduct my analyses.  First, for each 
stage of the study I produced histograms of continuous variables to visualise the 
data in terms of dispersion, centring and shape to check for normality (Altman, 
1990). This enabled me to determine whether descriptive data should be presented 
as means with standard deviations (SD) or medians with interquartile range (IQR).  
Categorical data were explored using frequencies and percentages. I used 
regression analysis to explore the univariable association of baseline variables with 
outcome variables. This was followed by multivariable regression modelling to 
identify potential factors associated with outcome variables (Altman,1990). The 
specific methods that were in each stage of the study are described below.  
 
4.10.3.1 Screening data 
At the screening stage, somatic symptom scores and basic characteristics such as 
age, sex and presence of any explanations or diagnoses were summarised.  
Responder self-reports of explanations for symptoms were categorised into 
unexplained, fully explained by physical diagnoses, partially explained by a physical 
diagnosis (e.g. diabetes, arthritis and medicine side effects), psychological 
explanations (e.g. stress, anxiety or depression) and functional diagnoses (e.g. 
irritable bowel syndrome or chronic fatigue). Characteristics of responders were 
also explored stratified by symptom severity according to the previously discussed 
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cut-offs 0-4 (minimal severity), 5-9 (low severity), 10-14 (moderate severity) and 
15> high severity. Results are discussed in Chapter 5.  
   
4.10.3.2 Baseline data 
At baseline, I compared the characteristics of those who returned baseline 
questionnaires to those who did not, using data from the screening questionnaire. 
This included basic characteristics such as age, sex and any explanations or 
diagnoses (or lack of). I then used summary statistics to describe baseline 
characteristics of the cohort study participants overall and stratified by gender. 
Results are discussed in Chapter 6.  
 
4.10.3.3 Longitudinal study 
4.10.3.3.1   Descriptive, univariable analyses and conceptual group analysis  
I compared the baseline characteristics of those of those who returned follow-up 
questionnaires to those who did not, using summary statistics. I then explored the 
characteristics of those who returned questionnaires overall and stratified by 
gender.  Univariable analyses was conducted with each of the baseline variables 
and the primary outcome measure somatic symptoms at six month follow-up, as 
well as the secondary outcome variables physical health functioning, mental health 
functioning, depression, anxiety and primary health care contact. In addition to 
exploring the baseline variables that I discussed in section 4.8.1, I also conducted 
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univariable analysis with practice as an independent variable. The residuals for 
continuous outcomes were checked for normality and all were found to be 
approximately normally distributed; hence, there was no need to transform any of 
the data.  
 
This step was followed by conceptual group modelling, a method used to reduce 
number of variables included in the final multivariable analysis (Marston et al., 
2007). Multivariable analyses were conducted using variables that are significantly 
associated with the outcome variables (p<0.05) and theoretically considered to be 
measuring similar characteristics amongst the study population. For example a 
conceptual group consisted of socioeconomic factors; education level, employment 
status, index of multiple deprivation score, and perception of financial well-being 
would be placed in the same conceptual group if they were significantly associated 
with the outcome. 
 
4.10.3.3.2   Multivariable regression modelling  
Finally, variables that showed strong significant associations (p <0.05) in the 
univariable and/or conceptual group analysis were included in the multivariable 
regression models (Mallet et al.,2010). I also chose to include gender and age in all 
multiple regression models a priori. Based on statistical reasoning, each model was 
also adjusted for the baseline value of the outcome variable of interest. 
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These models were used to determine which baseline factors were associated with 
the primary and/or secondary outcomes at six months follow-up. The decision 
making process on variables to include in modelling cannot be based on p-value 
alone but must identifying a meaningful difference on outcomes (Mallet et al.,2010; 
Lewis and Ward, 2013). The theoretical basis for the inclusion of variables in the 
modelling process for this study was based on prior evidence from literature and 
clinical judgement. All outcomes were continuous measures and so I conducted 
multivariable linear regression (Altman,1990).  Backwards elimination was used; all  
identified variables included in the model and then taken out  one by one starting 
with the one with the highest p-value and continuing until only variables with p-
value of <0.05 remained (and/ or those included in the model a priori).  
 
 Missing data 4.10.4
Specific ways of handling missing data have been prescribed in several of the 
validated questionnaires and instruments used. For example, for the PHQ-15, PHQ-
9 and GAD-7 several methods have been suggested including a ‘conservative 
approach’ to count missing responses as implying that the respondent was not 
bothered by the item (Kroenke et al., 2010). This method was developed based on 
the assumption that missing data on each of these questionnaires are generally 
small and less than 5% of participants (Kroenke et al., 2010). Any missing data for 
the questionnaires mentioned were entered as zero from the stage of data entry 
rather than as missing. Table 4.3 shows a summary of how missing data has been 
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handled. However, missing data was minimal and accounted for less than 0.5% of 
data at each time point.  The largest amount of missing data were found in health 
service contacts and accounted for 2.6% of data. This included a number of 
participants had joined the practice less than a year before study participation or 
left the practice before the end of the data collection period. Another four people 
did not wish their medical records to be accessed.  
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 Table 4.3 Methods of dealing with missing data on variables include in the study 
Questions and 
instruments used  
Methods of dealing with missing data Source 
Somatic symptom 
severity (PHQ-15) 
Missing data treated as respondent did not 
experience that symptom and therefore 
scored as ‘not bothered at all’ 
Kroenke et al., 2010 
Duration of 
symptoms 
If participant gave different dates for different 
symptoms, the duration for the longest 
bothersome symptom was included. If no data 
was available, it was left as missing and not 
imputed. 
In consultation with 
clinical and statistics 
supervisors 
Quality of life  
(SF-12) 
Missing Score Estimator (also referred to as 
Maximum Data Recovery) feature is included 
in the software used. It applies a value to a 
missing item if at least one of the items in the 
scale has valid data. A scale receives a missing 
score only if all the items in the scale are 
missing. Physical and mental health 
component summary scores are calculated 
when at least seven of the eight profile scales 
have valid data. For PCS this must include PF 
and for MCS it must include MF.    
QualityMetric 
Incorporated, 2012 
Management of 
symptoms  
If not ticked, it was assumed that specific 
source of support was not used. 
In consultation with 
clinical and statistics 
and supervisors 
Work and Social 
functioning (WSAS) 
If a respondent selected non-applicable for 
question 1, or if one value is missing, then 
total scores were pro-rated from non-
missing items.  
Department of 
Health,2011a 
General Self-Efficacy 
(GSE) 
As long as no more than three items on the 10 
item scale were missing, missing values were 
imputed with the mean scores of the total, from 
completed items as suggested by the developers 
of the questionnaire. 
Schwarzer, 2005 
List of threatening 
experiences (LTE-Q) 
Questions focused on whether the respondent 
experienced the event in the previous six months, 
if incomplete it was assume that they did not 
experience that particular event 
In consultation with 
clinical and statistics 
and supervisors 
Depression (PHQ-9) Missing data treated as respondent did not 
experience that symptom and therefore scored as 
‘not bothered at all’ 
Kroenke et al., 2010 
Panic (PHQ-PD) Missing data treated as respondent did not 
experience that symptom and therefore scored as 
‘not bothered at all’ 
Kroenke et al., 2010 
Anxiety (GAD-7) Missing data treated as respondent did not 
experience that symptom and therefore scored as 
‘not bothered at all’ 
Kroenke et al., 2010 
Family health during 
childhood 
If incomplete, left as missing, not imputed In consultation with 
statistician and 
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supervisors 
Traumatic 
experiences in 
childhood 
If incomplete, left as missing, not imputed In consultation with 
statistician and 
supervisors 
Age Determine age from screening questionnaire or 
from medical records if participant had provided 
consent to access these 
In consultation with 
statistician and 
supervisors 
Sex Refer screening questionnaire or if consent given 
to access medical records.  
In consultation with 
statistician and 
supervisors 
Education If incomplete, left as missing, not imputed  In consultation with 
statistician and 
supervisors 
Employment  If incomplete, left as missing, not imputed  In consultation with 
statistician and 
supervisors 
Financial situation If incomplete, left as missing, not imputed  In consultation with 
statistician and 
supervisors 
Perceived social 
support 
If incomplete. left as missing, not imputed  In consultation with 
statistician and 
supervisors 
 
  Summary 4.11
In this chapter, I have detailed the study design, described recruitment of 
participants, variables included in the questionnaires used and finally the analysis. 
In the next chapter, I present the results from the screening stage (see Chapter 5), 
followed by results of the main cohort study (Chapter 6 and Chapter 7). My findings 
have been presented at a number of national conferences and a paper for 
publication is in preparation (see Appendix 5).  In Chapter 8, I draw together the 
findings, by comparing them to existing literature, discuss the strengths and 
limitations of my study, implications and areas for future research before I make my 
final conclusions.  
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Results of screening stage Chapter 5 : 
 
 Chapter overview  5.0
In this chapter I report results of the screening stage of the study, conducted with 
the main aim to identifying those who would be eligible for the longitudinal study. 
First, I present characteristics of the general practices where screening took place. 
Second, I report the characteristics of those who completed the screening 
questionnaires overall, by gender and symptom severity (minimal, low, moderate 
and high).  
 
 Results of recruitment of general practices and 5.1
participants   
Twenty practices from urban and suburban areas of north London were contacted; 
one replied to say that they were not interested, nine practices took part in the 
study and I received no response from the others (see section 4.2). The list sizes of 
these practices varied from 5122 to 17,494.  Index of Multiple Deprivation score 
(IMD) for the practices ranged from 12 (least deprived) to 46.8 (most deprived). The 
number of doctors conducting surgeries during recruitment periods ranged from 2 
to 10 and numbers of nurse or health care assistant clinics ranged from 0 to 6. 
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In the nine practices where screening was conducted, 5,614 consecutive attenders 
were approached and invited to complete the screening questionnaire (see Section 
4.6 for details on recruitment). A note was kept of the numbers who were in 
attendance in the waiting rooms; in total I was able to approach 5,362/6,178 (87%) 
of attenders. Of these 524 were excluded, as they were unable to understand or 
complete the questionnaire in English, were under 18 years age or not registered at 
the practice. A further 458 attenders were called in for their appointment, before 
having a chance to finish reading the leaflet and/or complete the questionnaire and 
475 reported having already received information on the study or completing the 
questionnaire, on a previous occasion. Out of those who were approached 1,070 
declined to participate, including 187 who said the reason for this was that they had 
no unexplained symptoms. Therefore, 2,826/3,896 (73%) of potentially eligible 
attenders completed the questionnaire. Figure 5.1 shows detail on participant 
identification and screening, including numbers excluded or ineligible to take part in 
this stage of the study. 
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Figure 5.1 Flow diagram of entry and exclusion at screening phase. 
 
 
 
 
 
155 
 
 Descriptive findings of the screening data overall 5.2
Over two-thirds of respondents who completed the screening questionnaire were 
female (n=1,931/2,826, 68%) and age distribution was right skewed with a median 
age of 42 years with interquartile range (IQR) 30 to 55 (see Table 5.1). Those who 
completed the questionnaires had a median PHQ-15 symptom score of 7 (IQR 4, 
11), which is in the low symptom severity range on the PHQ-15.  Most had at least 
one unexplained symptom (2,425/2,826 (86%)) and close to half had symptoms that 
they reported as not having any explanation or diagnosis (1,393/2,826 (49%)). Just 
under half of those screened provided some explanation for their symptoms 
(1,248/2,826, (44%)), which were categorised as shown in table 5.1. These included 
functional diagnoses (100/2,826 (4%)); psychological explanations (187/2,826 (7%)) 
and physical explanations or diagnoses (921/2,826 (33%)). When the natures of 
symptom experienced by the participants were explored (Table 5.2) it was found 
that there was a good spread of most of the 15 symptoms.  Back pain (10%), pain in 
arms and legs (10%) and feeling tired or having little energy (12%) were the most 
frequently reported but more than two thirds had experienced some of the other 
12 symptoms.    
 
When characteristics of the cohort were stratified by gender, there were few 
differences between males and females on types of explanations given for 
symptoms or percentages who were consulting about their symptoms that day. The 
main difference between males and females was age and symptom severity. Female 
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(median 40 years IQR 30, 55) were younger than males (median 46 years IQR 32, 
61), and had greater median symptom scores (females 8 IQR 4, 12 vs males 5 IQR 3, 
9). In the next section, I provide descriptive results on the participants, stratified by 
symptom severity. 
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Table 5.1 Characteristics of all waiting room attenders who completed the screening questionnaire by total cohort and stratified by 
symptom severity. Results displayed as N (%) unless otherwise indicated 
 
 
 
 
 
 
 
 
 
 
 
 Total 
N=2826 
PHQ-15 0-4 
N=891 
PHQ-15 5-9 
N=963 
PHQ-15 10-14 
N=595 
PHQ-15 >15 
N=377 
Gender       
 Males 873 (31%) 375 (42%) 293 (30%) 133 (22%) 72 (19%) 
 Female 1931 (68%) 505 (57%) 665 (69%) 459 (77%) 302 (80%) 
 Missing 22 (1%) 11 (1%) 5 (1%) 3 (1%) 3 (1%) 
      
Age†  42 (30,55) 43 (31,59) 40 (29,55) 43 (31,59) 43 (33,53) 
      
Consulting about symptoms today  
  
   
 Yes 1073 (38%) 200 (22%) 360 (37%) 287 (48%) 226 (60%) 
 No 1321 (47%) 548 (62%) 471 (49%) 212 (37%) 90 (24%) 
 Missing 432 (15%) 143 (16%) 132 (14%) 96 (16%) 61 (16%) 
  
One or more unexplained symptoms 2425 (86%) 628 (71%) 890 (92%) 558 (94%) 349 (93%) 
      
Fully unexplained (no explanations for any of their 
symptoms) 
 
1393 (49%) 
 
463 (52%) 
 
496 (52%)  
 
286 (48%) 
 
148 (39%) 
      
Fully explained (explanations for all symptoms) 40 (1%) 33(4%) 4 (0%) 1 (0%) 2 (1%) 
      
Functional diagnoses 100 (4%) 11 (1%) 27 (3%) 31 (5%)  31 (8%) 
      
Psychological explanations or mental health 
diagnoses  
 
187 (7%) 
 
17 (2%) 
 
69 (7%) 
 
50 (8%) 
 
51 (14%) 
      
Physical explanations or health diagnoses (partial 
explanations or diagnosis for symptoms) 
 
921 (33%) 
 
163 (18%) 
 
350 (36%) 
 
236 (40%) 
 
172 (46%) 
† Median (IQR)      
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Table 5.2. Symptoms reported by waiting room attenders who completed the screening questionnaire by total cohort and stratified 
by gender. Results displayed as N(%). 
 
Symptom Total* 
N=2826 
Male 
N=873 
Female 
N=1,931 
Stomach Pain 953 (6%) 241 (6%) 702 (6%) 
Back Pain 1596 (10%) 442 (11%) 1141 (10%) 
Pain in arms, legs or joints (e.g. 
hips, knees) 
1676 (10%) 508 (12%) 1155 (10%) 
Menstrual cramps or other 
problems with your periods 
[women only] 
734 (5%) 9 (0%) 721 (6%) 
Headache 1352 (8%) 325 (8%) 1017 (9%) 
Chest pain 691 (4%) 221 (5%) 463 (4%) 
Dizziness 951 (6%) 254 (6%) 691 (6%) 
Fainting spells 317 (2%) 76 (2%) 239 (2%) 
Feeling your heart pound or race 903 (6%) 237 (6%) 660 (6%) 
Shortness of breath 975 (6%) 290 (7%) 677 (6%) 
Pain or problems during sexual 
intercourse 
367 (2%) 91 (2%) 274 (2%) 
Constipation, loose bowels or 
diarrhea 
1023 (6%) 266 (6%) 752 (6%) 
Nausea, gas or indigestion 1056 (7%) 265 (6%) 784 (7%) 
Feeling tired or having little energy 1939 (12%) 506 (12%) 1421 (12%) 
Trouble sleeping 1485 (9%) 410 (10%) 1067 (9%) 
Total symptoms reported 16018 (100%) 4141 (100%) 11764 (100%) 
*Gender information missing for N=22
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 Comparing characteristics stratified by symptom 5.3
severity 
The characteristics of primary care attenders were stratified by symptom severity 
(see Table 5.1). Scores were stratified by PHQ-15 groups where 0-4 (891/2,826) are 
considered to have minimal severity, 5-9 (963/2,826) is considered to be 
representative of low symptom severity, 10-14 (595/2,826) of moderate severity 
and >15 (377/2,826) high severity. Scores of >5 are considered to represent 
significant symptom severity; two thirds (1935/2,826) of all those who completed 
the screening questionnaires scored >5 (see Table 5.1). Of those who scored >5, the 
half experienced low symptom severity (963/1,935, 50%) with scores between 5-9, 
595 /1935 (31%) reported scores of 10-14 and 377/1,935 (19%) reported scores 
>15. Generally, the percentage of women increased as symptom severity increased 
but the median age of responders within each of the severity groups were similar 
(see Table 5.1).  
 
All severity groups consisted of similarly high percentages who had one or more 
unexplained symptom (PHQ-15 5-9, 92%; PHQ-15 10-14, 94%; PHQ-15 15>, 93%), 
except for the minimal severity group where fewer had at least one UPS as might be 
expected (PHQ-15 0-4, 71%). Similar percentages of responders whose symptoms 
were within the minimal and low symptom severity groups reported that their 
symptoms were fully unexplained (PHQ-15 0-4, 52%; and PHQ-15 5-9, 52%). 
However, as symptom severity increased, percentages of responders with fully 
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unexplained symptoms decreased (PHQ-15 10-14, 48%; and PHQ-15 >15, 39%) and 
those with functional diagnosis, psychological or partial explanations for their 
symptoms increased (see Table 5.1). The percentage of screening questionnaire 
completers who reported consulting about their symptoms that day also increased 
as symptom severity increased. Each severity group was explored stratified by 
gender; there was little variability between males and females within each of the 
severity groups, other than with regards to age, which consistently showed that 
males were older than females.  
 
 Participants considered eligible for next stage of study  5.4
Those who scored at five or more on the PHQ-15, after any explanations for their 
symptoms were taken to account were considered eligible for the cohort study (see 
section 4.7). A total of 1,632/2,826 (58%) were considered eligible for the next 
stage; 1,196/2,826 (42%) were eligible and also expressed interest in being 
contacted regarding the next stage of the study. The characteristics of those who 
took part in the longitudinal study will be discussed in further detail in Chapter 6.  
 
 Summary    5.5
This chapter presents findings from the first stage of the study, where consecutive 
waiting room attenders were invited to complete a screening questionnaire 
regarding their symptoms.  A high proportion of those who were present in the 
waiting room were approached (91%) and a high proportion completed the 
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questionnaires (73%). The screening questionnaire completers had a median 
symptom severity score of 7 (IQR 4, 11); over two-thirds were female and median 
age was close to 40 years. Females were younger than males and had higher 
symptom severity.  
 
When stratified by symptom severity, percentage of females in each group 
increased, as symptom severity increased. The majority of primary care attenders 
had at least one unexplained symptoms and close to half had symptoms that they 
reported as having no explanation or diagnoses (fully unexplained). Close to half of 
those screened also provided some explanations for their symptoms, which were 
categorised into partial physical, mental health or functional diagnoses. As 
symptom severity increased, the percentages of those who had mixed symptoms 
with partial physical explanations increased. Just over a third of all those screened 
were consulting about their symptoms that day; percentages of those who were 
consulting about their symptoms also increased with increasing symptom severity.  
Of all those considered eligible, nearly three-quarters agreed to be contacted for 
the longitudinal study. In the following chapter (see Chapter 6), I present the results 
of those took part in my cohort study. 
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Baseline results of cohort study  Chapter 6 : 
 
 Chapter overview 6.0
In this chapter, I present the findings of my cohort study. First, I describe the 
characteristics of the study participants, compared to those who were eligible and 
expressed interest in the longitudinal study but who did not return questionnaires. 
This is followed by a detailed description of the study cohort with respect to the 
baseline sociodemographic and clinical characteristics, and the frequency of 
primary and secondary health care contact. I explore the cohort characteristics 
overall and by gender. 
 
 The longitudinal study cohort  6.1
In total, 301 participants returned questionnaires. Questionnaires were 
inadvertently sent to four respondents from the screening stage that were later 
confirmed as ineligible and removed from the longitudinal study cohort (not shown 
in Figure 6.1). Three of the returned questionnaires were excluded as they were 
received after the study closed (see Figure 6.1). The final longitudinal study sample 
consisted of 294/1,196 participants; this was 25% of those eligible and consenting 
to take part in the study.  
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the baseline questionnaires; and 3) were included in the longitudinal study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Characteristics of the study cohort vs non-responders 6.2
The study cohort was fairly similar to non-responders on all key variables including 
age, symptom severity, and explanations of existing diagnoses provided for 
symptoms (completely unexplained, partially explained by physical symptoms, 
functional and mental health diagnosis). Suggesting that those who returned the 
questionnaires, were representative in their characteristics of those all who were 
eligible and consented to be contacted, but did not return the questionnaires (see 
Table 6.1). Female study participants and non-responders were comparable on all 
1196 Eligible and consenting 
297 returned baseline questionnaire   
Excluded as returned 
questionnaire after study 
closed (3) 
 
294 included in longitudinal study 
Figure 6.1 Shows number of those: 1) eligible and consenting to be contacted; 2) that 
returned the baseline questionnaires; and 3) were included in the longitudinal study. 
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items explored (see Table 6.1). Males who responded were older than those who 
did not; median age of responders was 53 years compared to non-responders 43 
years. Amongst males, a greater percentage of responders had partially explained 
physical symptoms (49%) compared to non-responders (29%); and a greater 
percentage of non-responders had completely unexplained symptoms (63%) 
compared to responders (40%). One can speculate that some of those who did not 
respond to the baseline questionnaire may have received an explanation for their 
symptoms following the initial visit to the doctor.  Others may have been waiting for 
their test results or follow-up appointments and therefore felt that their symptoms 
were not yet unexplained and hence chose not to return the questionnaire.  There 
may also have been a proportion of people whose symptoms subsided without the 
need for further investigation, tests or receiving a diagnosis.  All these possibilities 
would suggest that those responding were perhaps most likely to be more troubled 
by their problems that non-responders.     
 
In the next section, the study cohort will be described in further detail using data 
collected at baseline. 
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Table 6.1 Characteristics of study responders vs non-responders. Results displayed as: N (%) unless otherwise specified. 
  Cohort study participants Non-responders 
  
Total 
N=294 
Male 
N= 63 (21%) 
Female 
N=231 (79%) 
Total 
N=902* 
Male 
N=225 (25%) 
Female 
N=676 (75%) 
Age (years) †  44 (32,57) 53 (36,66) 41 (31,53) 40 (30,52) 43 (30,55) 39 (30,51) 
Symptom severity (PHQ-15 score)†  11 (8,14) 9 (7,13) 11 (8,14) 10 (7,17) 9 (7,12) 11 (8,14) 
Consulting about symptoms today  150 (51%) 24 (38%) 126 (55%) 416 (46%) 102 (45%) 314 (46%) 
Fully unexplained 159 (54%) 24 (40%) 134 (58%) 518 (57%) 141 (63%) 376 (56%) 
Partially explained by physical symptoms 113 (38%) 31 (49%) 82 (35%) 318 (35%) 66 (29%) 252 (37%) 
Partially explained by a functional diagnoses 17 (6%) 3 (5%) 14 (6%) 45 (5%) 8 (4%) 37 (5%) 
Partially explained by a mental health diagnosis 30 (10%) 8 (13%) 22 (10%) 85 (9%) 19 (8%) 67 (10%) 
† Median (IQR) 
* Gender missing for 1 respondent 
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 Baseline reporting of cohort characteristics 6.3
 Sociodemographic characteristics  6.3.1
The study cohort consisted of 231/294 (79%) females and the sample was 
ethnically diverse; less than half of the sample was white British (125/294 (43%)). 
Just over half the participants were married or in a long term relationship 
(155/294 (53%)) and most (247/294 (84%)) reported having someone they could 
rely on for practical or emotional support, which included family members and 
friends. Close to a half of participants were in paid employment (139/294 (47%)), 
whilst the majority of those who were not in paid employment were either retired 
(36/294 (12%)), unable to work due to long term sickness or disability (35/294 
(12%)), or unemployed (34/294 (12%)). The cohort included 125/294 (43%) who 
reported having a university degree or higher. Just over half of the cohort 
reported their perceived financial well-being as ‘doing well’ (140/294 (48%)). 
Mean Index of Multiple Deprivation (IMD) score for the cohort was 35 (SD 13).  
 
Baseline characteristics stratified by gender, showed female participants to be 
younger than males; mean age for females was 41 years compared to 53 years for 
males. However on all other sociodemographic variables, female and male 
respondents were fairly comparable (see Table 6.2).   
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Table 6.2 Sociodemographic characteristics for total study cohort and by gender 
Results displayed as N (%) unless otherwise indicated 
Sociodemographic characteristics Total 
(n=294) 
Male 
(n=63) 
Female 
(n=231) 
Age  (years)† 44 (32,57) 53 (36,66) 41 (31,53) 
Ethnic group   
    White (combined) 215 (73%) 44 (70%) 171 (74%) 
  White British 125 (43%) 27 (43%) 98 (42%) 
  White Irish 32    (11%) 6    (10%) 26 (11%) 
  White other 58    (20%) 11 (17%) 47 (20%) 
 Black 14   (5%) 2    (3%) 12 (5%) 
 Asian 45   (15%) 14 (22%) 31 (13%) 
 Mixed 10   (3%) 2    (3%) 8 (3%) 
 Other 9     (3%) 0   (0%) 9 (4%) 
 Missing 1     (0%) 1    (2%) 0 (0%) 
Marital status  
   
 
Married or in a long term 
relationship 155 (53%) 38 (60%) 117 (51%) 
 
Widowed, separated, 
divorced or single 135 (46%) 25 (40%) 110 (47%) 
 Missing 4 (1%) 0 (0%) 4 (2%) 
Employment status 
    In paid employment 139 (47%) 27 (43%) 112 (48%) 
 Other 153 (52%) 36 (57%) 117 (51%) 
  Retired 36 (12%) 12 (19%) 24 (10%) 
  Unable 35 (12%) 9 (14%) 26 (11%) 
  Unemployed 34 (12%) 10 (16%) 24 (10%) 
   Looking after family or home 25 (9%) 2 (3%) 23 (10%) 
  Full time education 15 (5%) 2 (3%) 13 (6%) 
  Doing something else 5 (2%) 0 (0%) 5 (2%) 
  Voluntary work 3 (1%) 1 (2%) 2 (1%) 
 Missing 2 (1%) 0 (0%) 2 (1%) 
Education  
   
 
No qualification/GCSE/A-
levels or equivalent 162 (55%) 42 (67%) 120 (52%) 
 
Bachelor's degree / Master's 
Degree/ PhD or equivalent 125 (43%) 20 (32%) 105 (45%) 
 
Missing 7 (2%) 1 (2%) 6 (3%) 
Financial situation  
    Doing well 140 (49%) 27 (48%) 113 (43%) 
 Doing badly 149 (49%) 35 (51%) 114 (56%) 
 Missing 289 (2%) 1 (2%) 4 (2%) 
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Sociodemographic characteristics Total 
(n=294) 
Male 
(n=63) 
Female 
(n=231) 
 
IMD score*§ 
 
35.1 (13.1) 
 
38.2 (13.4) 
 
34.3 (13.0) 
 Missing 10 (3%) 3 (5%) 7 (3%) 
Social support available 
    Yes 247 (84%) 47 (75%) 200 (87%) 
 No 45 (15%) 16 (25%) 29 (13%) 
 Missing  2 (1%) 0 (0%) 2 (1%) 
Results displayed as: † Median (IQR), § Mean (SD) 
*IMD = Index of Multiple Deprivation score 
 
 
 Clinical characteristics   6.3.2
In terms of clinical characteristics (see Table 6.3), the cohort was a moderately 
severe group with a mean baseline symptom severity of 11.5 (SD 4.9). As shown in 
Figure 6.2, symptom duration was right skewed; most participants had 
experienced their symptoms for over a year (212/294 (72%)) with a median 
duration of 36 months (IQR 15, 72). Figure 6.3 shows distribution of symptoms 
amongst those who reported experiencing symptoms for less than one year; the 
majority reported experiencing symptoms for 11 months. Physical and mental 
health functioning was fairly low with scores of 43.8 (SD 10.6) and 39.6 (SD 11.0) 
based on the SF-12 on the physical and mental health component scores (out of a 
potential score of 100).  Median depression (9 IQR 5, 14) and mean anxiety (8.9 SD 
5.8) scores fell into the to moderate severity range. Amongst the cohort, 134/294 
(46%) had scores >10 on the PHQ-9 for depression and 119/294 (40%) scored >10 
on the GAD-7 for anxiety; 97/294 (33%) scored >10 on their respective scales for 
both anxiety and depression. When a cut-off of >12 on the PHQ-9 was considered 
this accounted for 104/294 (35%) of the cohort.  
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The majority (70%) had experienced one or more stressful life events, in the 
previous six months with a median score of 1 (IQR 0, 2). With regard to childhood 
experiences, just over a third (94/294 (32%)) reported experience of poor physical 
health in family members whilst they were growing up and around a third (93/294 
(32%)) reported experiencing traumatic events. Types of trauma included illness in 
family members, death of loved ones, accidents, abuse and war. Close to a third 
(77/294 (26%)) reported experience of childhood abuse. Further enquiry was 
made to the type of abuse experienced, amongst the non-mutually exclusive 
categories of physical, sexual and emotional abuse; most reported experience of 
emotional abuse (59/294 (20%)).  
 
Figure 6.2 Symptom duration at baseline in years 
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Figure 6.3 Distribution of symptom duration at baseline, amongst those 
experiencing symptoms for a year or less in months 
 
 
 
                     
     
         
 
 
 
Clinical variables are also shown in Table 6.3 stratified by gender. The clinical 
characteristics of males and females were similar. There were only a few 
differences with reference to experiences during childhood. For example a slightly 
greater percentage of males reported having experienced physical illness in family 
members as a child compared to females (37% vs 31% respectively), whilst more 
females reported having experienced mental illness in family members as a child 
compared to males (18% vs 8% respectively).  Females also reported more sexual 
abuse (10% vs 3%) and experience of traumatic events (33% vs 27%).  
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In this chapter, the characteristics of the study cohort have been explored and 
reported, overall and stratified by gender. As there were few gender variations in 
both sociodemographic and clinical variables (see Table 6.2 and 6.3), the main 
analyses in this study have been conducted as a complete group without gender 
stratification (see Chapter 7).  
 
 
Table 6.3 Clinical characteristics for total study cohort and by gender 
Results displayed as N (%) unless otherwise indicated. No missing data unless 
otherwise indicated 
Clinical characteristics Total 
N=294 
Male 
N=63 
Female 
N=231 
Baseline symptom severity  
(PHQ-15 score)§ 
 
11.5 (4.9) 
 
11.0 (5.0) 
 
11.7 (4.9) 
Symptom duration    
 <1 year 63 (21%) 14 (22%) 49 (21%) 
 >1 year 212 (72%) 43 (68%) 169 (73%) 
 Missing  19 (6%) 0 (0%) 19 (8%) 
SF-12 score*§    
 Physical health functioning¹ 43.8 (10.6) 42.9 (10.6) 44.1 (10.6) 
 Mental health functioning 39.6 (11.0) 41.0 (11.1) 39.2 (11.0) 
Work and social adjustment score § 18.7 (11.5) 19.1 (11.5) 18.5(11.5) 
 
Missing 6 0 6 
Self-efficacy score§ 27.4 (7.4) 27.4 (7.2) 27.4 (7.4) 
 Missing  4 0 4 
Anxiety score§ 8.9 (5.8) 8.2 (5.8) 9.0 (5.7) 
Depression score§ 9(5,14) 9 (4,14) 9 (5,14) 
Panic    
 Yes 62(21%) 12 (19%) 50 (22%) 
 No 204(69%) 43 (68%) 161 (70%) 
 Missing 28(10%) 8 (13%) 20 (9%) 
 
Stressful life events† 
 
1 (0,2) 
 
1 (1,3) 
 
1(0,2) 
 
Missing 3 1 2 
 
Experienced physical illness in    
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Clinical characteristics Total 
N=294 
Male 
N=63 
Female 
N=231 
family as a child 
 Yes 94 (32%) 23 (37%) 71 (31%) 
 No 194(66%) 39 (62%) 155 (67%) 
 Missing  6(2%) 1 (2%) 5 (2%) 
Experience mental illness in family 
as a child    
 Yes 47(16%) 5 (8%) 42 (18%) 
 No  242(82%) 57 (90%) 185 (80%) 
 Missing  5(2%) 1 (2%) 4 (2%) 
Experienced 1 or more traumatic 
event as child    
 Yes 93(32%) 17 (27%) 76 (33%) 
 No  192(65%) 43 (68%) 149 (65%) 
 Missing  9(3%) 3 (5%) 6 (3%) 
Experienced any abuse as a child 
   
 Yes 77(26%) 16 (25%) 61 (26%) 
 No  204(69%) 46 (73%) 158 (68%) 
 Missing  13(4%) 1 (2%) 12 (5%) 
Type of abuse experienced as a 
child**    
 Physical abuse    
  Yes 31(11%) 8 (13%) 23 (10%) 
  No  253(86%) 54 (86%) 199 (86%) 
  Missing  10(3%) 1 (2%) 9 (4%) 
 
Sexual abuse  
  
  Yes 25(9%) 2 (3%) 23 (10%) 
  No  259(78%) 60 (95%) 199 (86%) 
  Missing  10(3%) 1 (2%) 9 (4%) 
 
Emotional abuse 
   
  Yes 59 (20%) 13 (22%) 46 (20%) 
  No  225(77%) 49 (78%) 176 (76%) 
  Missing  10(3%) 1 (2%) 9 (4%) 
*SF-12 = Short Form Health questionnaire ** Possible to tick more than one type of abuse 
Results displayed as: † Median (IQR), §Mean (SD) 
¹Missing data for one male participant 
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 Health service use in the year prior to study inclusion 6.3.3
Health care use of participants was explored for the year prior to study 
participation (see Table 6.4). In total, as shown the median frequency of primary 
care contacts was 8 (IQR 4, 12) and ranged from 1 to 54 contacts and was similar 
amongst males and females. Secondary care contacts were lower with median 
frequency of 1 (IQR 0, 2) ranging from 0 to 10.  In total, 51/294 (17%) had received 
a prescription for antidepressants, hypnotics or antipsychotics in the year before 
study enrolment and there was no large difference between receipt of 
prescription between males and females; 14% of males received a prescription 
compared to 18% of females.  
 
Table 6.4 Health service use for total study cohort and by gender in one year 
prior to study participation 
Results are displayed as median (IQR) unless stated 
 
 Health service use 
Total 
(n=288) 
Male 
(n=62) 
Female 
(n=226) 
Primary health contacts * 8 (4,12) 8 (4,14) 8 (4,12) 
Secondary care contacts **  1 (0,2) 1 (0,3) 1 (0,1) 
Psychotropic drug prescription¥  51 (17%) 9 (14%) 42 (18%) 
* Includes doctors, nurses, health care assistants and out of hours GP services 
** Includes secondary care referrals and A&E access 
¥ Results displayed as N (%)  
 
 
 
 
 
174 
 
 Preferences for help-seeking 6.3.4
The majority (217/294 (74%)) reported that they would seek help for their 
symptoms (see Table 6.5). Most (218/294 (74%)) reported that they would seek 
help from their general practitioners (GPs), the next largest source of help seeking 
was the internet (103/294 (30%)) followed by family (88/294 (30%)) and friends 
(82/294 (28%)). A few people reported turning to religious advisor (16/294 (5%)). 
There were no major differences in terms of preferences for sources of help 
seeking in terms of gender.  
 
Table 6.5: Preferences for sources of help-seeking for total study cohort and by 
gender  
Results displayed as N (%) unless otherwise indicated 
 
 Preferences for help-seeking  
Total 
(N=294) 
Male 
(n=63)  
Female 
 (n=231) 
On your own 54 (18%) 14(22%) 40(17%) 
Like some help  217(74%) 40(63%) 177(77%) 
Unsure 21 (7%) 9(14%) 12(5%) 
Missing 2(1%) 0(0%) 2(1%) 
Where do you turn for help?*  
 
  
 Internet  103 (35%) 20(32%) 83(36%) 
 Family 88(30%) 17(27%) 71(31%) 
 Friends 82(28%) 19(30%) 63(27%) 
 Religious advisor 16(5%) 3(5%) 13(6%) 
 GPs 218(74%) 44(70%) 174(75%) 
 Psychologist or counsellor 44(15%) 8(13%) 36(16%) 
 Complementary therapy 67(23%) 9(14%) 58(25%) 
 Other 33(11%) 5(8%) 28(12%) 
 Missing 1(0%) 0(0%) 1(0%) 
*Categories are non-mutually exclusive 
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 Summary  6.4
Data from the screening questionnaires were used to determine the 
representativeness of the longitudinal study cohort. Those who returned 
questionnaires were a representative sample of those who were eligible and 
consented to take part, although males who participated were older.  
 
The baseline questionnaire data was used to explore the characteristics of the 
longitudinal study cohort overall and by gender. The cohort consisted of a 
majority of females, who were younger in age to males; as there were few other 
notable differences in sociodemographic and clinical variables, the main analyses 
in this study have been conducted as a complete group without gender 
stratification.  
 
The cohort was a fairly morbid group with moderately severe somatic symptoms, 
depression and anxiety scores; a majority had experienced symptoms for a year or 
more. Most had experienced a stressful event in the previous six months. Around 
a third had difficult childhood experiences relating to abuse.  A third reported 
poor health in family members and a third reported experience of traumatic 
events. Most accessed primary care; with a median frequency of 8 (4, 12) and 
preferred to turn to others, generally their GPs, for health problems. Secondary 
referrals were low with a median frequency of 1 (0, 2). In the next chapter, I 
report the characteristics of the study cohort and main results of the study.  
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Follow-up results of cohort Chapter 7 : 
study  
 
 Chapter overview 7.0
In this chapter, I present the main results of my study. First, I use the baseline 
results to compare the characteristics of the responders at follow-up to non-
responders. Second, the cohort characteristics are described at follow-up. Finally, 
the main analyses of the study are reported with respect to factors associated 
with: 1) the primary outcome somatic symptom severity; and 2) the secondary 
outcomes (physical and mental health functioning, depression, anxiety and 
primary health care contact).   
 
 Characteristics of responders compared to non-7.1
responders at follow-up  
At follow-up, 245/294 (83%) of questionnaires were returned. Responders and 
non-responders were similar in terms of gender, consisting of close to 80% 
females in both groups. Baseline symptom severity scores were similar between 
the two groups. There were only a few notable differences (Table 7.1). Compared 
to non-responders, responders were older (median age 45 years with IQR 33,58 vs 
39 years with IQR 27,49) and reported experiencing symptoms for longer at 
baseline, with a median symptom duration of 36 months (IQR 17,72) compared to 
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24 months (IQR 14,58) amongst non-responders. There was a small difference in 
the two groups in median depression scores; responders scored 8 (IQR 4, 14) 
whilst non-responders scored 10 (IQR 6, 18). Finally fewer responders reported 
having experienced abuse during childhood compared to non-responders (24% vs 
35%). 
 
 
Table 7.1 Characteristics of responders compared to non-responders using 
baseline data 
 Results reported in N/% unless otherwise stated. No missing data unless 
otherwise stated. 
 Characteristics at baseline  
Responders 
N=245 
Non-responders 
N=49 
   Gender  
  
 
Males 52 (21%) 11 (22%) 
 
Females 193 (79%) 38 (78%) 
Age (years)† 45 (33,58) 39 (27,49) 
Symptom severity scores (PHQ-15)§ 11.6 (5.0) 11.5 (4.7) 
Symptom duration (in months)† 36 (17, 72) 24 (14,58) 
SF-12 scores§ 
  
 Physical health functioning¹  43.5 (10.6) 45.2 (10.5) 
 Mental health functioning 39.9 (10.8) 38.2 (12.0) 
Depression score† 8 (4,14) 10 (6,18) 
Anxiety score§ 8.6 (5.6) 10.0 (6.4) 
Type of abuse experienced as a child  
  
 
Yes 60 (24%) 17 (35%) 
 
No 173 (71%) 31 (63%) 
 
Missing 12 (5%) 1 (2%) 
Results displayed as: † Median (IQR), §Mean (SD) 
¹Missing data for one participant 
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 Comparison of baseline and follow-up characteristics 7.2
of those who responded at follow-up 
At follow-up, the cohort was fairly impaired and clinical characteristics were 
similar to baseline. Somatic symptom scores at follow-up were moderately severe, 
with a mean score of 10.5 (SD 5.3), physically and mentally health functioning 
scores were 43.7 (SD 11.1) and 40.7 (SD 10.9) respectively, which were also similar 
to baseline scores (see Table 7.2). In the six month period from baseline to follow-
up, participants made a median of 4 primary care contacts (IQR 2, 6), which was 
comparable to the number of contacts made in the year prior to baseline 
participation. 
 
Table 7.2 Characteristics of study cohort at baseline and follow-up. Results 
reported in N/% unless otherwise stated. No missing data unless otherwise stated. 
 
 
Total N=245 
Characteristics of study cohort Baseline  Follow-up 
  
Somatic symptom score (PHQ-15) § 11.6 (5.0) 10.5 (5.3) 
SF-12 scores§  
 
 
Physical health functioning¹ 43.5 (10.6) 43.7(11.1) 
 
Mental health functioning² 39.9 (10.8) 40.7 (10.9) 
Depression score† 8 (4,14) 8 (3,14) 
Anxiety score§ 8.6 (5.6) 7.9 (5.7) 
Panic³  
 
 
Yes 48 (20%) 51 (21%) 
 
No 175 (71%) 179 (73%) 
Primary health care contact† 8 (4,13)* 4 (2,6)** 
Secondary care contact†* 1 (0,2)* 0 (0,1)** 
Results displayed as: † Median (IQR), §Mean (SD) 
*In the year before starting enrolment 
** In the six months from baseline participation to follow-up 
¹ Missing data at baseline (N=1) and follow-up (N=2) 
² Missing data missing at follow-up only (N=1) 
 ³Missing data at baseline (N=12) and follow-up (N=15) 
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In self-reported outcomes of symptoms, a few (26/245 (11%)) reported being fully 
recovered at follow-up and close to a quarter (58/245 (24%)) reported having 
received a diagnosis. Just under half (103/245 (42%)) of respondents reported that 
they were still under investigation either by their GP or had been referred to the 
hospital for further investigation. However, over half (135/245 (55%)) reported 
their symptoms as still unexplained. Options were not mutually exclusive and 
participants could choose more than one. 
 
 Regression analyses 7.3
Univariable analyses were conducted with each of the baseline variables and the 
primary outcome, somatic symptoms severity at follow-up, as well as the 
secondary outcomes including physical health functioning, mental health 
functioning, depression, anxiety and primary health care contact.  Following 
univariable analyses, conceptual group modelling was carried out with 
significantly associated variables, which were theoretically considered to be 
closely associated to one another. This method was described in section 
4.10.3.3.1.  Variables identified from univariable analyses and conceptual group 
analysis, as well as gender and age, which were chosen a priori, were included in 
the modelling process.  Overall, there was no significant association between 
general practices and any of the outcomes, and therefore general practices were 
not considered in the multivariable analysis. In the following sections, each 
outcome will be discussed in relation to the univariable and multivariable 
regression analyses conducted.  
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 Primary outcome: somatic symptom severity  7.4
 Univariable analyses 7.4.1
The following tables show the coefficient estimates along with 95% confidence 
intervals and associated p-values for the univariable analyses carried out with the 
sociodemographic (Table 7.3) and clinical variables at baseline (Table 7.4), and 
health service use in the year prior to study participation (Table 7.5). The variable 
with the largest univariable association with follow-up somatic symptoms was 
experience of physical abuse during childhood (Table 7.4), which was associated 
with a 4 point increase in somatic symptom severity (95% CI 1.92 to 6.28).  Other 
variables which were significantly associated with increased symptom severity at 
follow-up included not being in paid employment, a lower level of education (i.e. 
O-levels, GCSE, A-levels or equivalent), perception of financial well-being as doing 
badly, duration of symptom at baseline longer than a year, reports of wanting 
help to deal with their symptoms, having experienced panic in the previous two 
weeks, experience of a traumatic events during childhood and experience of 
emotional abuse during childhood.  
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Table 7.3 Univariable analyses of baseline sociodemographic variables with 
outcome variable somatic symptom severity at follow-up. 
 
Baseline sociodemographic variables Somatic symptom severity (PHQ-15) 
 
Coefficient 
95% Conf. 
Interval 
p-value 
Gender    
 Male - - - 
 Female 1.50 -0.11,3.11 0.069 
Age (years) 0.01 -0.32, 0.05 0.653 
Ethnicity      
 White - - - 
 Black 0.14 -3.22, 3.49 0.935 
 Asian 1.52 -0.32, 3.37 0.105 
 Other (including mixed) 1.96 -0.73, 4.66 0.153 
Marital status     
 
 
Married or in a long term 
relationship - - - 
 
Widowed, separated, divorced 
or single 0.50 -0.85, 1.85 0.467 
Employment status     
 In paid employment - - - 
 Not in paid employment * 2.47 1.18, 3.77 <0.001 
Education     
 
GCSE, A-levels, up to NVQ-3 or 
equivalent - - - 
 
Undergraduate, Masters, 
higher or equivalent -2.80 -4.10, -1.51 <0.001 
Perception of financial well-being         
 Doing well - - - 
 Doing badly 3.83 2.59,5.07 <0.001 
IMD** 0.05 0.00, 0.10 0.06 
Social support     
 No    
 Yes -0.46 -2.27,1.35 0.614 
*Unemployed, retired, full time education, unable to work because of long term sick or 
other 
** IMD=IMD = Index of Multiple Deprivation score 
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Table 7.4 Univariable analyses of baseline clinical variables with outcome 
variable somatic symptom severity. 
 
Baseline clinical variables Somatic symptom severity (PHQ-15) 
 Coefficient 95% Conf. Interval p-value 
Baseline Somatic symptom score 0.70 0.60 , 0.80 <0.001 
Duration of symptoms at baseline    
 <1 year - - - 
 >1 year 3.15 1.56 , 4.75 <0.001 
Preference for help-seeking    
 By themselves - - - 
 Like some help 2.71 1.02 , 4.40 0.002 
SF-12 score    
 Physical health functioning -0.22 -0.28 , -0.17 <0.001 
 Mental health functioning -0.19 -0.25 , -0.14 <0.001 
Depression score 0.37 0.28 , 0.46 <0.001 
Anxiety score 0.33 0.22 , 0.44 <0.001 
Panic    
 No - - - 
 Yes 2.83 1.19 , 4.47 0.001 
Work and social adjustment score  0.22 0.17 , 0.27 <0.001 
Self-efficacy score -0.23 -0.31 , -0.14 <0.001 
Stressful life events 0.87 0.44 , 1.30 <0.001 
Experienced physical illness in family 
members as a child  
 
 
 
 
 
 
 No - - - 
 Yes 1.69 0.28 , 3.10 0.019 
Experience mental illness in family 
members as a child 
 
 
 
 
 
 
 No - - - 
 Yes 1.52 -0.28 , 3.32 0.098 
Experienced 1 or more traumatic event as 
child  
 
 
 
 
 
 
 No - - - 
 Yes 2.24 0.86 ,3.62 0.002 
Experienced abuse as a child    
 No - - - 
 Yes 2.14 0.61 , 3.68 0.006 
Physical Abuse as a child    
 No - - - 
 Yes 4.10 1.92 , 6.28 <0.001 
Sexual abuse as a child    
 No - - - 
 Yes 2.29 -0.07 , 4.65 0.058 
Emotional abuse as a child    
 No - - - 
 Yes 2.66 1.02 , 4.31 0.002 
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Table 7.5 Univariable analyses of health service use in the year before study 
participation with outcome variable somatic symptom severity at follow-up. 
Health service use in year before study 
participation  
Somatic symptom severity (PHQ-15) 
 Coefficient 95% Conf. Interval p-value 
Primary health service contact 0.14 (0.06 ,  0.22) 0.001 
Secondary health service contact 0.17 (-0.08 , 0.43) 0.178 
 
 
 Multivariable analyses 7.4.2
Following conceptual group modelling, fifteen variables were identified for 
inclusion in the analyses. Backward selection was carried out and variables were 
taken out one by one starting with the one with the highest p-value and 
continuing until only variables with p<0.05 remained (and/or those included in the 
model a priori). Six variables remained in the final model; these were gender, age, 
perception of financial well-being, somatic symptom severity at baseline, physical 
health functioning at baseline, and experience of physical abuse during childhood 
(Table 7.6). Somatic symptoms severity at follow-up were on average 1.31 (95% CI 
0.12 to 2.50) points higher amongst females compared to males, after adjusting 
for the other variables. Perception of financial well-being as doing badly was 
associated with a 1.90 (95% CI 0.89 to 2.91) point higher in somatic symptom 
scores at follow-up, compared to those who perceived that they were doing well, 
after adjusting for other variables. Similar findings were seen amongst those who 
had experience of physical abuse during childhood, with an increase in somatic 
symptom severity of 1.86 (95% CI 0.27 to 3.45) compared to those who had not. 
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Each additional point increase in symptom severity score at baseline were 
associated with a 0.53 (95% CI 0.42 to 0.64) point increase in symptom severity at 
follow-up, once adjusted for the other variables. Each additional point increase in 
physical health functioning at baseline were associated with a -0.10 point 
decrease (95% CI -0.15 to -0.04) in symptom severity at follow-up, once adjusted 
for other variables.  For each year increase in age, follow-up symptom scores 
increased by a very small amount (0.01, 95% CI -0.03 to 0.04) and this association 
was not significant. 
 
Table 7.6 Final multivariable model showing the association between baseline 
predictors and somatic symptom severity at follow-up. 
Baseline predictors Somatic symptom severity (PHQ-15) 
 Coefficient 95% CI p-value 
Gender    
 Female 1.31 0.12, 2.50 0.031 
Age (years) 0.01 -0.03, 0.04 0.559 
Perception of financial well-being     
 Doing well - - - 
 Doing badly 1.90 0.89, 2.91 <0.001 
Baseline somatic symptoms score 0.53 0.42, 0.64 <0.001 
Physical health functioning score -0.10 -0.15, -0.04 0.001 
Experience of physical abuse 
during childhood    
 No - - - 
 Yes 1.86 0.27, 3.45 0.022 
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 Secondary outcomes 7.5
 Quality of life: physical health functioning 7.5.1
7.5.1.1 Univariable analyses 
Physical health functioning was explored using the physical component score 
(PCS) of the short-form questionnaire (SF-12) which measures quality of life 
(health functioning). Univariable analysis of baseline variables with the outcome 
physical health functioning showed that employment status had the strongest 
association with physical health functioning at follow-up (see Appendix 4.1). This 
variable was associated with a reduction of -7.69 points (95% CI -10.35 to -5.04) in 
physical health functioning score, suggesting an increase in impairment amongst 
those who reported not being in paid employment compared those who were in 
employment. The experience of physical abuse during childhood was associated 
with a -7.65 point reduction (95% CI -12.50 to -2.79) in physical health functioning 
score at follow-up (Appendix 7.1). Other baseline variables which showed 
significant associations with physical health functioning included duration of 
somatic symptoms at baseline, which suggested that those who had symptoms for 
longer than a year had poorer physical health functioning and greater impairment 
at follow-up (-7.29, 95% CI -10.59 to -3.99). Perceived financial well-being 
reported as doing badly was associated with a point reduction of -6.46 (95% CI -
9.16 to -3.74) in physical health functioning score compared to those who reported 
doing well financially. Help-seeking preferences for support from others were 
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associated with a -5.93 point reduction (95% CI -9.40 to -1.46) in physical 
functioning score at follow-up.  
 
Both greater primary health care contact (-0.60, 95% CI -0.84 to -0.44) and 
secondary health care contact (-0.92, 95% CI -1.45 to -0.40) were associated with 
greater impairment at follow-up (see Appendix 7.1). However, average rate of 
secondary care referrals was low with median 0 (IQR 0, 1), and therefore, it has 
not been included in any of the multivariable models, even when statistically 
significant. 
 
Factors associated with better physical health functioning at follow-up included 
education, where higher education which was strongly associated with a 7.84 
(95% CI 5.17 to 10.50) point increase in physical health functioning score, 
compared to those with A- levels or less. Being female was associated with a 2.34 
point increase in physical health functioning score, suggesting less impairment at 
follow-up.  
 
7.5.1.2 Multivariable analysis 
Sixteen variables were included in the full multivariable model. The final model 
included the following variables: gender, age, somatic symptom score at baseline, 
physical functioning at baseline and primary care use in the year before study 
recruitment (see Table 7.7). Higher somatic symptom scores at baseline were 
associated with lower physical functioning scores at follow-up (-0.30, 95% CI -0.51 
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to -0.09). There was a positive association between physical health functioning 
score at baseline and at follow-up, with every point increase in baseline score 
being associated with a 0.61 point increase in the score at follow-up (95% CI 0.51 
to 0.72). Higher primary health service use in the year before study enrolment was 
associated with lower physical functioning scores at follow-up, after controlling 
for all other variables.  Older age was associated with decreased physical 
functioning, after adjusting for all other variables. 
 
Table 7.7 Final multivariable model showing the association between baseline 
predictors and physical health functioning at follow-up. 
Baseline predictors Physical health functioning (PCS) 
 Coefficient 95% CI p-value 
Gender 
  
 
 Female 0.83 -1.47, 3.13 0.479 
Age (years) -0.08 -0.15, -0.02 0.014 
Somatic symptom score -0.30 -0.51, -0.09 0.005 
Baseline physical health 
functioning score 0.61 0.51, 0.72 <0.001 
Primary health service 
contact  -0.18 -0.31, -0.04 0.011 
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 Quality of life: mental health functioning 7.5.2
7.5.2.1  Univariable analyses 
Mental health functioning was explored using the mental component score (MCS) 
of the short-form questionnaire (SF-12) which measures quality of life (health 
functioning). Univariable analysis of baseline variables showed a large association 
between mental health functioning and physical (-7.83, 95% CI -12.58 to -3.08), 
sexual (-7.79, 95% CI -12.65 to -2.94) and emotional abuse (-6.71, 95% CI -10.17 to 
-3.26) at follow-up (see Appendix 4.2). Other variables including panic (-7.64, 95% 
CI-11.07 to -4.21), financial perception of doing badly (-5.95, 95% CI -8.62 to -
3.28), preference for health seeking reported as wanting help (-5.20, 95% CI-8.71 
to -1.69), traumatic experiences as a child (-3.89, 95% CI -6.84 to -0.93), primary 
health care contact at baseline (-0.22, 95% CI -0.39 to -0.04), not being in paid 
employment (-3.47, 95% CI-6.21 to -0.73) and not being in a relationship were all 
associated with lower mental health functioning at follow-up. Baseline variables 
associated with increased mental health functioning at follow-up included higher 
mental health functioning (0.58, 95% CI 0.48 to 0.69), higher physical health 
functioning (0.15, 95% CI 0.02 to 0.28) and greater self-efficacy at baseline (0.59, 
95% CI 0.41 to 0.76). 
 
7.5.2.2 Multivariable analysis 
Eighteen variables were included into the full multivariable model.  Following 
backwards selection, the final model included the following variables: gender, age, 
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mental health functioning and depression (see Table 7.8).  Each unit increase in 
mental health functioning score at baseline was associated with 0.40 point (95% 
CI 0.27 to 0.54) increase in mental health functioning score at follow-up and each 
unit increase in depression score at baseline was associated with a -0.45 point 
decrease (95% CI -0.67 to -0.23) in mental health score at follow-up. 
 
Table 7.8 Final multivariable model showing the association between baseline 
predictors and mental health functioning follow-up. 
Baseline predictors Mental health functioning (MCS) 
 Coefficient 95% CI p-value 
Gender     
 Female -2.47 -5.18, 0.25 0.075 
Age (years) -0.21 -0.09, 0.48 0.543 
Baseline mental health 
functioning score 0.40 0.27, 0.54 <0.001 
Depression score -0.45 -0.67,-0.23 <0.001 
 
 Depression 7.5.3
7.5.3.1 Univariable analyses 
As with the mental health functioning outcomes (section 7.5.2.1), variables 
physical (4.64, 95% CI 1.92 to 7.35), sexual (3.38, 95% CI 0.46 to 6.30) and 
emotional abuse during childhood (3.74, 95% CI 1.71 to 5.77) had some of the 
largest individual associations with depression score at follow-up (Appendix 4.3). 
Other variables which were associated with depression scores at follow-up 
included panic (4.54, 95% CI 2.56 to 6.51) financial perception of doing badly 
(4.46, 95% CI 2.89 to 6.03), preference for help seeking reported as wanting help 
(3.49, 95% CI 1.42 to 5.56), experience of traumatic experience as a child (1.93, 
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95% CI 0.20 to 3.67), not being in paid employment (3.36, 95% CI 1.76 to 4.95), 
duration of somatic symptoms at baseline (2.66, 95% CI 0.63 to 4.69) and stressful 
life events in the previous six months (1.11, 95% CI 0.57 to 1.64).  Those who had 
attained higher education had a lower depression scores compared to those with 
A-levels or less. Higher physical health functioning (-0.20, 95% CI-0.27 to -0.13) 
and mental health functioning scores (-0.33, 95% CI -0.40 to -0.26) at baseline 
were associated with a reduction in depression score. Finally, better self-efficacy 
was associated with a reduction in depression scores (-0.45, 95% CI -0.55 to -0.36). 
 
7.5.3.2 Multivariable analysis 
As shown in Table 7.9, after a modelling process which started with sixteen 
variables, the final model included the following variables: gender, age, somatic 
symptom severity, depression score and self-efficacy score.  Somatic symptom 
score at baseline was associated with a 0.16 point (95% CI 0.03 to 0.30) increase in 
depression score at follow-up after adjusting for other variables. Depression score 
at baseline was associated with a 0.54 point (95% CI 0.42 to 0.65) increase in 
depression scores. Better self-efficacy was found to be protective, with a 0.18 
decrease in depression scores for each point increase in self-efficacy at baseline. 
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Table 7.9 Final multivariable model showing the association between baseline 
predictors and depression at follow-up. 
Baseline predictors Depression score (PHQ-9) 
 Coefficient 95% CI p-value 
Gender     
Female 0.79 -0.64, 2.23 0.277 
Age (years) 0.02 -0.02, 0.05 0.339 
Somatic symptom score 0.16 0.03, 0.30 0.016 
Baseline Depression score 0.54 0.42, 0.65 <0.001 
Self-efficacy score -0.18 -0.27, -0.09 <0.001 
 
 
 Anxiety 7.5.4
7.5.4.1 Univariable analyses 
Findings of the univariable analyses are shown in Appendix 4.4. Those who 
reported having experienced panic in the two weeks prior to baseline 
questionnaire had the highest association with anxiety at follow-up, with a 3.77 
point (95% CI 2.02 to 5.52) increase in anxiety scores. Experience of any abuse 
during childhood (2.01, 95% CI 0.36 to 3.68) as well as physical (3.22, 95% CI 0.84 
to 5.59), sexual (2.19, 95% CI 0.36 to 4.73) and emotional abuse (2.90, 95% CI 1.12 
to 4.67) were also associated with increased anxiety scores at follow-up (Appendix 
7.4). 
 
 Other baseline variables which were significantly associated with anxiety score 
included financial perception of doing badly (2.50, 95% CI 1.09 to 3.91), preferring 
help from others for managing symptoms (2.14, 95% CI 0.33 to 3.95), somatic 
symptoms that had lasted a year or more at baseline (2.22, 95% CI 0.47 to 3.97) 
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and experience of mental illness in family members as a child (1.98, 95% CI 0.03 to 
3.92). There was a -0.10 point (95% CI -0.16 to -0.03) reduction in anxiety scores 
for every point increase in physical health functioning score at baseline and a -
0.24 point (95% CI -0.30 to -0.18) reduction in anxiety scores for each point 
increase in mental health functioning score at baseline. Higher self-efficacy scores 
were also associated with decreased anxiety scores at follow-up (-0.28, 95% CI -
0.37 to -0.19). 
 
7.5.4.2 Multivariable analysis 
Sixteen variables were included in the multivariable model following conceptual 
group analysis, in addition to gender and age included a priori. Following 
backwards elimination, five variables remained in the model (see Table 7.10). For 
every point increase in baseline depression score, follow-up anxiety score 
increased by 0.20 (95% CI 0.06 to 0.34) once adjusted for all other variables. For 
each point increase in baseline anxiety, follow-up anxiety increased by 0.44 points 
(95% CI 0.27 to 0.61).  
 
Table 7.10 Final multivariable model showing the association between baseline 
predictors with anxiety at follow-up. 
Baseline predictors Anxiety score (GAD-7) 
 Coefficient 95% CI p-value 
Gender  
  
 
 Female 0.55 -0.85, 1.96 0.437 
Age (years) 0.02 -0.01, 0.06 0.227 
Depression score 0.20 0.06, 0.34 0.007 
Baseline anxiety score 0.44 0.27, 0.61 <0.001 
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 Primary health care contacts 7.5.5
Primary health care contacts included general practitioner, nurse, health care 
assistant and out of hours services contact. 
 
7.5.5.1 Univariable analyses 
Univariable analyses showed that primary health care contact at follow-up had 
the largest association with employment status (Appendix 4.5). There were on 
average 2.27 (95% CI 1.21 to 3.33) higher primary health care contacts amongst 
those who were not in paid employment compared to those who were in paid 
employment. A 2.13 unit (95% CI 0.79 to 3.47) increase in health service contact 
was found amongst those who reported experiencing emotional abuse during 
childhood compared to those who had not. Having experienced any type of abuse 
(1.31, 95% CI 0.07 to 2.56) was also associated with greater primary health care 
use. A 0.70 point (95% CI 0.40 to 1.10) increase in primary health care contact was 
observed for every ten years increase in age. 
 
 Other variables positively associated with primary health care contact included 
baseline symptom severity score (0.19, 95% CI 0.09 to 0.30), depression score 
(0.13, 95% CI 0.05 to 0.21) and work and social adjustment score (0.10, 95% CI 
0.05 to 0.15). Higher number of baseline primary health care contacts (0.41, 95% 
CI 0.35 to 0.46) and secondary health care contacts (0.85 95% CI 0.66 to 1.05) in 
the year before study enrolment were associated with greater primary health care 
contacts at follow-up.  
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Variables which showed a significant negative association with and a reduction in 
primary health care contact at follow-up were higher education level (-1.77, 95% 
CI -2.87 to -0.67), as well as higher baseline physical health functioning scores  (-
0.14, 95% CI -0.19 to -0.92), mental health functioning scores (-0.05 95% CI -0.09 
to 0.00) and higher self-efficacy (-0.10 95% CI -0.17 to -0.02). 
 
7.5.5.2 Multivariable analysis 
Following conceptual group modelling, twelve variables were included in the 
modelling process. Finally, four variables including those which were chosen a 
priori remained in the model. There was a 1.28 unit (95% CI 0.26 to 2.32) increase 
in health care contact amongst those who reported having experienced emotional 
abuse during childhood compared to those who had not, after adjusting for the 
other variables. Each unit increase in primary health care contact in the year 
before study enrolment was associated with a 0.40 unit increase in primary health 
care contact at follow-up (95% CI 0.34 to 0.45) (see Table 7.11).   
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Table 7.11 Final multivariable model showing the association between baseline 
predictors and primary health care contacts at follow-up. 
Baseline predictors Primary health care contacts 
 Coefficient 95% CI p-value 
Gender  
    Female -0.57 -1.60, 0.46 0.274 
Age (years) 0.01 -0.02, 0.04 0.568 
Experience of emotional 
abuse during childhood  
    No - - - 
 Yes 1.28 0.26, 2.32 0.015 
Primary health care 
contact*  0.40 0.34, 0.45 <0.001 
*In the year before study enrolment 
     
 Summary  7.6
Following screening of nearly 3,000 patients in primary care, 1,196 eligible 
participants were invited to take part in the cohort study.  This chapter reports the 
main results of those who took part in the longitudinal study. My study cohort 
included 294 participants at baseline and follow-up response rate was high. 
Although responders and non-responders were fairly similar, there were a few 
differences; responders were older, had experienced symptoms for a longer 
duration at baseline, had slightly lower median depression scores and fewer 
reported having experienced childhood abuse compared to non-responders. The 
cohort remained impaired at follow-up; over half reported that their symptoms 
were still unexplained. On average, somatic symptoms scores were moderately 
severe, and physical and mental health functioning was poor.  
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A number of sociodemographic and clinical baseline variables were significantly 
associated with the primary outcome somatic symptoms severity, following 
univariable analyses. These included: perception of financial well-being; baseline 
symptoms; poor physical and mental health functioning; anxiety; depression; 
number of stressful life events; and historic variables relating to childhood 
experiences such as physical illness in family members, trauma and abuse.  
 
Multivariable analysis identified being female, higher baseline somatic symptom 
severity, worse physical health functioning, perception of financial well-being as 
doing badly and experience of physical abuse during childhood as significantly 
associated with higher somatic symptom severity at follow-up. Although age was 
included a priori, there was no significant association at follow-up.  
 
All final multivariable models for the secondary variables included several similar 
baseline variables. These are summarised in Table 7.12. For all secondary 
outcomes the baseline measure of the same variable was associated with its 
follow-up severity, after adjusting for all other variables. For example, poor 
physical health functioning at baseline was associated with poor physical health 
functioning at follow-up, and higher baseline depression scores were associated 
with higher depression at follow-up.  
 
The final multivariable models for physical health functioning and depression 
included baseline somatic symptoms scores. All final models for depression, 
anxiety and mental health functioning included baseline depression score. Health 
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service use in the year before study participation was included in the final models 
for physical health functioning and health service use at follow-up. Additionally, 
self-efficacy at baseline remained in the final models for depression, and 
emotional abuse in childhood in the final model for primary health care contacts 
at follow-up. Age and gender were included a priori in all models, however only 
age showed a significant association with one of the outcomes, physical health 
functioning. I discuss the meaning and implications of these findings in Chapter 8.
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Table 7.12 Summary of baseline predictors which were significantly associated with each of the outcomes in multivariable analyses 
Baseline variables Primary 
outcome 
Secondary outcomes 
 
Somatic 
symptom 
severity 
Physical 
health 
functioning 
Mental 
health 
functioning 
Depression Anxiety Primary 
health care 
contact 
Female x      
Age (years)  x     
 Perception of financial well-being as 
doing well 
x      
Somatic symptom score x x  x   
Mental Health Functioning score   x    
Physical Health Functioning score x x     
Self-efficacy score    x   
Anxiety score     x  
Depression score   x x x  
Experienced physical abuse during 
childhood  
x      
Experienced emotional abuse during 
childhood 
     x 
Primary care health service contacts 
in year prior to study participation 
 x    x 
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Discussion Chapter 8 : 
 
 Chapter overview  8.0
In this final chapter of my thesis, first I summarise the main results of my study and 
compare my findings to existing literature. I then discuss the methodological 
strengths and limitations of the research. Finally, the clinical and policy implications 
of the findings, as well as the scope for future research will be explored 
 
 Summary of findings  8.1
In this study, I examined the outcome of UPS in primary care attenders and 
identified prognostic factors associated with somatic symptom severity at six 
months follow-up. To achieve this, first, I systematically reviewed previous research 
on UPS. The review found that a few studies focused on primary care attenders in 
the UK with UPS, highlighting the need for my research.  
 
I screened nearly 3,000 attenders in nine general practices in North and Central 
London for UPS. Most respondents reported at least one unexplained symptom and 
about half had no explanation or diagnoses for any of their symptoms. From this 
sample, those with multiple somatic symptoms were recruited to participate in a 
cohort study.  
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The study cohort was largely made up of women, around half were educated to a 
high level and reported that they were ‘doing well’ financially. On average, at 
baseline the cohort had moderately severe somatic symptoms; their quality of life 
relating to physical and mental health functioning was poor. Average anxiety and 
median depression scores were within the range for moderate severity.  Although, 
using a cut-off of >10 on their respective scales, less than half of responders had 
clinically significant anxiety or depression, and around a third had comorbid 
depression and anxiety. A third of responders fell into the range of clinical 
significance at a higher cut-off of >12. In the year prior to study enrolment, the 
cohort had frequently accessed health care with a median of eight consultations to 
primary care.   
 
At six months follow-up, scores for all the outcome measures were similar to 
baseline scores demonstrating poor recovery; only one in ten reported being fully 
recovered. Over half of the cohort reported that their symptoms were still 
unexplained and just under half said that were still under investigation. One quarter 
reported having received a diagnosis for at least some of their symptoms.  
 
Multivariable analysis indicated a significant association between higher somatic 
symptom severity at six months and several baseline variables: being female, 
perception of doing poorly financially, higher baseline somatic symptom severity, 
poorer physical health and experience of childhood physical abuse. Several baseline 
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factors were significantly associated with each of the secondary outcomes. There 
was a clear dichotomy between baseline variables associated with the physical 
outcomes (somatic symptom severity and physical health functioning) and 
psychological outcomes (mental health functioning, depression and anxiety). 
Physical health functioning at follow-up had a similar trend to the primary outcome; 
high baseline somatic symptom scores were associated with poor physical health 
functioning at follow-up. With each of the psychological outcomes there was a 
similar association; poor mental health functioning, and higher depression and 
anxiety at baseline were associated with poor mental health functioning, and higher 
depression and anxiety at follow-up. Greater self-efficacy was associated with a 
better outcome for depression at follow-up. Only reports of emotional abuse in 
childhood and health care contacts in the year prior to the study were associated 
with primary health use at follow-up. 
 
 Relating findings to existing literature 8.2
In this section I discuss the findings from the screening stage of my study and the 
cohort study with existing literature. The following areas will be explore in detail: 
prevalence of somatic symptoms in GP attenders; characteristics of the cohort; 
outcomes of UPS; factors associated with somatic symptom severity at follow-up; 
and factors associated with secondary outcomes at follow-up. 
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 Prevalence of somatic symptoms in GP attenders 8.2.1
The severity of somatic symptoms amongst those screened in my study is 
comparable to other primary care attender studies in which the same measure was 
used in Germany, USA and Australia (Steinbrecher and Hiller, 2011; Kroenke et al., 
2002; Clarke et al, 2008). There are only a few studies that have explored 
prevalence of UPS in primary care in the UK. These are difficult to compare due to 
the use of different definitions and methods to identify those with UPS (Peveler et 
al 1997; Duddu et al 2008; Morriss et al., 2012).  The proportion of those with five 
or more symptoms, amongst those who completed screening questionnaires in my 
study were similar to that of another primary care attender study in the UK, which 
explored persistence based on abridged somatisation (Peveler et al., 1997).  
 
Most of the people screened in my study had at least one unexplained symptom, 
which is slightly higher than percentages confirmed by GPs as having at least one 
unexplained symptom amongst consecutive primary care attenders, in Germany 
(Steinbrecher et al., 2011). However, they do compare favourably to those whose 
symptoms lacked a clear medical explanation but where the nature of the 
symptoms were considered ambiguous, in the same study (Steinbrecher et al., 
2011). Numbers with UPS in my study also compare closely to percentages who 
reported experiencing at least one symptom in the past seven days in a recent 
population based study in New Zealand (Petrie et al., 2014).  
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Two thirds of the respondents at both the screening stage and in my cohort study, 
were women, in line with the higher rates of general practice consultation amongst 
women compared to men amongst various studies, including those on UPS (Barsky 
et al., 2001; Green and Pope, 1999; Vedsted and Christensen, 2005; Hippisley-Cox 
and Vinogradova,2009; Taylor et al.,2012; Mayor,2015). Younger and working aged 
men are less likely to attend primary care (Patel et al 2003; Vadsted and 
Christensen, 2005; Wang et al., 2013) and gaps in consultation rates between 
genders are greatest between the ages of 16 and 60 years (Wang et al., 2013).  
 
At the screening stage, fewer than may be expected indicated that a mental health 
or functional diagnoses underlined their symptoms, in comparison to research on 
prevalence of mental illness such as depression or anxiety, and functional 
syndromes such as irritable bowel syndrome amongst general practice attenders in 
the UK (King et al., 2008; Canavan et al., 2014). It is possible that some respondents 
did not want to admit to a mental illness; however, in another study amongst 
consecutive primary care attenders at ten general practices in the UK, similar 
percentages were given psychological explanations for their symptoms, by GPs 
(Taylor et al.,2012). With regard to the low report of functional diagnoses such as 
irritable bowel syndrome or chronic fatigue, some may have considered these 
diagnoses to be unsatisfactory and so reported their symptoms as unexplained.  
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A third of those screened reported consulting their GP about their bothersome 
symptoms. There are several possibilities for this finding. Although, it is said that 
90% of the most common somatic symptoms with which people consult are 
covered by the PHQ-15, it is possible that some consulted with the remaining 10% 
of symptoms that were not included (Kroenke et al., 2002). It is, however, more 
likely, that some were attending the surgery for other reasons such as: routine 
appointments, to monitor existing chronic illness; health checks, to test for risk of 
chronic illnesses; to obtain contraceptives; for screening (e.g. smear tests); or for 
lifestyle advice (e.g., services such as stop smoking) (Kontopantelis et al 2015). 
 
 Characteristics of the cohort 8.2.2
The sociodemographic characteristics of the cohort were comparable to the 
population of the four London boroughs from which the sample was recruited, in 
terms of ethnicity and education (Office for National Statistics, 2011). Over half of 
the respondents reported their marital status as either married or in a long-term 
relationship compared to just over a third, in the four boroughs included in the 
study (i.e. married or in a civil partnership) (Office for National Statistics, 2011). The 
higher rate in my study could be explained by the inclusion of those in long-term 
relationships, regardless of legal status.  
 
More of the cohort was economically inactive compared to the population of 
London in 2011 (Greater London Authority, 2013). This is likely when sampling from 
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general practice population who are more likely to be sick and older than the 
general population. Participants’ perceptions of financial well-being, were on 
average worse compared to figures reported in both the UK and in London (Self et 
al., 2013). 
 
Finally, a major difference in the study participants compared to the general 
population in the four boroughs was the high level of perceived social support 
reported by them. This is interesting as London is considered to be one of the 
loneliest places in Europe and the UK; in one report, up to 52% of people in London 
reported feeling lonely (ComRes, 2013). Although loneliness is a subjective 
experience and some may feel lonely even in the company of friends and family. 
However, some of the boroughs from which GP practices were recruited also have 
some of lowest rates of marriage in the UK (Office for National Statistics, 2011). 
Based on these multiple sources of evidence, it is likely that that levels of social 
support identified in my study may be higher than amongst the actual population 
from which the sample was drawn. In contrast to my study, other research has 
suggested that perceived presence of social support may act as protective factor 
against physical morbidity (Reblin and Uchino, 2008). 
 
My study cohort had somatic symptom scores within the range for moderate 
severity on the PHQ-15; suggesting that on average they experienced at least five or 
more unexplained symptoms (Kroenke et al., 2010). This, as previously mentioned, 
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is comparable to the diagnostic criteria ‘abridged somatisation’ (Peveler et al., 
1997). On average, the number of symptoms reported amongst my cohort is much 
lower than primary care attenders who met the criteria for DSM-IV diagnosis of 
undifferentiated somatoform disorder, who on average experienced 10 physical 
symptoms (De Waal et al., 2008). Most of my study cohort also had fairly chronic 
symptoms, having experienced symptoms for over a year and on average close to 
three years. 
 
Physical and mental health functioning scores based on the SF-12 suggest that on 
average my study cohort were moderately functionally impaired and likely to 
experience a poor quality of life. Physical functioning scores in my study were 
similar to those with limiting long-term illness in the UK and also comparable to 
those with respiratory disease and cancer, whilst their mental health functioning 
scores were similar to those with clinical depression (Booker and Sacker, 2011). The 
average physical and mental health functioning scores amongst my cohort were 
comparable to average scores amongst those identified by Creed et al. (2012) as 
having high symptom severity6.  
 
Scores on the work and social adjustment scale for my study cohort were 
comparable to those with mild and persistent depression-dysthymia reported 
amongst primary care patients recruited from 42 GP practices, across the UK 
                                                     
6
 This study was discussed in detail in the systematic review in chapter 2. 
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(McMahon et al., 2012) and considered to be in the range associated with 
significant functional impairment but less severe clinical symptomology (Mundt et 
al., 2002). These scores suggest that functioning amongst my cohort was fairly poor.  
 
Lower mean and median levels of anxiety and depression were found in my study 
compared to scores suggested to be clinically significant at a cut off of >10 (Spitzer 
et al., 2006; Kroenke et al., 2002). Scores were also lower compared to primary care 
attenders with somatisation disorder (Löwe et al., 2008) and those with medically 
unexplained symptoms in primary care, in the UK (Duddu et al., 2008). Comorbid 
depression and anxiety rates reported amongst those with UPS vary (see section 
1.6.3). The percentages in my study with anxiety and/or depression scores 
considered clinically relevant, are fairly consistent with past reports of populations 
with similar symptom counts (Kroenke, 2003). They are however higher than 
prevalence estimates reported more recently, amongst primary care attenders 
diagnosed with somatoform disorder in Germany (Steibrecher et al. 2011). 
Childhood experiences such as deprivation, traumatic experiences, family illness 
and abuse have been commonly reported amongst adults with UPS, these were 
discussed in detail in 1.6.5. Such experiences were common in my study; I found 
that more females reported experience of sexual abuse compared to males, in line 
with previous findings (Edwards et al., 2003). Where different types of abuse have 
been explored, emotional abuse has been identified as the most frequently 
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reported type of abuse (Edwards et al., 2003; Radford et al., 2011) and this was also 
the case in my study.  
 
Primary care consultation rates amongst my study cohort in the year prior to study 
participation were higher than average national rates reported in the UK between 
2008 and 2009, based on 496 practices (Hippisley-Cox and Vinogradova,2009). My 
findings are slightly higher than those reported by Taylor et al., (2012), amongst 
consecutive primary care attenders in the UK, determined to have UPS by their GPs; 
however their rate is based on GP contact alone, whilst my study included GP, 
nurse, HCA or out of hours contact.  The average frequency of primary care 
consultation in my study was comparable to a control group of another large UK 
primary care study, who were older than 61 years; this study compared the rates of 
consultation between those with severe mental illness and a matched control group 
(Kontopantelis et al., 2015).  
 
 Outcomes of UPS  8.2.3
Over half of the participants in my cohort reported that their symptoms were still 
unexplained at follow-up, indicating chronicity. This refutes the suggestion by Olde 
Hartman et al. (2009) that symptoms are transient and that a majority of patients 
will improve over time; this was not so in my study. Only 10% of my study cohort 
reported that their symptoms had resolved; this is much lower than rates of 
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resolution amongst consecutive primary care attenders at three month follow-up, 
found by Jackson and Passamonti (2005) in the USA. Over half of my study cohort 
reported symptoms were still unexplained at six months. My finding is comparable 
to the rates of persistence reported amongst primary care attenders meeting 
diagnostic criteria for somatoform disorders, somatisation disorder and abridged 
somatisation, at between six and twelve months follow-up (Steinbrecher and Hiller, 
2011; De Gutch et al., 2004; Gureje and Simon, 1999).  
 
 Factors associated with symptom severity at follow-up 8.2.4
Higher baseline somatic symptom severity was associated with increased severity at 
follow-up; suggesting that greater severity at baseline is likely to be associated with 
worse outcome at follow-up. This is supported by other studies in which baseline 
symptom severity is associated with symptom severity, persistence of symptoms or 
presence of unexplained symptoms/somatoform disorders and less recovery at 
follow-up (Tomenson et al 2013; Jackson and Passamonti 2005; van der Windt et 
al.,2008; Hilbert et al., 2010; Steinbrecher and Hiller, 2011; Creed et al., 2012).  
 
Women in my study were likely to have higher symptom severity compared to men 
at follow-up, when other variables were adjusted for (including baseline somatic 
symptoms). This finding is consistent with other literature; women experience a 
greater number of physical symptoms, more frequently and have a greater 
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symptom burden (Kroenke and Spitzer, 1998; Barsky et al., 2001; Tomenson et al., 
2013). Studies in primary care also report that being female is associated with 
persistence of UPS and high symptom severity over time (De Gucht et al., 2004; 
Verhaak et al., 2006; Koch et al., 2009).  
 
Perception of financial well-being as doing poorly was associated with an increase in 
symptom severity at follow-up, compared to those who perceived their financial 
well-being as doing well. Although an individual may be educated to a high level and 
be in full time employment, indicating a high socioeconomic status, they may yet 
not meet their expectations in terms of income and standard of living (Montpetit et 
al., 2015). In such instances, perception of financial well-being can provide valuable 
insight into an individual’s outlook and perspective. Financial stress in particular has 
been associated with poorer psychological well-being (Montpetit et al., 2015) as 
well as the onset and maintenance of common mental health disorders (Weich and 
Lewis, 1998) and depression (King et al., 2006) over a 12 month period. There are 
two possible explanations for the association of financial stress with symptom 
severity over time. First, although wealth may not directly promote well-being, it 
may act as a buffer against some difficult events and poor financial well-being may 
create additional difficulties during periods of poor health (Smith et al., 2005). 
Second, regardless of income or education status, those who perceive their 
situation positively may have a generally more positive outlook on their living 
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situation as well as their physical health; such individuals may be better at 
developing coping strategies to deal with their symptoms (Falvo, 2013). 
 
In my study, higher scores for physical health functioning at baseline were 
associated with a small but significant decrease in somatic symptom scores at 
follow-up. This suggests that those with better physical functioning at baseline are 
more likely to experience improvement in their symptom severity. Other primary 
care studies have found similar results, which suggests that greater functional 
disability and poor physical health are associated with the persistence of UPS or 
high somatic symptoms scores at 12 month follow-up (Steinbrecher and Hiller, 
2011; Creed et al., 2012). These studies were discussed in detail in section 2.9.2.   
 
Finally, those who had experienced physical abuse in childhood reported an 
increase in somatic symptom severity at follow-up, compared to those who did not 
report experience of abuse. This suggests that childhood physical abuse may have a 
long term impact on physical health. Increased rates of somatic symptoms such as 
back pain, headaches, pelvic pain, frequent tiredness, depression  anxiety, 
functional syndromes (e.g., Irritable Bowel Syndrome, Chronic Fatigue Syndrome), 
and medically unexplained symptoms have all been reported amongst those who 
experienced childhood abuse (Kamiya et al., 2015). In a longitudinal study in 
primary care, Creed et al. (2012) found that psychological abuse but not physical 
abuse was associated with the persistence of a high level of somatic symptoms. 
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Childhood physical abuse has been reported to be predictive of poorer physical and 
mental health (Springer et al., 2009) and persistence of UPS (Barsky et al.,1994; 
Waldinger et al.,2006; Van Boven et al., 2011).  This association may be due to a 
poor lifestyle (i.e alcohol consumption or risk taking behaviour) relating to poor 
coping (Springer et al 2003). Past experiences may also influence how symptoms 
are perceived; they may be mediated through pathways such as immune system 
sensitisation, endocrine dysregulation and abnormal proprioception and impact on 
individuals’ help-seeking behaviour (Van Ravenzwaaij et al., 2010).  
 
Age was not associated with an increase in symptom severity. Reports of whether 
UPS are more common amongst younger or older people vary (Morriss et al., 2012; 
Escobar et al., 1998; Verhaak et al.,2006). My findings are supported by 
Steinbrecher and Hiller (2011), who also found that age did not show a significant 
association with persistence of medically unexplained symptoms and somatoform 
disorders in primary care attenders. Creed et al., (2011), however, suggests that 
higher reports amongst younger people may be influenced by the use of diagnostic 
criteria (for example for somatoform disorder, the DSM-IV criteria require 
symptoms occurring before age 30). Furthermore, for older people, difficulties of 
recall as well as the natural increase in physical symptoms with age may make 
identification of medically unexplained symptoms difficult (Hilderink et al.,2015) 
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 Factors associated with secondary outcomes  8.2.5
8.2.5.1 Physical health functioning  
Higher somatic symptom scores suggestive of greater symptom burden were 
associated with poor physical health functioning and recovery at six months follow-
up. Many authors have also found that UPS, symptom severity and total number of 
symptoms are associated with greater physical impairment in cross-sectional and 
longitudinal studies (Katon et al 1991; Kroenke et al., 2002; Barsky et al., 2006; 
Jackson and Kroenke, 2006; Koch et al., 2007; Zonneveld et al., 2009; Hansen et al., 
2011; Creed et al., 2012; Tomenson et al., 2013). As might be expected, poorer 
physical health functioning at baseline is likely to be associated with poorer 
recovery of physical health functioning at follow-up, implying that recovery may be 
limited over six months; similar findings were reported by Hansen et al. (2011) in 
their primary care study over 24 month follow-up. 
 
A greater number of primary health contact in the year prior to study participation 
was associated with poor physical health functioning. It is plausible that those who 
have greater symptom burden and poorer physical functioning at baseline access 
more health care but may not experience recovery over time. In my study, older age 
was also associated with poor physical functioning and may be due to a natural 
decline in physical health functioning as people get older; this is consistent with 
previous findings (Henchoz et al., 2008; Hilderlink et al., 2013).  
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8.2.5.2 Mental health functioning, depression and anxiety 
Poorer baseline mental health functioning and greater depression and anxiety were 
associated with less recovery of psychological well-being at follow-up. Other studies 
have found similar associations among people with UPS (Koch et al., 2009).  This 
persistence in poor psychological well-being may also be a result of the prolonged 
nature of recovery from depression and anxiety, which may take a long time or not 
at all, in some people (Boland and Keller, 2002; Terre et al 2003; Tylee and Haddad, 
2007; McMohn et al.,2012).   
 
Baseline somatic symptom scores were associated with higher depression scores at 
follow-up (after adjusting for baseline depression); others have reported similar 
findings amongst primary care attenders with UPS (Kisely and Simon, 2006; Kroenke 
et al., 1994). This relationship is likely to be bi-directional. It is possible that 
participants presenting with somatic symptoms but with underlying depression get 
worse over the follow-up, if it is not recognised and managed appropriately 
(Kamphuis et al.,2012). For others, the high symptom burden and uncertainty of 
their UPS may lead to depression as a result of poor coping. Higher self-efficacy at 
baseline was independently associated with lower depression scores; this suggests 
that self-efficacy is associated with better recovery, potentially acting as a 
protective factor (Maciejewski et al.,2002).  
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Several studies have shown that somatic symptoms are associated with increased 
health care use as well as increased health care costs (Tomenson et al 2013; de 
Waal et al., 2008; Hilbert et al., 2010; Hansen et al., 2011; Zonneveld et al., 2013). I 
found that greater primary care contacts in the year before study enrolment was 
associated with higher primary care use at follow-up; this association has been 
reported in previous primary care studies in patients with UPS (Blankenstein,2001; 
Hilbert et al 2010). It is possible that people who consume higher levels of health 
care may have greater levels of health anxiety or other comorbidities which are 
reflected in their continued high frequency of health care use at over time (Hilbert 
et al., 2010). 
 
I found childhood emotional abuse was associated with increased primary care use 
in adults. This is in line with numerous studies that have reported that childhood 
physical, sexual, psychological or emotional abuse may result in long-term health 
consequences (Springer et al 2003; Arnow, 2004;Norman et al., 2012). Childhood 
abuse has been suggested to have impact on adult health through emotional, 
behavioural, social, and cognitive pathways that can result in poor mental health 
well-being, poor lifestyle and engaging in harmful activities (Kendall-Tackett et al., 
2002); which may explain high health care use over time.  
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 Strengths and limitations  8.3
 Study design 8.3.1
Cohort studies are useful for studying a group of participants who are at risk of a 
specific outcome and following them over time to explore the outcome of interest. I 
considered the use a prospective cohort study design the most suitable to address 
the aims of my research, i.e. to: 1) investigate the outcome of UPS at six months 
follow-up, amongst adult primary care attenders; and 2) to identify prognostic 
factors associated with persistence of somatic symptom severity, quality of life, 
anxiety, depression and health care use. There are disadvantages associated with 
cohort studies. One of the main disadvantages is its resource intensive nature in 
terms of the time required to set up and follow-up the cohort (Sedgwick, 2013). In 
order to identify a population of a suitable sample size, recruitment for my study it 
took place over eleven months.  
 
An alternative sampling method that could have been used is population based 
sampling (i.e. contacting all people in a defined population using electoral lists or GP 
registers). This method may have increased the representativeness of the sample 
and thus increased the external validity of the findings (Mann,2003). Conversely, 
this method could also have potentially resulted in higher non-response rates 
(Gordis,2014).  Electronic medical records could also have been used for 
identification of participants by developing an algorithm to identify UPS or through 
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GP identification. However it is likely to have resulted in under identification of 
cases because of the differences in recording symptoms and diagnoses (Morriss et 
al., 2012); additionally, this would identify a sample based on the general 
practitioner's judgment.  
 
Postal questionnaires were used as the main source of data collection rather than 
another method (e.g., semi-structured interviews) due to the time and resource 
restrictions. An option of face-to-face or telephone questionnaire completion was 
offered to participants but few took this up. A possible alternative (or addition) to 
postal questionnaires is the use of online questionnaires, which are less resource 
intensive regarding data entry. However, at the inception of this study, resources to 
securely collect identifiable data for a longitudinal study in this way were not 
available.  
 
A number of methods such as structured diagnostic interviews, structured 
screening questionnaires, clinician or researcher identification or medical records 
can be used in research to identify patients. Their benefits and drawbacks were 
discussed in section 1.4.  However, I chose to use patient self-reports because they 
reflect the patients’ beliefs and perceptions, without the influence or interpretation 
of their GP. Self-reported symptoms are crucial to understanding needs and help-
seeking behaviour. However, as they rely on the patients understanding of their 
diagnosis/explanation and their ability to recall it is possible that there may be 
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biased by inaccurate reporting. Nevertheless, the patients’ understanding, 
perceptions and belief of whether their symptoms are unexplained are more likely 
to offer an accurate picture of the level of burden, frequency of consultation and 
other health care use (Sumathipala et al., 2008) irrespective of any diagnosis or 
physiological explanations that a general practitioner may have recorded in the 
person’s medical notes. Therefore in my study the use of self-reported data was an 
extremely valuable method of identification of patients in studies of UPS and it 
offered a more meaningful patient oriented insight into burden of the problem to 
the patient and their help-seeking behaviours. 
 
The outcomes in this study were explored over six months, rather than a longer 
duration. Short term outcome is important as it provides an indication of whether 
symptoms are self-limiting over that period of time. A few studies have explored 
outcomes over six months and report similar rates of persistence of UPS but higher 
rates of recovery than my study (De Gucht et al.2004; Arnold et al., 2006).  
 
 Setting 8.3.2
People with UPS are known to make up a large proportion of those attending 
primary care. Therefore, general practice was deemed the best setting to capture 
this population. In terms of feasibility, this setting provided access a large number 
of people who had symptoms that were bothering them. Furthermore, the 
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exploration of outcomes of a population attending primary care is valuable as it can 
provide information on the scale of the problem, prognosis in this setting and 
potentially aid in determining how best to intervene in the management of 
patients.  
 
An important strength of my study is the inclusion of nine general practices with 
differing levels of deprivation. However, these practices may not be representative 
of other general practices in the UK; practices were recruited through a research 
network which identified them as being as research active. In some practices, I was 
approached by doctors and practice managers who had a special interest in this 
area of study. Their interest in the area may have reflected on the patient 
experiences within the practice, in relation to management of UPS. The research 
active nature of the practice may have also resulted in research fatigue amongst the 
patients which may explain the relatively high dropout rate from the screening to 
baseline questionnaire. Additionally, due to time and resource restrictions only 
general practices in London were included thus the generalisability of the findings is 
limited.   
 
 Response rates and representativeness 8.3.3
Only 25% of those who were eligible at the screening stage of the study, and who 
expressed interest to take part in the longitudinal study returned baseline 
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questionnaires. Recruitment from primary care is acknowledged to be increasingly 
difficult, particularly in the UK. King et al. (2006) achieved higher response rates at 
44% by approaching attenders in general practices in the UK, for a study on the 
natural course and outcome of depression. However, a more recent cohort study in 
primary care, which included GP practices from London and North West England, 
found that the response rate varied depending on the type of long term condition, 
the region in which the practice was located and by practice deprivation score 
(Peters et al., 2014). Average response rates for all long term conditions were 38%, 
but were as low as 30% (Peters et al., 2014). Based on these findings, decreasing 
response rates may reflect a trend that is occurring over time.  
 
It has been suggested in the past that in order to obtain a representative sample 
from the target population, a response rate of 70% or above is required (Patel et al., 
2003). However, one of the strengths of my study is that those who returned 
baseline questionnaires were comparable to non-responders in terms of clinical 
characteristics, which suggests that despite the high dropout, the findings are likely 
to be comparable to a larger study population with similar characteristics to the 
responders. There were only a few differences, with non-responders being more 
likely to be male and younger. This appears to be common in many primary care 
studies (Patel et al., 2003).  
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Another strength of this study is the high response rate (83%) at six month follow-
up. At follow-up responders were similar to non-responders except that they were 
slightly older than non-responders, reported experiencing symptoms for longer at 
baseline, had lower median depression scores and reported lower levels of abuse 
during childhood. This suggests that responders may have been experiencing more 
chronic symptom burden but less underlying psychological morbidity.  
 
As I conducted screening at all practices myself, it is likely that there is very little 
variation in how the study was presented to participants. It is important to 
acknowledge that my style of communication regarding the study may have 
changed with increasing familiarly and confidence over the 11 month period, 
although every attempt was made to ensure consistency. 
 
Whilst the study was ongoing, due to the low response rates in participation in the 
cohort study it was necessary to make some changes to the study design in order to 
reach the target sample size. In consultation with my research supervisors, clinicians 
and other experts in primary care, as well as with reference to literature on 
response rates, three changes were made. The amendments were approved by the 
local research ethics committee and applied to the last three practices included in 
the study. A £10 voucher was provided per questionnaire as to compensate for time 
and inconvenience. The colour of the envelopes used was changed from brown 
manila to white envelopes. An invitation printed on the letter head from the 
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general practice to which eligible participants were registered at was also used. This 
made no difference to the response rate and similar numbers responded to the 
baseline questionnaires as in the earlier practices.  
 
With consideration to the participation rates and non-response rates, the findings 
of my study are likely to be generalisable to a middle-aged, female population who 
have symptoms for longer at baseline, who are less likely to be suffering from 
depression and less likely to have experience abuse in childhood. Hence, it is 
important to be cautious about the generalisability of these findings when 
extrapolating results to dissimilar populations. 
 
 Inclusion and exclusion criteria 8.3.4
A potential limitation of the study is that those who were unable to complete the 
questionnaire in English were excluded. This was due to time and resource 
constraints. In spite of this, a fairly diverse population was accessed with 27% 
reporting their ethnicity as Black, Asian, or Mixed. Within those who reported their 
ethnicity as White, a further 11% reported their ethnicity as White Other.  
 
Another potential limitation was the exclusion of those with impaired cognitive 
ability or learning difficulties; however, only a minority of people stated this as a 
reason for not completing the questionnaire. It is difficult to know whether those 
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who expressed a lack of interested in the study and did not want to complete the 
screening questionnaire actually had underlying cognitive or learning difficulties or 
were unable to read or understand the questionnaire, which they did not want to 
reveal. 
 
 Identification of participants  8.3.5
The PHQ-15, a self-report measure, was used to determine the extent of symptom 
severity. Those who were considered eligible were identified as having at least 
three UPS, and a score of five or more, after any explanations or diagnoses offered 
for the symptoms were considered. Patient self-reports of symptoms and their 
understanding of explanations may have resulted in a different population to those 
who would have been identified by their doctors or by using patient notes. On the 
other hand, it is very possible that some people were not aware of their diagnosis, 
were unable to recall their diagnosis, did not understand a diagnosis, or did not feel 
that their diagnosis or explanation provided an adequate explanation for their 
symptoms. There may also have been some participants who were screened, who 
received a diagnosis after their first consultation and therefore decided not to 
return the baseline questionnaire.  
 
Those identified as meeting the threshold for inclusion were based on my 
judgement in consultation with my three clinical supervisors, who are practising 
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GPs. Efforts were taken to ensure consistency through development of a coding list 
of potential diagnoses that explained symptoms on the PHQ-15. This list was revised 
iteratively in discussion with my clinical supervisors, as I came across new diagnoses 
or explanations or when any uncertainty occurred. However, this subjective 
judgement may have led to some bias and may reduce the reliability of the study in 
terms of participant identification. It is possible that some of the participants may 
have had some explanation or diagnosis which clinicians would consider to be 
adequate or reasonable and therefore not considered unexplained or even partially 
unexplained.  
 
 Sources of error 8.3.6
8.3.6.1 Measurement 
Strengths of all the measures used in the study were discussed in section 4.9, 
however, some limitations warrant mention. First, the PHQ-15 does not identify 
whether the symptoms are unexplained. Therefore, I included a question to the 
screening questionnaire, which allowed participants to report whether they had an 
explanation for their symptoms, and if so what this explanation was.  However, I did 
not enquire about each of the symptoms separately and it is possible that some 
participants only reported explanations for some of their symptoms.  
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The measures for depression (PHQ-9) and anxiety (GAD-7) are also widely used in 
clinical practice and research (Kroenke et al 2010). Scores of 10 are considered to be 
clinically relevant and facilitate the diagnosis of major depressive disorder, although 
some suggest that in primary care higher cut-offs of 12 or even 14, may increase 
accuracy (Kendrick et al., 2009; Mitchell et al., 2016). The GAD-7 is a measure of 
severity; although as scores increase the likely presence of anxiety disorder 
increases, a clinical interview is necessary to determine the presence of an anxiety 
disorder (Kroenke et al., 2010). The SF-12, which was used to measure physical and 
mental health functioning; it has been suggested that there are may be a bias with 
self-reported scores being consistently lower than when the measure is interviewer 
administered (Busjica et al., 2011).  
 
A number of existing questionnaires were adapted and some new ones were 
developed for the purposes of this study. These included questions about childhood 
experiences, abuse, and self-management. For example, many validated 
questionnaires on childhood abuse were long and potentially too intrusive for a 
postal questionnaire therefore questions were reduced and adapted in consultation 
with my supervisors. This may have decreased the sensitivity and specificity of these 
measures, which may have impacted my findings. I also developed new questions 
on the availability of social support and to enquire about preferences for 
management of symptoms.  
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It was also noted that due to a typographical error in development of the 
questionnaire a running page header was incorporated in the questionnaire 
booklet, which asked the respondent to “please check that all questions were 
answered before turning the page”. This was despite the clearly stated statement 
within the body of the questionnaire, that those who did not want to answer 
questions on abuse could skip the question. This error may have inadvertently 
made some participants refrain from returning the questionnaire.  
 
 Sources of Bias 8.3.7
There are a number of biases that can occur in cohort studies that must be 
considered. These include selection and information bias.  
 
8.3.7.1 Selection bias  
Selection bias results from the impact of non-participation, non-response and loss 
to follow-up on how results are interpreted and the generalisability of the findings 
(Gordis, 2014). Although I aimed to screen consecutive patients, it is possible that 
this did not always happen, especially during busier times at each practice. Also, 
there may be some bias due to the fact that different demographics may be more 
likely to attend the surgery at certain times, for example, those who are working 
may be more likely to attend evening appointments. The impact of this bias was 
minimised by attending morning, afternoon and evening sessions. It was not 
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possible to obtain details of those who did not take part in the screening stage of 
the study other than brief reasons for non-participation. This is discussed in the 
next section. 
 
8.3.7.2 Information bias 
Information bias can result when: the quality or extent of information obtained for 
exposed participants is different to those who are unexposed; the assessor who 
determines the disease status is aware of the exposure status; or due to 
preconceptions which may result in unintentional biases to the analyses of data 
(Gordis, 2014). Due to the prospective nature of the study, information on exposure 
was collected prior to assessing the outcome using self-report questionnaires, thus 
minimising the potential for bias in assessment of exposures. Unintentional biases 
being introduced to the analysis of data was minimised by developing a statistical 
analysis plan prior to the data collection where it was decided that variables 
included in the multivariable models would be based on theoretical considerations 
and on statistical testing. 
 
Another source of potential bias may have occurred during the collection of 
outcome data and data entry as I was not blinded to the details of the participants. 
Although this is a potential weakness, there was no other way to do this as the sole 
researcher for the study. In order to minimise this potential bias during data entry 
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from misclassification or by error, data was double checked at each stage. Between 
10-25% of the data at each stage of the study was double entered by an 
independent person. There were minimal errors found; at each stage this was less 
than 1% and therefore such bias is unlikely. 
 
 Missing data 8.3.8
Missing data can introduce potential bias into a study and needs to be dealt with 
using an appropriate statistical method depending on how much is missing and the 
reason why it may be missing. In section 4.10.4, I discussed in detail the way in 
which missing data was handled with reference to guidance literature for the 
individual items used.  As my study had very little missing data, both in terms of loss 
to follow-up and missing data in individual questions it was not necessary to use 
statistical methods to impute the data.  
 
 Chance: sample size and power 8.3.9
The study sample size was determined using a rule of thumb commonly used for 
determining sample size of prognostic studies, as discussed in section 4.10.2. Even 
after loss to follow-up, there was the potential to include up to 24 continuous 
variables in the model, provided there was no missing data. In order to ensure that 
each model was sufficiently powered, consideration was given to the amount of 
missing data and number of variables reduced using theoretical decisions and 
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conceptual group analysis. However, due to the large sample size and the numbers 
of variables that were carefully considered in each model, there can be reasonable 
confidence that the findings are not due to chance. 
 
 Confounding  8.3.10
Another important factor that must be considered is confounding; variables may 
directly or indirectly correlate with both the independent variable and outcome 
variable and contribute to false positive findings (Gordis, 2014). Potential variables 
associated with the primary outcome were carefully considered with reference to 
the literature and consideration of clinical value. For prospective cohort studies 
there is the potential to collect information on a wide range of potentially 
confounding variables. Although stringent efforts were taken to ensure that models 
were adjusted for potential confounding, it is possible that some confounding 
variables might not have been considered i.e., unmeasured confounding. For 
example, other comorbidities or long-term conditions with clear diagnoses (other 
than depression and anxiety), and current experience of abuse were not adjusted 
for.  
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 Clinical, research and policy implications 8.4
The meaning of the study findings and the clinical and policy implications will be 
discussed in the following sections in relation to findings from the systematic 
literature review, the screening study, and the cohort study.  
 
Past studies on UPS have used various terminologies and diagnostic criteria, thereby 
including participants with varying degrees of symptom severity and clinical 
characteristics. This means that it is difficult to determine what factors might be 
relevant to the majority of patients with UPS in primary care. It is therefore 
important to be clear about how UPS are defined in order to ensure that research 
carried out is applicable to the majority of those attending primary care as well as 
to identify best practice for managing these patients. 
 
My study found that UPS are extremely common in primary care. It may be useful 
to screen frequently attending patients as a routine practice to detect potential 
patients with UPS and to engage with them before their symptoms become 
persistent or worse requiring further input. My findings also indicated that just 
under half of those screened reported some explanation for their symptoms; the 
majority of these were physical explanations. It is important to recognise that UPS 
can occur alongside existing medical diagnoses, increasing the level of burden and 
distress. The new developments to the DSM-5 are based along this line of thinking, 
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take into consideration symptom burden regardless of whether symptoms are 
explained or not (Dimsdale et al., 2013). It may therefore be beneficial for doctors 
to be taught to recognise and manage UPS alongside diagnosed disease or illness 
accordingly. Additionally, it may be useful to consider the development of more 
systematic and consistent ways to identify patient with such mixed explained and 
unexplained symptoms, for both clinical and research purposes.  
 
A few participants reported psychological and functional explanations for their 
physical symptoms and some provided functional syndromes as explanations. This 
indicates that some individuals may be accepting of explanatory models that 
consider psychological explanations whilst for others a label is important. Tailoring 
explanations about their UPS to individual patients based on their explanatory 
models may be useful for doctors and beneficial to patients. 
 
The percentage of those who reported planning to consult their GP about their UPS 
on the day of screening was relatively small and increased as symptom severity 
increased; this suggests that there may be a significant number with milder 
symptoms who are managing their symptoms themselves.  Therefore, it may be 
advisable to identify those likely to have a poor outcome earlier in the process and 
manage them appropriately to prevent a chronic course. 
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I found that my study cohort was functionally impaired; with moderately severe 
somatic symptoms and that the majority had experienced symptoms for longer 
than one year. This study confirms the presence of patients with underlying 
psychological morbidity, but also that a large number of patients in primary care 
who are functionally impaired may not necessarily be suffering from comorbid 
depression and anxiety.  Different management approaches may need to be 
considered for these two groups of patients.  
 
At follow-up, my study cohort continued to be symptomatic and functionally 
impaired; over half reported that their symptoms were still unexplained, and 
physical and mental health functioning was poor. This suggests that for many, UPS 
may not be transient and that many will continue to be impaired over time. 
Therefore, it is vital that individuals are managed appropriately in the long term, to 
reduce the burden on themselves, health care resources and the wider economy. It 
may be useful to take an approach to health care advocated for other long term 
conditions, by engaging with the patient, involving them in decisions about their 
care and supporting self-management as well as providing emotional, psychological 
and practical support (Coulter et al 2013).  
 
Preferences for support in my study were more often from general practitioners. 
This was closely followed by the internet and family and friends. There may be value 
233 
 
 
 
in considering management strategies that connect general practice with validated 
online resources and developing existing resources further.  
 
Based on the current findings, baseline symptom severity is a good indication of 
how the patient will progress over a six-month period. This should be taken into 
consideration by general practitioners, policy makers and health service planners, 
as well as in research when developing interventions. A fairly high proportion of 
study participants were still receiving investigations at the follow-up stage and it is 
important for doctors to be aware that continuing investigations can perpetuate 
symptoms rather than resolve them, as well as lead to a number of iatrogenic 
consequences (Page and Wessley, 2003). 
 
The results of my study suggest that a relatively small range of identifiable 
predictors are associated with adverse outcomes over time, within my study cohort. 
It may be beneficial for general practitioners to explore the role of current and past 
context within the life of the patient in managing symptoms. Management 
strategies both at the early stages and over time can consider addressing symptom 
burden, current physical and mental health, recent stressful life-events and 
historical factors such as abuse.   
 
Importantly, this thesis makes a valuable contribution to informing the guidance 
mentioned in chapter 1.11 titled ‘Guidance for health professionals on medically 
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unexplained symptoms’ developed by Chitnis and Colleagues (2014). Due to the 
scarcity of studies of primary care attenders with UPS, the evidence used in this 
guidance focussed on people with psychiatric disorders, hypochondriasis, hysteria 
or somatoform disorder as well as on those seen in secondary care or recruited 
from the community rather than primary care. As previously discussed in this thesis, 
these populations are likely to differ from primary care attenders. The findings from 
my study will inform the guidance based on data from a UK primary care population 
with UPS.   
 
The guidance suggests that ‘75% remains unexplained at 12 months’; my findings 
suggest that this figure may be lower, I found that 55% continue to experience UPS 
at 6 month follow up.  The document further suggests that UPS are more likely to 
be common amongst women and those who have experience of physical abuse and 
that there was no preponderance of these symptoms in any specific age group.  My 
work supports these suggestions and additionally identified potential risk factors 
such as poor financial situations (which may be a proxy for current stressful 
situation) and poor physical health functioning (proxy for poor physical health). 
 
 The guidance states that around 30% (10-80%) have an associated psychiatric 
disorder; I found that around a third have associated depression and anxiety. This 
leaves us with a considerable proportion of people with UPS that do not have 
clinical significant depression and anxiety.  My study provides evidence that 
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patients often present with unexplained symptoms alongside explained symptoms. I 
found that 33% of those who were screened at baseline had symptoms that were 
explained by a physical diagnosis alongside their UPS. Finally, the guidance suggests 
that patients should be reassured that long-term improvement may occur without 
providing an estimate of recovery.  In my study I found that 11% of people report 
recovery at six months. 
 
 Future research 8.5
This study explored participant outcomes over a six month period, but it may be 
useful to explore outcomes over a longer period. Additionally, the majority of those 
participating in this study reported baseline symptoms that had been present for 
over a year; therefore, it would be useful to explore those attending general 
practice with symptoms for the first time and identify prognostic factors which can 
predict those whose symptoms will remain unexplained. However, such a study 
would need a large sample size as a proportion of people are likely to receive an 
organic diagnosis. The time required to confirm that a symptom is unexplained 
would mean that the study would require a long follow-up period.  
This study identified a number of prognostic factors associated with somatic 
symptom severity, such as quality of life, depression, anxiety and primary health 
care use. However, it does not have an adequate sample size to conduct 
confirmatory prognostic model analysis. Future research can take further the 
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factors identified in this study to develop a prognostic model from a new study 
cohort and then validate it in an external cohort (see section 3.1). This would 
involve the identification of a new sample of primary care attenders with adequate 
follow up over an appropriate time frame to develop a prognostic model that would 
then be validated in another longitudinal cohort of primary care attenders  
 
Finally, future research would benefit from the inclusion of qualitative 
methodologies. Semi-structured individual interviews and focus groups could be 
employed to further explore patients’ perspectives on UPS. The use of such 
methods would be particularly useful in helping us to understand in greater depth 
at which point patients decide to see their doctor and what influences this decision. 
 
 Conclusion  8.6
To my knowledge, this is the first study carried out on primary care attenders in the 
UK, who were recruited based on the severity of their somatic symptom and their 
self-reported presence of UPS, to explore outcomes of UPS and prognostic factors 
associated with symptom severity.   
 
My study has found that primary care attenders with UPS are functionally impaired 
and around half remain symptomatic and functionally impaired at six months. 
Several prognostic factors were associated with somatic symptom severity at six 
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months. These were: being female, higher baseline somatic symptom severity, 
poorer physical health functioning, perception of poor financial well-being and 
experience of childhood physical abuse. Future work should determine whether 
these findings are maintained over longer periods. The value of developing 
prognostic prediction models based on factors identified in this study should also be 
explored.  
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Appendix 1 
Appendix 1.1 Past diagnostic categories relating to UPS 
DSM-IV Somatoform disorders ICD-10 Somatoform disorders 
Somatisation Disorder  
 
History of physical complaints beginning 
before age 30 years occurring over several 
years , resulting in treatment being sought 
or a significant impairment of functioning/ 
not fully explained following appropriate 
investigation by a known general medical/ 
physical condition or in excess. Not 
intentionally produced or feigned. 
 Symptoms from following areas:          
 1) Four pain symptoms and a history of 
pain related to at least four different sites 
or functions                                            
 2)  Two gastrointestinal symptoms and a 
history of at least two gastrointestinal 
symptoms other than pain                                                          
 3) One sexual symptom and a history of at 
least one sexual or reproductive symptom 
other than pain                      
4) One pseudo-neurological symptom with 
a history of at least one symptom or 
deficit suggesting a neurological condition 
not limited to pain.  
 
 
 
Somatisation disorder  
 
A) A history of at least two years 
complaints of multiple and variable 
physical symptoms that cannot be 
explained by any detectable physical 
disorders. Known physical disorders or 
social disability do not explain the 
severity, variety, extend or persistence. 
B)  Preoccupation with the symptoms 
causes persistent distress repeated 
seeking (three or more) of consultations 
or sets of investigations with medical 
practitioner/persistent self-medication/ or 
multiple consultations with local healers  
C)  Persistent refusal to accept medical 
advice that there are no adequate physical 
causes except for short periods or during/ 
immediately after medical investigations.  
D) A total of six or more symptoms from 
the group gastro-intestinal symptoms, 
genito-urinary symptoms, skin and pain 
symptoms, with symptoms occurring in at 
least two separate groups 
 
E) Symptoms not restricted to any 
schizophrenic or related disorders, or any 
mood or affective disorders.  
Undifferentiated Somatoform Disorder  
 
One or more physical complaints with 
duration of at least 6 months. After 
appropriate investigation symptoms, 
cannot be fully explained by a known 
general medical condition, direct effect of 
a substance/ or when related to a medical 
condition, physical complaints and 
functional impairment (social/ 
occupational) is in excess of expected 
(from the history, physical examination or 
laboratory findings) and clinically 
distressing.  
Disturbances not accounted for by any 
other mental disorder 
Undifferentiated Somatoform Disorder  
 
Criteria C and B for somatization disorder 
are incompletely filled. 
 
A) A history of at least two years 
complaints of multiple and variable 
physical symptoms that cannot be 
explained by any detectable physical 
disorders. Known physical disorders or 
social disability do not explain the 
severity, variety, extend or persistence. 
Duration of disorder is at least 6 months. 
C) Persistent refusal to accept medical 
advice that there are no adequate physical 
causes except for short periods or during/ 
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DSM-IV Somatoform disorders ICD-10 Somatoform disorders 
Symptoms not intentionally produced or 
feigned (fictitious disorder or malingering) 
immediately after medical investigations.  
E) Symptoms not restricted to any 
schizophrenic or related disorders,  or any 
mood or affective disorders.  
 
Conversion Disorder  
 One or more symptoms or deficits 
which affect voluntary motor or sensory 
function that suggest a neurological or 
other general medical condition.   
 Causes clinically significant 
distress and impairment in all areas of 
functioning or warrants medical 
evaluation 
 Initiation or exacerbation of 
symptoms are preceded by conflicts or 
other stressors 
 Symptoms or deficit not produced 
or feigned/ Not explained by a general 
medical condition or effect of substances 
after appropriate investigation  
 Symptoms or deficit not limited to 
pain and does not occur exclusively during 
course of somatization disorder 
 
 
 Pain Disorder  
 Associated with psychological 
factors 
 Associated with both 
psychological factors and a general 
medical condition  
Persistent Somatoform Pain Disorder 
Hypochondriasis  
Preoccupation with fear or idea that one 
has a serious disease based on the 
persons’ misinterpretation of bodily 
symptoms, which persists despite 
appropriate investigation and 
reassurance. Causes clinically significant 
distress and duration of disturbance is at 
least 6 months.  
Preoccupation not explained by GAD, 
OCD, PD, Major depressive episode, 
separation anxiety of somatoform 
disorder.  
Hypochondriacally Disorder 
Persistent belief of at least 6 months’ 
duration of the presence of a maximum of 
two serious physical diseases of which at 
least one must be named by the patient or 
persistent preoccupation with a presumed 
deformity or disfigurement 
Preoccupation with beliefs and symptoms 
causes distress or interference with 
personal functioning and results in seeking 
treatment 
Refusal to accept that there is no physical 
cause for the symptoms or physical 
abnormality. 
Body Dysmorphic Disorder  - 
Somatoform Disorder Not Otherwise 
Specified (NOS) 
Somatoform disorders which do not meet 
criteria for any specific somatoform 
Other/ Unspecified Somatoform Disorder 
Any other disorders or sensation, function 
and behaviour not due to physical 
disorders, which are not mediated 
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DSM-IV Somatoform disorders ICD-10 Somatoform disorders 
disorder  through the autonomic nervous system, 
which are limited to specific systems or 
parts of the body, and which are closely 
associated in time with stressful events or 
problems.  
 Somatoform Autonomic Dysfunction 
Symptoms presented by the patients as if 
they were due to physical disorder of a 
system or organ that largely or completely 
under autonomic innervation and control 
such as the cardiovascular, 
gastrointestinal, respiratory.  
Complaints are based on objective signs or 
autonomic arousal such as palpitations, 
sweating, flushing  
Secondly there are subjective complaints 
of non-specific or changing nature such as 
fleeting aches and pains, sensations of 
burning, feeling of bloated or distended.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
267 
 
Appendix 1.2 Changes to diagnostic categories 
DSM-V Somatic Symptom and Related Disorder 
 
Somatic Symptom Disorder   
A. One or more somatic symptoms that are distressing or result in significant disruption of daily 
life 
B. Excessive thoughts, feelings, or behaviours related to the somatic symptoms or associated 
health concerns as manifested by at least one of the following:  
 
1. Disproportionate and persistent thoughts about the seriousness of one’s symptoms. 
 2. Persistently high level of anxiety about health or symptoms.  
3. Excessive time and energy devoted to these symptoms or health concerns. 
C. Although any one somatic symptom may not be continuously present, the state of being 
symptomatic is persistent (typically more than 6 months).  
 
Specify if: With predominant pain (previously pain disorder 
 Specify if: Persistent: A persistent course is characterized by severe symptoms, marked 
impairment, and long duration (more than 6 months).  
Specify current severity:  
Mild: Only one of the symptoms specified in Criterion B is fulfilled. Moderate: Two or more of 
the symptoms specified in Criterion B are fulfilled.  
Severe: Two or more of the symptoms specified in Criterion B are fulfilled, plus there are 
multiple somatic complaints (or one very severe somatic symptom). 
Illness Anxiety Disorder 
Specify whether: care seeking type, care avoidance type 
 
Conversion Disorder (Functional Neurological Symptom Disorder 
Specific symptom type: With weakness of paralysis; with abnormal movement; with swallowing 
symptoms; with speech symptom; with attacks or seizures; with anaesthesia or sensory loss; 
with special sensory symptoms 
 
Psychological factors affecting other medical conditions  
Specific current severity: Mild, Moderate, Severe, Extreme  
 
Factitious Disorder (includes Factitious Disorder Imposed on Self, Factitious Disorder Imposed 
on Another)  
Specify Single episode/ recurrent 
 
Unspecified somatic symptom and related disorder 
Other specified somatic symptom related disorder 
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Appendix 2 
Appendix 2.1 Key words and terms for UPS used in 
literature search 
Key words and phrases for unexplained symptoms  
Somatoform Disorders 
Psychosomatic Medicine 
Somatisation  
Somatoform.mp 
(non organic$ or nonorganic) 
(unexplain$ adj1 medical$)  
((non specific or nonspecific) adj3 (symptom$ or problem$ or condition$ or 
complain$)).ti,ab. 
(unexplain$ adj3 (symptom$ or problem$ or condition$ or complain$)).ti,ab. 
((unexplain$ or inexplain$ or nonspecific or non specific) adj3 (health$ or 
medical$ or physical$) adj3 (symptom$ or problem$ or condition$ or 
complain$)).ti,ab. 
(frequent$ adj1 attender$).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier] 
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Appendix 2.2 Key words and terms for UPS used in 
literature search 
Key terms and phrases for primary care 
(primary adj2 (care or healthcare)).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
(community adj2 (care or healthcare)).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
 
exp General Practice/ 
Primary Health Care/ 
exp general practitioners/ or exp physicians, family/ or exp physicians, 
primary care/ 
general practitioners.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier] 
family adj1 physician$).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier] 
(general adj1 practitioner$).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier] 
(primary adj2 (care or healthcare)).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
general practice.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
GP.mp. 
((family or community or district or practice or general *) and (doctor or 
physician or practitioner*)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier] 
physicians, family/ or physicians, primary care/ 
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Appendix 2.3 Studies short listed for full text 
screening but excluded from the systematic review 
Reference/ country Cohort 
recruited for 
an 
intervention 
Restricted 
population* 
Other reason/ further 
details 
Arnold et al., 2006/ 
Netherlands 
X X  
Blankenstein et al., 2001/ 
Netherlands. 
X X  
Cape et al., 2001/ UK  X  
Craig et al., 1993/UK  X Prior to 1994- an criteria 
to study 
De Gucht et al 2004/ 
Netherlands 
 X  
De Waal et al., 2008/ 
Netherlands 
X   
Downes-Grainger et al., 
1998/ UK 
 X  
Frostholm et al., 2007/ 
Denmark 
X   
Gureje and Simon al., 
1999/ 15 sites in 14 
countries (WHO Mental 
Health Study). 
 X  
Hansen et al., 2011/ 
Denmark 
   
Hansen et al., 2011/ 
Denmark 
X   
Hilbert et al., 2010/ 
Germany 
X   
Jackson and 
Passamnoti,2005 /USA 
X   
Frostholm et al., 2007 X   
Koch et al., 2009/ 
Netherlands 
X  Based on one primary  
illness complaint 
Kisely and Simon, 2006/ 
15 sites in 14 countries 
(WHO Mental Health 
Study). 
 
 X  
Kooiman et al., 2004/ 
Netherlands 
X  Based on outpatients 
with Alexithymia 
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Reference/ country Cohort 
recruited for 
an 
intervention 
Restricted 
population* 
Other reason/ further 
details 
 
Ladwig et al.,/ Germany 
 
 
 
  Data from population 
based study on MONICA 
(monitoring trends and 
determinants on 
cardiovascular diseases) 
Mewes et al., 2008/ 
Germany 
  Not a longitudinal study 
and Not based on 
primary care population. 
Rosmalan et al., 2010/ 
Netherlands 
 
  A population-based 
cohort study which 
screened and included 
people with  high micro-
albuminuria and 
cardiovascular diseases 
Salmon et al., 2009/ UK   Not a longitudinal study. 
Focus also different to 
aim of literature review  
Speckens et al., 1996/ 
Netherlands 
  Included patients 
identified in out-patient 
clinics 
Taylor et al., 2012/ UK 
 
 
  Specific focus to explore 
role of insecure 
attachment amongst 
frequent attenders 
Van den Berg et al., 
2009/ Netherlands 
 
 X Participants recruited 
after a traumatic 
experience (disaster) 
 
Van Boven et al.,  2011/ 
Netherlands 
 X Based on single illness 
episodes 
Van der Windt., et al 
2008/Netherlands 
  Not a longitudinal study 
Verhaak and Tijhuis, 
1994/ Netherlands 
 
 X Patients recruited 
specifically after a 
disaster 
Veerkhak et al., 2006/ 
Netherlands 
  Based on symptom 
clusters- Pain, Irritable 
Bowel Syndrome, 
Fatigue, Depression, 
Anxiety 
 
*includes populations with somatoform disorders, somatisation, single illness 
episodes and/or populations with psychiatric morbidity. 
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Appendix 2.4 Summary of potential prognostic factors to consider from excluded studies 
Reference/ 
Country 
Reason for exclusion from 
systematic review 
Definition (criteria 
used) 
Number enrolled/ 
duration of Follow-
up 
Outcome and Direction of significant association 
Blankenstien, 
2001/ 
Netherlands 
Data from two studies with 
identical designs that were 
testing two  interventions 
for somatisation 
Somatisation (DSM-
III-R) 
376 (Baseline ) 
339 (2 years) 
 
Predictors of better subjective health (adjusted) 
-Baseline subjective health status(adjusted OR 1.03 p<0.001) 
-Social support (adjusted OR=1.03 p=0.05) 
Higher health care visits  
-Baseline health care visits (adjusted OR=1.02 p=0.04) 
-Social support (adjusted OR=0.95 p=0.002) 
Craig et al 1993/ 
UK 
Based on population with 
emotional disorder and 
recent physical symptoms  
Somatisers (DSM-III-
R)  
 
184 (BL) 
153 (2 years) 
 
Predictors of somatisation in adults 
-Childhood illness (OR=3.97 95% CI 1.81 to 8.72) 
-Lack of care (OR=3.96 95% CI 1.5 to 10.33) 
De Gucht et al 
2002/ 
Netherlands 
Focus on those with 
alexithymia and 
neuroticism, extreme 
personality dimensions.  
Somatisation 
disorder (SD) (DSM-
III-R/DSM-IV)/MUS 
377 (BL) 
318/377 (6 months) 
6months 
Increase in number of MUS  
-Negative affect (OR=1.78 95% CI 1.33 to 2.39 
-Positive affect (OR=0.71 95% CI 0.54 to 0.94 
Symptom persistence or recurrence 
-Females (OR=2.29 95% CI 1.14 to 4.62 
-High negative affect  (OR= 2.77 95% CI 1.46-5.27  
-Difficulty identifying feelings (dimension of alexithymia) 
(OR=1.08 95% CI 1.02-1.14 
De Waal et al 
2008/ 
Netherlands 
 
Participants were followed 
up for a period of six 
months in order to identify 
those eligible for 
participation in a CBT trial. 
SD (DSM-IV) 404 high-risk sample 
and 83 low risk 
sample. 
 
FP-consultation rate (adjusted) 
-Undifferentiated SD (IRR= 1.3 95% CI 1.1–1.7) 
-Somatic morbidity score 
       Intermediate (5-8) (IRR=1.2 95% CI 1.0 to 1.4) 
       High score (>9) (IRR=1.6 95%1.3 to 1.9) 
-Depressive disorders (IRR= 1.5 95% CI 1.0 to 2.3)  
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Reference/ 
Country 
Reason for exclusion from 
systematic review 
Definition (criteria 
used) 
Number enrolled/ 
duration of Follow-
up 
Outcome and Direction of significant association 
-Anxiety disorders (IRR=0.9 95% 0.7 to 1.4) 
Gureje and 
Simon, 1999 
Inclusion of participants 
based on presence of 
psychiatric morbidity  
Abridged 
somatization/ 
Somatic symptom 
Index 
1596 met the criteria 
for SSI at baseline. 
522/1071 met 
criteria at FU/12 
months 
Persistence of abridged somatisation (adjusted) 
-Self-rated poor overall health (OR 1.82  95% CI 1.32 to 2.52) 
-Moderate/severe occupational disability  (OR  1.55 95% CI 
1.17-2.06) 
Emergence of new somatoform disorder  
-Self-rated poor health (OR=2.26 95% CI 1.61 to 3.19 p) 
-Depression (OR=1.62 95% CI 1.10 to 2.37) 
Hansen et al 2011 
Denmark 
Data from a large 
prospective intervention 
study 
MUS and Functional 
diagnosis/ ICD-10/ 
GP rated 
1728 
(550 included in self-
reported health 
analysis & 670 
included in health 
service costs analysis) 
 
Predictors of poor physical health (adjusted)  
- GP rated MUS (OR=0.56 95% CI 0.32 to 0.98)  
- > 4 symptoms  (OR=5.35 95% CI 2.28 to 12.56) 
Predictors of good physical health (adjusted) 
- Education (>basic school) (OR=0.20 95% CI 0.07 to 0.57)  
Predictors of poor mental health (adjusted)  
-MUS GP rated (OR 1.90 95% CI 1.00 to 3.58) 
 - > 4 symptoms (OR 2.17 95% CI 1.02 to 4.59 p=0.04) 
Predictors of good mental health (adjusted) 
Education (>basic school) (OR=0.68 95% CI 1.02 to 4.59) 
Predictors of high primary health care use 
-Female gender (OR=2.63 95% CI 1.4 to 4.9) 
Predictors of high total health care costs  
-High users of health care (OR=5.56 95% CI 3.21 to 9.50) 
-Female (OR=3.34 95% CI 1.92 to 5.81) 
->4 symptoms (OR=2.82 95% CI 1.11 to 7.16) 
Hilbert at el 2010 
Germany 
 
Part of an intervention study MUS/ SD (DSM-IV) 
  
127/6 months Symptom severity (adjusted) 
-Duration of relationship (B=0.08 SE 0.05) 
-Baseline symptom severity (B=0.68 SE 0.09) 
-Baseline health care use (B=0.01 S.E 0.00) 
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Reference/ 
Country 
Reason for exclusion from 
systematic review 
Definition (criteria 
used) 
Number enrolled/ 
duration of Follow-
up 
Outcome and Direction of significant association 
Health care use (adjusted) 
-Baseline health care use (B=0.56 S.E 0.06) 
Jackson and 
Passamonti, 2005 
USA 
Cohort established for an 
intervention. 
Physical 
symptoms/multi-
somatoform disorder 
500/ 
3 months and  
Symptom resolution at 3 months 
- Shorter symptom duration at presentation (p<0.001) 
-No immediate post-visit worry (RR: 1.41, 95% CI: 1.02 to 1.92), 
-Baseline functional status (p=0.002) 
-Multi-somatoform disorder (RR= 0.70, 95% CI 0.51 to 0.96) 
-Symptom resolution at 2 weeks (RR=2.6%, 95% CI 2.1 to 3.3) 
Frostholm et al 
2007/Denmark- 
Aarhus county 
Cohort established for 
intervention  
MUS/ GP rated 1785 
229 with MUS/  3 
months 
Mental health (adjusted) 
- 1 Illness perceptions (b=-0.3 95% CI -4.1 to 3.5) 
-2 Illness perceptions ( b=-0.9 95% CI -6.7 to 4.9) 
-3 Illness perceptions ( b=-2.7 95% CI -8.2 to 2.8) 
Physical health (adjusted) 
-1 Illness perceptions (b=-2.0 95% CI -4.7 to 0.6) 
-2 Illness perceptions ( b=-5.7 95% CI -10.3 to -1.1 ) 
-3 Illness perceptions ( b=-2.9 95% CI -6.0 to 0.3) 
Kisely & Simon 
2006  
Inclusion of participants 
based on presence of 
psychiatric morbidity 
MUS/ CIDI diagnostic 
interview/ Patient 
report and 
interviewer rated  
3201 ( 
2198 with at least 
one medically 
unexplained 
symptom) / 12 
month  
Psychiatric case based on GHQ (adjusted) 
- MUS (OR 1.05 95% 1.02-1.08) 
Psychiatric case based on CIDI (adjusted) 
- MUS (OR 1.13 95% ci 1.1 to 1.2) 
 Generalised anxiety (adjusted) 
- MUS (OR 1.07 95% 1.03 to 1.1) 
Depression (adjusted) 
-MUS (OR 1.06 95% 1.02 to 1.1) 
Physical disability (adjusted)   
-MUS (OR 1.12 95% 1.1 to 1.15) 
Social disability (GSDS) (adjusted)  
- MUS (OR 1.06 95% 1.03 to 1.9) 
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Reference/ 
Country 
Reason for exclusion from 
systematic review 
Definition (criteria 
used) 
Number enrolled/ 
duration of Follow-
up 
Outcome and Direction of significant association 
Prescribed psychotropic (adjusted)  
- MUS (OR 1.06 95% 1.02 to 1.1) 
>4 Clinic visits (adjusted) 
- MUS (OR 1.05 95% 1.03 to 1.09) 
Koch et al 2009 
Netherlands 
Part of a randomised 
controlled trial and based 
on a single main illness 
complaint 
Unexplained 
complaints (included 
fatigue, 
musculoskeletal and 
abdominal)/ GP 
identified 
444 /12 months Remission of unexplained symptoms  
-Male (OR= 0.6 95% CI 0.4–0.8) 
-Abdominal complaints (OR=0.5 95% CI 0.3–0.8) 
Persistence of unexplained symptoms  
-Musculoskeletal complaints (OR2.3; 95% CI 0.81–1.76) 
Unfavourable course, mental health functioning 
-Presence of psychosocial factors such as stress, depression or 
anxiety  (B=-5.02 95% CI -6.90 to -3.15) 
-Presence of complaints >6 months before presentation  B=-
2.81 95% ci -4.88 to -0.74 
Favourable course of mental health functioning 
-Musculoskeletal complaints (B=5.45 95% CI 3.00 to 7.90) 
-Self-perceived quality of life (B=0.16 95% CI 0.11 to 0.21) 
-Passage of time  b= 0.37 (per month 95% 0.29 to 0.45)  
Unfavourable course, physical functioning  
-Older age (B=-0.10 95% CI -0.14 to -0.05) 
-Musculoskeletal complaints (B=-4.65 95% CI -6.70 to -2.60) 
-Psychological factors (b=1.96 95% CI 0.45 to 3.46) 
-Presence of previous episodes (b=-2.04 95% CI -3.71 to -0.38) 
Positive course,  physical functioning  
-Abdominal complaints (B=0.39 95% CI -1.80 to 2.59) 
-Self-perceived quality of life at baseline (0.13 95% CI 0.08 to 
0.17) 
-Passage of time (b=0.3 per month 95% CI 0.22 to 0.36)  
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Reference/ 
Country 
Reason for exclusion from 
systematic review 
Definition (criteria 
used) 
Number enrolled/ 
duration of Follow-
up 
Outcome and Direction of significant association 
-Establishment of explanation (b=1.11 95% CI 0.06 to 2.16) 
Van Boven et al 
(2011)/ 
Netherlands 
Symptom episodes Unexplained 
symptoms/ 
somatoform 
disorder/ PHQ-15  
(excluding menstrual 
and sexual 
symptoms) 
16,000 symptom 
episodes/ 3 months 
Anxiety episode within three months 
Somatoform symptom episode ‘palpitations’ tripled the 
risk of anxiety post-test 
Disturbances in sleep doubled risk of anxiety 
Depressive disorder within three months 
Not raised by somatoform symptom 
Episodes of lower back complaint decreased risk of depression 
by half 
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Appendix 4 
Appendix 4.1 Table showing results from univariable 
analyses of baseline variables with physical health 
function score (SF-12) at follow-up 
Baseline variables Coefficient 95% CI p-value 
Female 2.34 -1.02 to 5.75 0.170 
Age (Median/IQR)  -0.22 -0.31 to -0.14 0.00 
Ethnicity    
  White  - - - 
  Black 1.18 -5.90 to 8.25 0.743 
  Asian -3.51 -7.40 to 0.37 0.076 
  Other (including mixed) -2.59 -8.26 to 3.10 0.372 
Marital status    
    In a relationship 
    (Married/ In a long term    
     relationship) - - - 
Other (Widowed, separated, single) -1.25 -4.11 to 1.61 0.389 
Employment status     
    In paid employment - - - 
    Not in paid employment  -7.69 -10.35 to -5.04 <0.001 
Education     
    O-levels, GCSE, A-levels or equivalent - - - 
    Undergrad, masters or higher or     
    equivalent 7.84 5.17 to 10.50 <0.001 
Finance    
   Doing well  - - - 
    Doing badly -6.46 -9.16 to -3.74 <0.001 
IMD -0.10 -0.21 to 0.00 0.06 
Preference for dealing with symptoms     
Alone  - - - 
With help from others -5.93 -9.40 to -2.46 0.001 
Baseline symptom severity (PHQ-15) -0.87 -1.13 to -0.60 0.00 
Duration of symptoms at baseline -7.29 -10.59 to -3.99 <0.001 
SF-12 scores     
   Mental health functioning 0.16 0.03 to 0.28 0.018 
   Physical functioning  0.76 0.67 to 0.85 <0.001 
Depression  -0.59 -0.79 to -0.39 <0.001 
Anxiety   -0.41 -0.65 to -0.16 0.001 
Panic -2.69 -6.30 to 0.91 0.142 
Work and social adjustment -0.48 -0.59 to -0.37 0.00 
Self-efficacy  0.37 0.19 to 0.56 0.00 
Stressful life events -1.65 -2.57 to -0.73 <0.001 
Experienced physical illness in family    
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Baseline variables Coefficient 95% CI p-value 
members as a child  
   No - - - 
   Yes -3.87 -6.86 to -0.88 0.011 
Experience mental illness in family 
members as a child    
  No - - - 
  Yes 0.09 -3.70 to 3.88 0.964 
Experienced 1 or more traumatic event 
as child     
  No - - - 
  Yes -5.36 -8.28 to -2.43 <0.001 
Experience abuse    
  No  - - - 
  Yes -2.95 -6.28 to 0.36 0.080 
Type of abuse experienced    
Physical Abuse -7.65 -12.50 to -2.79 0.002 
Sexual Abuse -2.00 -7.06 to 3.04 0.434 
Emotional Abuse -4.80 -8.28 to -1.21 0.009 
Primary health care contacts -0.60 -0.84 to -0.44 0.001 
Secondary care contacts -0.92 -1.45 to -0.40 0.001 
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Appendix 4.2 Table showing results from univariable 
analyses of baseline variables with mental health 
function score (SF-12) at follow-up 
Baseline variables Coefficient 95% CI p-value 
Female  -3.34 -6.65 to -0.03 0.048 
Age 0.03 -0.05 to 0.11 0.458 
Ethnicity     
   White - - - 
   Black 6.40 -0.55 to 13.35 0.071 
   Asian -1.61 -5.43 to 2.21 0.418 
  Other (including mixed) -3.11 -8.70 to 2.47 0.273 
Marital status     
   Married or in a long term   
   relationship 
- - - 
    Widowed, separated, single -3.21 -5.95 to -0.48 0.022 
Employment status     
    In paid employment - - - 
    Not in paid employment  -3.47 -6.21 to -0.73 0.013 
Education     
    O-levels, GCSE, A-levels or       
    equivalent 
- - - 
    Undergraduate, masters or higher    
     or equivalent 
2.35 -0.48 to 5.18 0.103 
Finance     
    Doing well - - - 
    Doing badly -5.95 -8.62 to -3.28 <0.001 
Indices of multiple deprivation  -0.08 -0.18 to 0.03 0.166 
Baseline symptom severity (PHQ-15 -0.80 -1.05 to -0.54 <0.001 
Duration of symptoms at baseline    
     <1 year - - - 
      >1 year -2.69 -6.13 to 0.75 0.124 
Preference for help seeking    
 By my-self - - - 
Like some help -5.20 -8.71 to -1.69 0.004 
Mental  0.58 0.48 to 0.69 <0.001 
Physical 0.15 0.02 to 0.28 0.025 
Depression  -0.88 -1.06 to -0.70 <0.001 
Anxiety    -0.91 -1.12 to -0.70 <0.001 
Panic -7.64 -11.07 to -4.21 <0.001 
Work and social adjustment -0.42 -0.52 to -0.31 <0.001 
Self-efficacy  0.59 0.41 to 0.76 <0.001 
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Baseline variables Coefficient 95% CI p-value 
Stressful life events -1.42 -2.32 to -0.52 0.002 
Experienced physical illness in family 
members as a child 
   
No - - - 
Yes -0.85 -3.71 to 2.00 0.557 
Experience mental illness in family 
members as a child  
   
No - - - 
Yes -3.28 -6.99 to 0.43 0.083 
Experienced 1 or more traumatic 
event as child 
   
No - - - 
Yes -3.89 -6.84 to -0.93 0.010 
Experience abuse    
 No  - - - 
Yes -5.45 -8.67 to o-2.24 0.001 
Physical Abuse -7.83 -12.58 to -3.08 0.001 
Sexual Abuse -7.79 -12.65 to -2.94 0.002 
Emotional Abuse -6.71 -10.17 to -3.26 <0.001 
Social support    
No - -- - 
Yes 1.11 -2.70 to 4.92 0.565 
Primary health service use  -0.22 -0.40 to -0.04 0.015 
Secondary health service use  -0.22 -0.75 to 0.31 0.408 
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Appendix 4.3 Table showing results from univariable 
analyses of baseline variables with depression (PHQ-
9) at follow-up 
Baseline variables  Coefficient 95% CI p-value 
Female  1.04 -0.97 to 3.05 0.311 
Age   0.01 -0.04 to 0.06 0.816 
Ethnicity     
   White - - - 
   Black -1.11 -5.31 to 3.10 0.605 
   Asian 0.12 -2.19 to 2.43 0.918 
   Other (including mixed) 1.59 -1.78 to 4.97 0.353 
Marital status     
   Married or in a long term   
   relationship 
- - - 
    Widowed, separated, single 1.34 -0.31 to 2.99 0.110 
Employment status     
   In paid employment - - - 
   Not in paid employment  3.36 1.76 to 4.95 <0.001 
Education     
   O-levels, GCSE, A-levels or   
   equivalent 
- - - 
   Undergrad, masters or higher or      
    equivalent 
-2.95 -4.58 to -1.32 <0.001 
Finance    
   Doing well - - - 
   Doing badly 4.46 2.89 to 6.03 <0.001 
IMD 0.06 0.00 to 0.13 0.055 
Dealing with symptoms    
   By my-self - - - 
   Prefer help 3.49 1.42 to 5.56 0.001 
Duration of symptoms  2.66 0.63 to 4.69 0.010 
Baseline symptom severity (PHQ-
15) 
0.59 0.44 to 0.74 <0.001 
SF-12 scores     
Physical -0.20 -0.27 to -0.13  <0.001 
Mental -0.33 -0.40 to -0.26 <0.001 
Depression  0.70  0.61 to 0.79 <0.001 
Anxiety   0.71 0.60 to 0.83 <0.001 
Panic 4.54 2.56 to 6.51 <0.001 
Work and social adjustment 0.30 0.23 to 0.36 <0.001 
Self-efficacy  -0.45 -0.55 to -0.36 <0.001 
Stressful life events 1.11 0.57 to 1.64 <0.001 
Experienced physical illness in 
family members as a child 
   
   No - - - 
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Baseline variables  Coefficient 95% CI p-value 
   Yes  0.96 - 0.80 to 2.73 0.283 
Experience mental illness in family 
members as a child 
   
   No - - - 
   Yes 1.69  -0.54 to 3.92 0.136 
Experienced 1 or more traumatic 
event as child 
   
   No - - - 
   Yes 1.93 0.20 to 3.67 0.029 
Experience abuse    
   No  - - - 
   Yes 2.65 0.75 to 4.54 0.007 
Physical Abuse 4.64 1.92 to 7.35 0.001 
Sexual Abuse 3.38 0.46 to 6.30 0.024 
Emotional Abuse 3.74 1.71 to 5.77 <0.001 
Social support 4.94 1.14 to 8.74 0.186 
Primary health care contacts 0.22 0.12 to 0.33 <0.001 
Secondary health care contacts 0.21 -0.11 to 0.53 0.191 
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Appendix 4.4 Table showing results from univariable 
analyses of baseline variables with anxiety (GAD-7) at 
follow-up 
Baseline variables Coefficient 95% CI p-value 
Gender 0.86 -0.88 to 2.61 0.330 
Age   0.01 -0.04 to 0.05 0.777 
Ethnicity    
   White  - - - 
   Black 0.5 -3.14 to 4.15 0.787 
   Asian 0.22 -1.78 to 2.22 0.828 
   Other (including mixed) 1.61 -1.31 to 4.54 0.279 
Marital status    
   Married/ In a long term   
   relationship) - 
 
- 
 
- 
   Widowed, separated, single) -0.07 -1.50 to 1.36 0.926 
Employment status    
  In paid employment  - - - 
  Not in paid employment  1.37 -0.06 to 2.79 0.061 
Education     
O-levels, GCSE, A-levels or 
equivalent 
- 
 - 
 
- 
Undergrad, masters or higher or 
equivalent -0.88 -2.33 to 0.57 0.234 
Finance    
Doing well  - - - 
Doing badly 2.50 1.09 to 3.91 0.001 
IMD 0.00 -0.05 to 0.06 0.871 
Preference for dealing with 
symptoms    
By myself - - - 
Help from others   2.14 0.33 to 3.95 0.021 
Duration of symptoms at baseline 2.22 0.47 to 3.97 0.013 
Baseline symptom severity (PHQ-
15) 0.44 0.30 to 0.57 <0.001 
SF-12 scores     
Physical -0.10 -0.16 to -0.03 0.003 
Mental -0.24 -0.30 to -0.18 <0.001 
Depression  0.50 0.41 to 0.59 <0.001 
Anxiety  0.62 0.52 to 0.72 <0.001 
Panic 3.77 2.02 to 5.52 <0.001 
Work and social adjustment 0.20 0.14 to 0.25 <0.001 
Self-efficacy  -0.28 -0.37 to -0.19 0.00 
Stressful life events 0.81 0.34 to 1.28 0.001 
Experienced physical illness in    
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family members as a child  
No - - - 
Yes 0.66 -0.89 to 2.20 0.404 
Experience mental illness in family 
members as a child    
No - - - 
Yes 1.98 0.03 to 3.92 0.047 
Experienced 1 or more traumatic 
event as child     
No - - - 
Yes 1.07 -0.46 to 2.59 0.169 
Experience abuse    
No  - - - 
Yes 2.01 0.36 to 3.68 0.017 
Physical Abuse 3.22 0.84 to 5.59 0.008 
Sexual Abuse 2.19 -0.36 to 4.73 0.092 
Emotional Abuse 2.90 1.12 to 4.67 0.001 
Social support -1.13 -3.08 to 0.82 0.255 
Primary health care 0.18 0.09 to 0.27 <0.001 
Secondary health care 0.29 0.02 to 0.56 0.036 
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Appendix 4.5 Table showing results from univariable 
analysis of baseline predictors with primary health 
care contact 
Baseline Predictors Coefficient 95% CI p-value 
Female -1.11 -2.42 to 0.21 0.099 
Age   0.07 0.04 to 0.11 <0.001 
Ethnicity    
White  - - - 
Black 0.39 -2.26 to 3.03 0.773 
Asian -0.04 -1.58 to 1.51 0.963 
Other (including mixed) 0.34 -1.87 to 2.56 0.761 
Marital status    
Married/ In a long term 
relationship - 
- 
 
- 
 
Widowed, separated, single 0.58 -0.52 to 1.68 0.299 
Employment status    
In paid employment  - - - 
Not in paid employment  2.27 1.21 to 3.33 <0.001 
Education     
O-levels, GCSE, A-levels or 
equivalent - - - 
Undergrad, masters or higher or 
equivalent -1.77 -2.87 to -0.67 0.002 
Finance    
Doing well - - - 
Doing badly  0.96 -0.13 to 2.06 0.085 
Index of multiple deprivation 0.00 -0.04 to 0.04 0.968 
Preference for dealing with 
symptoms    
Myself - - - 
Like some help 1.39 -0.00 to 2.79 0.051 
Symptom duration at baseline 0.04 -1.28 to 1.36 0.948 
Baseline symptom severity (PHQ-
15 0.19 0.09 to 0.30 <0.001 
SF-12 scores  
    
Physical -0.14 -0.19 to -0.92 <0.001 
Mental -0.05 -0.09 to -0.00 0.046 
Depression  0.13 0.05 to 0.21 0.001 
Anxiety   0.08 -0.01 to 0.18 0.085 
Panic    1.60 0.25 to 2.95 0.020 
Work and social adjustment 0.10 0.05 to 0.15 <0.001 
Self-efficacy  -0.10 -0.17 to -0.02 0.011 
Stressful life events 0.21 -0.15 to 0.57 0.253 
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Experienced physical illness in 
family members as a child    
No    
Yes    0.31 -0.86 to 1.49 0.598 
Experience mental illness in family 
members as a child    
No    
Yes -0.65 -2.12 to 0.83 0.390 
Experienced 1 or more traumatic 
event as child     
No    
Yes 0.54 -0.64 to 1.72 0.371 
Experience abuse    
No     
Yes 1.31 0.07 to 2.56 0.039 
Physical Abuse 1.62 -0.17 to 3.42 0.075 
Sexual Abuse 1.39 -0.60 to 3.37 0.170 
Emotional Abuse 2.13 0.79 to 3.47 0.002 
Social support    -0.71 -2.23 to 0.82 0.361 
Primary health care use at 
baseline 0.41 0.35 to 0.46 <0.001 
Secondary health care use at 
baseline 0.85 0.66 to 1.05 <0.001 
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Appendix 5 
 
Appendix 5.1 Dissemination of findings: 
 
 A longitudinal cohort study to identify prognostic factors associated with 
outcome in primary care attendees with unexplained physical symptoms. To be 
presented at the 45th Annual Conference for the Society of Academic Primary 
Care, Dublin, July 2016.  
 
 Preferences for sources of support for management of symptoms 
amongst primary care attendees with unexplained physical symptoms. To be 
presented at the 45th Annual Conference for the Society of Academic Primary 
Care, Dublin, July 2016.  
 
 Prognostic factors associated with persistence of somatic symptoms: 
findings from a longitudinal cohort study of unexplained physical symptoms in 
primary care, NIHR School for Primary Care Research Annual Showcase, Oxford, 
September 2015.  
 
 Unexplained physical symptom severity in patients attending nine 
general practices in London: a cross-sectional study, 44th Annual Conference for 
the Society of Academic Primary Care, Dublin, July 2015.  
 
 Self-reported somatic symptom explanations and attributions: cross-
sectional findings from the screening phase of an on-going longitudinal cohort 
study on unexplained physical symptoms in primary care, NIHR School for 
Primary Care Research Annual Showcase, Oxford, September 2014. 
 
Appendix 5.2 Paper in preparation  
 A prospective cohort study to determine prognostic factors associated 
with outcomes in primary care attenders with unexplained physical symptoms.  
 
 
